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Abstract 
 
A Disintegrin And Metalloproteinase 15 (ADAM15) is a membrane-bound 
metalloproteinase which has been shown to be significantly raised throughout breast 
cancer progression. The intracellular domain (ICD) of ADAM15 exists in multiple splice 
variants that contain varied combinations of polyproline regions, which interact 
preferentially with proteins containing Src Homology 3 (SH3) domains. Patients suffering 
from node-negative breast cancer exhibited a poorer prognosis when expressing high 
levels of variant A and B whereas those patients suffering from node-positive cancer 
exhibited an improved prognosis when expressing high levels of ADAM15 variant C.  
Nuclear Magnetic Resonance (NMR) spectroscopy titrations were used to elucidate the 
interaction interface between the ADAM15 ICD variants and the SH3 domains of Grb2, 
Src and Brk. Chemical Shift Perturbations (CSPs) indicated that Grb2 interacted with all 
ADAM15 ICD variants via residues 22Glu, 44Trp and 56Phe. Analysis of the common 
regions of the ICD variants implicated the polyproline region 4 in this interaction. The 
Src SH3 domain interacted with ADAM15 B, C and E via residues 17Arg, 21Asp, 40Trp 
and 56Ser-58Tyr; residues which are present in the hydrophobic pocket of the domain. 
This interaction likely involves a RPLPXDPV motif apparent in polyproline regions 2 and 
3 of the ADAM15 ICD. The Brk SH3 domain also interacted with ADAM15 B via residues 
34Arg, 56Trp, 74Val, 77Asn and 79Leu in a manner similar to the internal interaction of 
the Brk SH3 domain with its own linker region. ADAM15 D does not interact with any of 
the SH3 domains as it does not include any polyproline regions. 
This work has highlighted the manner by which certain SH3 domains preferentially 
interact with the polyproline regions of the ADAM15 ICD and open a line of investigation 
into the downstream functions of these interactions particularly with regards to breast 
cancer expression.  
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Chapter 1: Introduction 
 
1.1 Breast Cancer 
Breast cancer was the most common cancer affecting women in the United Kingdom in 
2011 with 49,936 women and 349 men diagnosed and approximately 1.68 million cases 
worldwide. Women have a 1 in 8 lifetime chance of developing the disease in Western 
Europe. The number of cases of breast cancer in the UK have increased 74% since the 
mid-1970s but due to increased screening rates (16,500 cases detected by the NHS 
screening program in 2009-2010 financial year) and more effective treatments, death 
rates have decreased by 40% since the mid-1980s. Although the 10-year survival rates 
have increased from half of those diagnosed to 8 in 10 in the last 40 years, only 15% of 
those diagnosed with the most advanced forms of the disease survive for at least 5 years 
after diagnosis. Despite progress in the treatment, detection and awareness of breast 
cancer, the disease remains the second most common cause of death for women in the 
UK after lung cancer (2011a).  
The normal breast comprises fatty tissue, milk ducts, glands and lymph nodes (figure 
1.1) and cancer can arise in any of these structures. The most common form of breast 
cancers are carcinomas which arise from epithelial cells such as those of the lining of the 
milk ducts or lobes and account for 75% of all breast tumours (Bombonati and Sgroi, 
2011).  
  
Figure 1.1 A) Structure of the breast. B) Network of lymph nodes in the breast and under-arm. Adapted 
from Cancer Research UK (2011a). 
A B 
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The lymph nodes are a common biopsy target as the system drains the tissue fluid from 
around the breast cells and so can contain any cancer cells that have broken away from 
a tumour. If there are no cancer cells present in the lymph nodes, the likelihood of the 
cancer having metastasised beyond the breast tissue is low. 
Carcinomas emerge due to a loss of functional control of processes such as proliferation 
and cell cycle which cause a colony of neoplastic pre-cancerous, benign cells to develop 
(figure 1.2). Under the right micro-environmental conditions, this can further progress 
to atypical ductal hyperplasia (ADH) and eventually to ductal carcinoma in situ (DCIS) 
through the accumulation of genetic and epigenetic changes (Burstein et al., 2004). 
While DCIS is non-invasive and can stay as such for many years without developing 
further, it has the potential to eventually gain invasive characteristics. 
 
Figure 1.2 Histological images of progression of breast cancer development from normal ductal lumen 
tissue through Ductal Carcinoma in Situ to invasive carcinoma. Adapted from Burstein et al, N Engl J Med, 
2004 (Burstein et al., 2004). 
 
The TNM System (Tumour, Node, Metastasis) is used to assess the severity of a patient’s 
condition upon diagnosis taking into account the size of the tumour, whether it has yet 
infected the lymph nodes and whether it has metastasised to distant tissues and organs. 
DCIS is classed as Stage 1 by this system and is shown in figure 1.3 along with stages 2 
and 3 which also exhibit cancerous cells in the lymph nodes which DCIS does not. Under 
the TNM System, Stage 4 is invasive carcinoma that has metastasised to remote tissues 
and organs (2011d). Other classifications used to distinguish the severity of the disease 
include the differentiation status of the tumour (grade) and steroid hormone receptor 
status. 
 
20 
 
Figure 1.3 TNM System of grading the severity of breast cancers. Stage 1 is also known as DCIS. Stages 2 
and 3 display lymph nodes positive for cancerous cells and Stage 4 is metastatic disease (not shown here). 
Adapted from Cancer Research UK (2011d). 
 
The expression of certain receptors is also used to define different breast cancers, 
specifically the Progesterone Receptor (PR), the Estrogen Receptor (ER) and the Human 
Epidermal Growth Factor Receptor 2 (Her2) (Burstein et al., 2004). Hormone based 
treatments have been effective in treating cancers expressing these receptors. 
However, those patients whose cancer is “triple-negative” for these receptors do not 
respond to such treatments and are consequently much more difficult to successfully 
treat.  
Although the hereditary forms of breast cancer (those who have inherited mutations in 
the BRCA1 and BRCA2 genes for example) have been well publicised, 95% of all breast 
cancers are sporadic in nature (2001). Risk factors include obesity, age, menopausal 
status, the use of oral contraceptives and smoking (2011b).  
Breast cancer research has increasingly demonstrated the importance of multiple 
metalloproteases in cancer progression. Some metalloproteases, such as MT1-MMP, 
have been shown to increase invasion, metastasis, angiogenesis and 3-dimensional 
tumour growth (Lee et al., 2007). Alternatively, some, such as MMP8 and ADAMTS15, 
have been shown to possess tumour suppressive abilities (Decock et al., 2011). The 
family of metalloproteases to be investigated here is that of the ADAMs. As will be 
explained in more detail later, ADAM15 has been implicated in varying prognoses in 
women with node-negative tumours compared to node-positive tumours (Zhong et al., 
2008). 
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1.2 A Disintegrin And Metalloproteinase (ADAM) Family 
The ADAM family of metzincin endopeptidases, belong to the M12B adamalysin 
protease subfamily (MEROPS) (Rawlings et al., 2008) and are related to the ADAMTS (A 
Disintegrin And Metalloproteinase with Thrombospondin motifs) family and the SVMP 
(Snake Venom Metalloproteinase) family. They are generally approximately 750 
residues in length and are mostly transmembrane proteins, with a few secreted 
exceptions (Edwards et al., 2008). Well-conserved in evolutionary terms, orthologs of 
ADAMs can be found in vertebrates, with only ADAM22 missing from the mus musculus 
genome compared to humans (Puente et al., 2003).  
In humans, 25 ADAM genes have been identified, 4 of which appear to be pseudogenes 
(Edwards et al., 2008). Of the 21 active genes, only 12 include the reprolysin-type active 
site sequence (HEXGHXXGXXHD) and the Metzincin specific “Met turn” necessary for 
proteolytic action (Bode et al., 1993). Those that do not include these sequences would 
appear not to have catalytic capabilities although several have been shown through 
gene knock-out mice studies to still have important roles in development (Edwards et 
al., 2008) . 
The ADAM family proteins exhibit tissue specific expression. Within both the 
catalytically active and inactive subgroups, the human ADAMs are divided into testis-
specific and non-testis-specific groups. Those that are testis specific are involved in 
spermatogenesis and sperm function whereas the non-testis specific proteins are 
expressed in a widespread manner throughout other tissues. A minority buck this trend 
and are expressed predominantly in haematopoietic tissues, for example ADAM8 and -
28 (Edwards et al., 2008). These variations within the family are highlighted in Figure 
1.4. 
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Figure 1.4 Schematic of the subdivisions of the ADAM family of metalloproteinases (Edwards et al., 2008). 
 
1.2.1 Structure of the ADAM family proteins 
The general structure for this family is consistent with each ADAM including a pro-
domain, a metalloprotease domain, a disintegrin-like, a cysteine-rich domain, an EGF-
like domain, a transmembrane region and an intracellular domain (ICD) (Edwards et al., 
2008). The organisation of these domains is comparable to other members of the 
Metzincin superfamily as shown in figure 1.5. ADAMs differ from the rest of the 
superfamily through having a combination of the disintegrin domain, the cysteine-rich 
region and the EGF-like domain while lacking any thrombospondin repeats or a 
hemopexin domain (Seals and Courtneidge, 2003). 
Figure 1.5 Schematic of the general structure of the ADAM family along with other Metzincins including 
SVMPs, ADAMTS’, MTMMPs and MMPs. Adapted from Edwards et al 2008 (Edwards et al., 2008). 
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The Pro-Domain 
The ADAM family proteins are synthesised as inactive enzymes, inhibited by a cysteine 
switch mechanism generated by the pro-domain (Roghani et al., 1999; Seals and 
Courtneidge, 2003). The cleavage of this region and thus activation of the enzyme, is 
catalysed by a pro-protein convertase enzyme, such as furin, which recognises a 
conserved RX(R/K)R motif (Lum et al., 1998). ADAM -8 and -28 are unusual are they have 
the ability to auto-catalyse their pro-domain and thus activate themselves (Howard et 
al., 2000; Schlomann et al., 2002). The pro-domain is also necessary for correct protein 
folding (Roghani et al., 1999). Once cleaved, the pro-domain can act as a signalling ligand 
to inhibit mature ADAMs as is the case for ADAM -10 and -17 (Gonzales et al., 2004; 
Moss et al., 2007). 
The Metalloprotease domain 
The two globular subdomains of the metalloproteinase domain are orientated to hold 
the active site in a cleft. The N-terminal upper domain is a 5 stranded β-sheet holds the 
substrate parallel to itself once in the active site and the C-terminal lower domain is an 
α-helix and contains the HEXXH zinc-binding catalytic site. These are held in place by the 
Met turn, which is characteristic of the Metzincin family of endopeptidases and uses a 
1,4 β-turn to do so, further stabilised by three disulphide bonds (Bode et al., 1993; 
Gomis-Ruth, 2003). The main function of this domain is as a sheddase. 
The Disintegrin-like domain 
Disintegrin domains have the ability to bind to heterodimeric adhesion receptors called 
integrins through a conserved RGD sequence (Lu et al., 2010). Integrins include an α type 
chain and a β type chain to which disintegrins bind (specifically the β-1 and β-3 type 
chains). A normal disintegrin domain includes of two sub domains that form an arc and 
can include calcium ions for stability (Lu et al., 2010). However, most ADAMs do not 
actually contain the conserved RGD sequence necessary for integrin interactions hence 
being termed “disintegrin-like” here. The only exception is that of human ADAM15 
which does have the RGD sequence and has been shown to interact with αvβ3 though 
this (Lu et al., 2010). The functional relevance of this is unclear as this is not the case in 
mouse ADAM15. ADAM15 can also interact with α9β1 through an alternative integrin 
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binding sequence, RXXXXXXDLPEF, as can ADAM10 and -17 (Eto et al., 2002). However, 
as the disintegrin loop, which is responsible for integrin interactions, is buried within the 
3D structure of ADAM15, the functional roles of this are less clear. The predicted 
homology structure for the ADAMs is shown in figure 1.6. 
 
 
Figure 1.6 Schematic showing the structure of 
the domains of the ADAM family 
metalloproteases. Pro indicates the pro-
domain, MP: the metalloprotease domain, Dis: 
the disintegrin domain, CR: the cysteine-rich 
region, EGF: the EGF-like region, TM: the 
transmembrane domain and CD: the 
intracellular domain. HVR indicates the high 
variability region. Taken from Murphy, Nature 
Reviews: Cancer, 2008 (Murphy, 2008) 
 
 
The Cysteine-rich Region and EGF-like Domain 
There is significantly less evidence as to the role of the cysteine-rich region in ADAM 
biology as for other domains. It contains a hypervariable region and appears, in some 
cases, to allow the ADAM to bind to the extracellular matrix although its role appears 
varied (Smith et al., 2002). For example, in ADAM12, it has been shown to allow 
interaction with proteoglycans, specifically syndecans (Iba et al., 2000). In ADAM13, it is 
involved with interactions with fibronectin (Smith et al., 2002). ADAM17 is incapable of 
shedding IL-1 Receptor-II without it, although it remains able to shed other substrates 
(Reddy et al., 2000).  The cysteine-rich region also shares a strong homology with viral 
fusion proteins and so is potentially involved in the membrane fusion process for 
example myoblast fusion (Edwards et al., 2008). This has yet to be proven through 
experimentation. 
Of all of the domains within the ADAMs, the least is known about the function of the 
EGF-like domain and currently no function of any ADAM has been linked their the EGF-
like domain (Janes et al., 2005). 
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The Intracellular Domain 
This is the most varied of the domains within the ADAMs. Those ADAMs that are 
secreted do not have an intracellular domain (ICD). For those that do, the length of this 
domain can vary from as little as 11 residues in ADAM11 to 231 residues in ADAM19 
(Seals, 2003). The most common motif found within this domain is the PXXP proline-rich 
region capable of binding to proteins which contain Src homology domain 3 (SH3) 
domains. This motif is highly conserved across the family occurring in ADAMs -7, -10, -
12, -15, -17, -19, -22, -29 and -33 (Edwards et al., 2008). 
One example of the importance of the ICD of the ADAMs is that of ADAM10. If the 
proline-rich regions of the ICD of ADAM10 are removed, it is not correctly localised to 
the right basolateral location in polarised epithelial cells, removing its ability to cleave 
E-cadherin and thus removing ADAM10’s effect on the promotion of cell migration 
(Wild-Bode et al., 2006). ADAM15 is an unusual case, in terms of its ICD, as it has 11 
possible splice variants of this domain. These have been shown to preferentially interact 
with different SH3-containing signalling proteins which will form the basis of this project 
(Zhong et al., 2008). 
An alternative function of the ICD in ADAMs derives from the availability of potential 
sites for phosphorylation by serine-threonine kinases and/or tyrosine kinases. 
Speculation would suggest that these give the ADAMs a role in outside/in signalling 
pathways. These sites could be involved in regulation of the ADAMs but would also 
create sites with the potential for binding to proteins containing SH2 domains. In the 
case of ADAM9, phosphorylation of these residues by PKCδ is necessary in order for 
ADAM9 to be activated by phorbol esters (Izumi et al., 1998). 
 
1.2.2 Biological Functions of the ADAMs 
ADAMs have a wide variety of functions. For example, ADAMs 1-3 have a role in fertility 
displaying functions in cell-cell adhesion between sperm and ovum through integrin-
binding ability. By comparison, ADAM12 has a major role in myoblast fusion in skeletal 
muscle deposition which requires the removal of the pro-domain and the 
metalloprotease domain. 
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Shedding 
The primary proteolytic function of ADAMs is that of shedding; the proteolytic cleavage 
of the ectodomain of a membrane-bound protein in order to release a potential ligand 
for downstream signalling or terminate signalling by removing a ligand from a receptor 
or removing the ectodomain of the receptor itself. As this requires an active 
metalloprotease domain, only those ADAMs that contain the HEXGHXXGXXHD sequence 
required for activity can act as sheddases (Bode et al., 1993). ADAM17, which is also 
known as tumour necrosis factor-α-converting enzyme (TACE) due to its ability to shed 
TNFα, is the most well-known sheddase. It has subsequently been shown to shed HB-
EGF, TGFα, epiregulin, amphiregulin, IL-6 and β-cellulin amongst many other cell surface 
proteins (Gooz, 2010). The release of ligands for signalling by shedding has a wide range 
of roles from cell migration to cell fate determination to osteoclast differentiation and 
angiogenesis. In the case of ADAM15, an example of its shedding is that of E-cadherin 
which leads to an increase in β-catenin which initiates a signalling cascade to induce 
epithelial-mesenchymal transition and cell proliferation mechanisms (Najy et al., 2008b). 
RIPping 
Regulated intramembrane proteolysis (RIPping) is the cleavage of the intracellular 
domain of a transmembrane protein by a presenilin-containing γ-secretase complex. 
This process is regulated by ADAMs as the extracellular cleavage of the substrate by 
shedding is necessary for the binding of the nicastrin unit of the γ-secretase complex. 
While this is mainly a role fulfilled by ADAM10, other ADAMs can also be involved 
instead. Some examples of RIPping targets are Notch, CD44, ERBB4 and amyloid 
precursor proteins (Murphy et al., 2008). 
Cellular Adhesion 
Conflicting functions in cellular adhesion displayed by members of the ADAM family 
have made this topic a source for some debate. The ability of some ADAMs to solubilise 
adhesion molecules such as L-selectin, L1-CAM, VCAM1, CD44, E-cadherin and N-
cadherin implies a role in reducing cellular adhesion. However, this is in contrast with 
the ability of other ADAMs to bind to syndecans and integrins through their disintegrin 
and cysteine-rich domains (Edwards et al., 2008; Seals, 2003). 
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1.2.3 Regulation of the ADAMs 
Post-Translational Modifications 
A primary form of post-translational modification of the ADAMs is the removal of the 
pro-domain by proprotein convertases such as furin which target conserved recognition 
sequences in the ADAM (Lum et al., 1998) thus activating enzymatic activity. 
Another form of modification is phosphorylation. Many ADAMs require a change in the 
phosphorylation state of their ICD by intracellular kinases and phosphatases in order to 
function. For example, phorbol esters activate protein kinase C to phosphorylate 
ADAM9, thus increasing activity (Izumi et al., 1998). In the case of ADAM10, an increase 
in calcium in the cell causes an increase in ADAM10 mediated CD44 shedding although 
the mechanism and kinases involved are unknown (Stoeck et al., 2006). 
Other major forms of post-translational modification involved in ADAM regulation are 
trafficking and cell membrane compartmentalisation. Most ADAMs are only active once 
presented on the surface of the cell and so incorrect trafficking would prevent the ADAM 
from its purpose (Seals, 2003). Additionally, some ADAMs need to be further localised 
on the cell surface in order to function such as ADAM10 targeting to adherens junctions 
of polarised epithelial cells where many of its substrates are present (Wild-Bode et al., 
2006).  
Finally, recycling is an important regulator of ADAM function through post-translational 
modification. For example, endocytosis of ADAM17 regulates activity. While phorbol 
esters increase the activity of ADAM17 via the action of protein kinase C, in the long 
term, the presence of phorbol esters leads to the endocytosis of ADAM17 (Doedens and 
Black, 2000). 
Inhibitors 
The main type of inhibitor to the ADAMs is the TIMP family. These co-ordinate with the 
Zn from the active site and thus prevent any metalloprotease functionality. TIMP-3 has 
been shown to inhibit ADAMs -10, -12, -17, -28 and -33 (Edwards et al., 2008). A second 
inhibitor is RECK (reversion inducing cysteine-rich protein with kazal motif), a 
28 
 
membrane-anchored glycoprotein, primarily a MMP-9 inhibitor that has also been 
shown to regulate Notch signalling via its inhibition of ADAM10 (Muraguchi et al., 2007). 
Synthetic Inhibitors 
Due to the many roles of the ADAMs in disease, as will be discussed shortly, a number 
of small molecule inhibitors have been developed. The ADAMs are sufficiently different 
to the rest of the Metzincin family to allow more specific inhibitors to be designed. For 
example, a number of ADAM17 inhibitors are in phase I trials but it is important to note 
that due to mechanism-based liver toxicity, several other inhibitors were halted in phase 
II trials (Edwards et al., 2008). Other ADAMs currently being targeted include ADAM10 
which is being targeted due to its role in Her2 shedding in breast cancer (Moss et al., 
2008). 
 
1.2.4 Role of ADAM Family in Disease 
Cancer 
As the normal functions of the ADAM family proteins include cell proliferation, adhesion 
and ECM cleavage, it is not unexpected that the ADAMs are often implicated in cancers. 
Extracellular matrix (ECM) cleavage, such as ADAM9 cleavage of laminin, has a role in 
increasing metastasis and invasion (Mazzocca et al., 2005). Other repercussions of 
ADAM-mediated proteolysis include the release of many growth factors and 
chemokines which can lead to a number of processes in tumour cells such as 
proliferation or angiogenesis. The shedding and RIPping of N-/ E-/ VE- cadherin, along 
with that of selectins, ICAM1, VCAM1 and PECAM1, lead to altered tumour cell adhesion 
and changes to local vasculature (Edwards et al., 2008). Also, the ability of several 
ADAMs to interact with integrins and proteoglycans has implications for the ability of 
tumour cells to adhere to each other.  
Inflammation 
An important process in inflammation is the recruitment of leukocytes. This involves 
many of the substrates of the ADAMs including selectins, integrins and adhesion 
partners, PECAM1 and CD99 (Ponnuchamy and Khalil, 2008). An example is that of TNFR-
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associated periodic syndrome, a chronic inflammatory disorder which is caused by 
mutations in TNF-R1 which prevent the shedding of this receptor by ADAM17 (Garton 
et al., 2006). 
Other Diseases 
For the purpose of this report, the role of ADAMs in cancer will be the focus, however 
ADAMs have been linked to many different diseases including asthma and Alzheimer’s 
disease. ADAM33 expression is increased in asthma sufferers, as is ADAM8, although to 
a lesser extent. It is also usually over-expressed along with several polymorphisms that 
appear to be specific to asthma (Holgate, 2010). The mechanism underlying these 
observations is unknown. 
ADAMs -9, -10 and -17 have been linked to Alzheimer’s disease through their role as α-
secretases which are required for altering the balance of amyloid precursor protein 
towards the non-amyloidogenic pathway. ADAM10 is the only ADAM to be shown to be 
reduced in the brains of patients (Deuss et al., 2008). 
The ability of ADAMs to act as sheddases and as participatants in RIPing is associated 
with immunity. ADAM10 and ADAM17 are required for cleavage of LAG3, necessary for 
clonal expansion of lymphocytes.  FasL is required to kill T lymphocytes after an antigen 
has been dispatched and this is also shed by ADAMs -10 and -17. ADAM10 also has links 
to the allergic response through the shedding of FcεRI and  CD23 (FcεRII) which bind to 
IgE during this response (Murphy et al., 2008).  
 
1.3 Introduction to ADAM15 
ADAM15 follows the standard structure of the ADAM family and contains a furin-
sensitive pro-domain, an active metalloprotease domain, a disintegrin domain, a 
cysteine-rich region, an EGF-like domain, a transmembrane region and an intracellular 
domain (Kratzschmar et al., 1996) as can be seen in figure 1.7. It exists in 11 potential 
splice variants with all the variation in the intracellular domain and was chosen for study 
here due to links to breast cancer prognosis as will be discussed further in 1.3.5. 
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1.3.1 Functions of ADAM15 
Integrin Binding Ability 
ADAM15 is one of the few ADAMs with the capability to interact with integrins through 
its disintegrin-like domain due to possession of the canonical RGD sequence required 
for this function (Zhang et al., 1998), although α9β1 interacts here through an alternative 
sequence RXXXXXXDLPEF instead. Through this ability ADAM15 has been linked to cell 
adhesion and cell-cell interactions. For example, it has been shown to mediate cell 
adhesion to fibrinogen through αvβ3 by interfering with its function in such a manner 
that can also alter cell motility (Lu et al., 2010). In addition, it has been reported that 
α5β1 was also an ADAM15 ligand (Kratzschmar et al., 1996) but it was later demonstrated 
that this was dependent on cellular source, with different cell lines responding 
differently in immunoprecipitation and immunofluorescence experiments. Despite this 
contradicting evidence for a direct interaction, it has been shown that ADAM15 can 
upregulate α5β1 in chinese hamster ovary (CHO) cells via down regulation of ERK 1/2 
phosphorylation (Ham, 2002).    
Shedding 
Unlike other highly catalytically active ADAMs such as ADAM17, which has a high 
number of substrates (Arribas and Esselens, 2009), ADAM15 has relatively few 
substrates for its metalloprotease function. One such substrate is CD23, otherwise 
known as FcεRII, which is a low-affinity receptor for IgE (Fourie et al., 2003). When 
cleaved by ADAM15, the soluble form of CD23 interacts with non-sensitised B-cells 
(those that have not become specific to an allergen) to increase the production of IgE 
(Acharya et al., 2010) whereas the membrane-bound version of CD23 binds to IgE, when 
it is bound to an allergen, to initiate an immune response. 
Desmoglein-2 (Dsg-2) is another substrate of ADAM15 (Brooke et al., 2012; Klessner et 
al., 2009) that forms a transmembrane glycoprotein component of a type of cell-cell 
junction called a desmosome. Shedding of the extracellular domain of Dsg-2 removes its 
capability to anchor the junction to the desmocollin 1 component of a desmosome of a 
neighbouring cell, thus reducing cell adhesion. 
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Epithelial specific cadherin (E-cadherin) is also a reported substrate of ADAM15 (Acharya 
et al., 2010) which links ADAM15 catalytic function to cell adhesion changes through E-
cadherin’s role in adherens junction complexes (Klessner et al., 2009). Proteolytic 
cleavage of E-cadherin by ADAM15 causes a loss in cell contact integrity resulting in the 
dissolution of the adherens junction (Najy et al., 2008a). The soluble ectodomain of E-
cadherin (sE-cad) can act as a competitive inhibitor of normal E-cadherin, disrupting its 
role in tissue integrity, wound healing, embryonic development and organ 
morphogenesis (Brooke et al., 2012). The sE-cad fragment can also stabilise HER2 and 
HER3 homodimerisation, initiating ERK-dependent signalling which increases cell 
proliferation, differentiation and survival (Gooz, 2010). 
Proteolytic cleavage of neural cadherin (N-cadherin) by ADAM15 (Najy et al., 2008a) 
interferes with N-cadherin’s role in such biological mechanisms as myoblast 
differentiation, migration and FGFR dimerisation (Derycke and Bracke, 2004). 
Additionally, the soluble fragment of N-cadherin generated has been implicated in 
increased angiogenesis and increased migration in wound healing assays. 
Fibroblast Growth Factor Recepter 2iiib (FGFR2iiib) is most commonly expressed in 
epithelial cells and binds to stromal cell derived factor FGF7 with roles including 
proliferation, morphogenesis and tissue effects. While shedding of this receptor by 
ADAM15 has been demonstrated (Maretzky et al., 2009a),  the full downstream function 
of this has yet to be elucidated. 
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1.3.2 Intracellular Domain Splice Variants of ADAM15 
Eleven splice variants of the intracellular domain of ADAM15 exist. In this thesis, the 
nomenclature established by Poghosyan et al (2001, (Poghosyan, 2001)) will be used 
and the alternative nomenclatures used in the literature are listed in Table 1.1, along 
with the amino acid length of the whole proteins. A schematic of the exon usage in five 
of the splice variants is shown in figure 1.7. 
 
 
Table 1.1 Nomenclature of the 
ADAM15 splice variants used in the 
literature. The Poghosyan style will be 
used here (Kleino et al., 2009; 
Poghosyan, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADAM15 expression is widespread across a variety of tissues but the proportion of the 
potential variants varies by tissue, as can be seen in the heat map shown in figure 1.8. 
The placenta, for example, expresses high proportions of variants A, D and E but very 
little, if any, of the other variants. Other tissues, such as the spleen and peripheral 
leukocytes, have more varied expression profiles. Expression of ADAM15 variant A 
accounts for 58.6% of all ADAM15 expression across all tissues, followed by variant D at 
Poghosyan 
Style (2001) 
Kleino Style 
(2009) 
Uniprot Amino 
Acids No 
D 1 Q13444-10 772 
A 2 Q13444-2 814 
 3a Q13444-9 796 
B 4a Q13444-4 839 
E 5 Q13444-5 838 
C 6a Q13444-3 862 
 6b Q13444-1 863 
 7a Q13444-7 821 
 7b Q13444-6 822 
 8 Q13444-8 797 
 9  809 
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11% and B/E at 7.6% It was not possible here to detect the differences in mRNA of 
variants B and E using the size dependent techniques applied (Kleino et al., 2009). 
Figure 1.7 Schematic of the proline-rich regions of the ADAM15 ICD splice variants with the exons that 
encode for them indicated. Adapted from Zhong et al (2008, (Zhong et al., 2008)). 
 
All the variants studied in this thesis contain two potential phosphorylation sites at 
tyrosine 735 and the penultimate residue at the C-terminus. The variants arise due to 
the variable inclusion of exons 19-22 during splicing, with the exception of D which also 
includes a frameshift after tyrosine 735 and this does not contain any of the proline-rich 
regions encoded by the exons of the intracellular domain, nor the terminal C-terminal 
tyrosine. 
 
Figure 1.8 Heat map of the expression 
variability of the ADAM15 splice variants 
across different tissues. Adapted from 
(Kleino et al., 2007). 
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Proline-rich motifs including the sequence ΦPpΦP, where Φ is a hydrophobic residue 
and p can be another proline, can interact with Src homology 3 (SH3) domains via a left-
handed poly-proline helix which aligns along a flat hydrophobic surface on the SH3 
domain within which there are hydrophobic clefts. The ΦP sequences then sit within 
these clefts formed by conserved aromatic residues. Any binding specificity arises from 
interactions of the residues in the surrounding regions (Kaneko et al., 2008). There are 
two types of proline-rich motif possible within this general mechanism. Class I poly-
proline motifs follow the general sequence +ΨPpΨP where the aliphatic (Ψ) residues is 
preferably hydrophobic to match the general sequence above and + indicates a basic 
residue. Class II poly-proline motifs follow the sequence ΨPpΨPp+. However, the 
thermodynamics for these interactions were unusual for what appears to be a simple 
interaction based upon hydrophobicity. This was explained by Martin-Garcia et al (2012, 
(Martin-Garcia et al., 2012)), as being due to the presence of highly conserved, tightly 
bound, structural water molecules found in many SH3 domains which act to add polar 
interactions across the interface. The proline-rich regions included in the splice variants 
of the ADAM15 intracellular domains (ICDs) are displayed in figure 1.7. 
The interaction capability of the ADAM15 ICDs with SH3 domain-containing proteins has 
been established in a number of publications. Many of the proteins studied have similar 
phenotypic functions as ADAM15. In some cases, such as those of endophilin 1 and 
SH3PX1, the variant required has not been elucidated but it was shown that they only 
interacted with the pro form of ADAM15, implying a role in ADAM15 localisation 
(Howard et al., 1999). PACSIN3, which is necessary for ADAM12-mediated shedding of 
proHB-EGF, also interacts with the ADAM15 ICD (Mori, 2003). As endophilin 1 and 
SH3PX1 also bind to ADAM12, a crossover of functions between ADAM15 and ADAM12 
could be suggested.  Another such case is that of the Src family tyrosine kinase Fyn which 
can interact with the ADAM15 ICD and has overlapping roles in integrin signalling, T/B 
cell receptor signalling, cell adhesion and platelet activation (Poghosyan, 2001). The SH3 
domain-containing protein Mad2 functions as a spindle checkpoint protein essential for 
transition of the cell from metaphase to anaphase during mitosis and preferentially 
interacts with the phosphorylated ICD of ADAM15 (Poghosyan, 2001), which also 
promotes cell proliferation as discussed before.  
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As with Mad2, the interactions of some SH3 domain-containing proteins with the 
ADAM15 ICD are phosphorylation dependent. Two such examples are Hck and Lck which 
show greater binding when the ADAM15 ICD is tyrosine-phosphorylated. In the case of 
Hck, ADAM15 is a substrate. In the case of Lck, the N-terminal tyrosine of the ADAM15 
ICD was required for functional interaction, regardless of phosphorylation status 
(Poghosyan, 2001). 
While some SH3-domain containing proteins preferentially bind to the ADAM15 ICD 
based upon phosphorylation status, others interact in a splice variant dependent 
manner. A summary of these can be seen in table 1.2 and include further studies into 
Hck and Lck.  
  
Table 1.2 Summary of the preferential interactions studied across the literature. Techniques used to 
establish these interactions include Binding ELISA using a phage library, binding blot, co-
immunoprecipitation assays (Kleino et al., 2009; Yasui et al., 2004) and pull down assays (Zhong et al., 
2008). Interactions are indicated by a tick, no interaction a cross and those not investigated are 
highlighted by N/A. 
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Further confirmation that these interactions require the proline-rich regions of 
ADAM15, rather than any non-specific pathways, comes from Kleino et al (2009, (Kleino 
et al., 2009)). By repeating their interaction studies using synthetic peptides 
corresponding to the proline-rich clusters of the ADAM15 ICD, they confirmed the 
necessity of the proline-rich regions for many interactions and also indicated some 
preference for specific clusters by the SH3 domains as can be seen in figure 1.9. In some 
cases, this correlates with the variants they preferentially bind to and which proline-rich 
clusters those variants include. None showed significant interaction with the peptide 
corresponding to proline-rich region 1 as this contains a glycine residue within the PxxP 
motif, which is unusual and could potentially hinder any interaction through this motif. 
 
Figure 1.9 Selective binding of SH3 domains to different ADAM15 proline clusters. GST fusion SH3 domains 
were used to probe synthetic peptides corresponding the proline-rich clusters of the ADAM15 ICD (printed 
onto solid support). The height of the bar indicates the relative affinity of each SH3 domain within the set 
of proline cluster peptides and the bars were averaged from three parallel spots (Kleino et al., 2009). 
 
The ADAM15 splice variant expression profile of a cell affects behaviour in vitro. In the 
cell line, MDA-MB-435, which express protein markers for both breast cancer and 
melanoma, those cells transfected with ADAM15 B, as opposed to ADAM15 A or a vector 
control, were less well spread, smaller and contained fewer, shorter actin fibres, despite 
displaying similar levels of vinculin, ERK 1/2, FAK, Src and pSrc (Poghosyan, 2001). In 
adhesion assays using these cells, those transfected with ADAM15 A demonstrated 
greater adhesion than those transfected with ADAM15 B. Poor cell adhesion was 
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exhibited by cells transfected with ADAM15 B even compared to the vector control, 
irrespective of the adhesion material (tissue culture plastic, fibronectin or laminin). 
These results were consistent with de-adhesion assays and in the breast cancer cell line, 
MCF-7. In scratch wound assays, ADAM15 A transfected cells migrated faster than 
ADAM15 B transfected cells or the vector control, also supported by Matrigel Invasion 
assays (Zhong et al., 2008). 
 
1.3.3 Regulation and Inhibition of ADAM15 
The mechanism of transcriptional regulation for ADAM15 expression has yet to be fully 
explored. Its promoter lies at -266 to -23 base pairs relative to the start of the ADAM15 
gene (Kleino et al., 2007) and contains potential binding sites for the transcription 
factors Sp1, p300, MZF1 and c-Ets. This promoter is sensitive to upregulation in response 
to VEGF and potentially to TNF-α, TGF-β and IL-1β (Murphy, 2009). The promoter for the 
ADAM15 gene also contains seven adjacent series of 3 or more consecutive guanines 
which, when under superhelical stress, can relax from duplex form into intrastrand 
secondary G-quadruplex structures. These can function as a biological silencer for the 
gene and provide a potential therapeutic target (Brown et al., 2013).  
As the expression of the different ADAM15 splice variants varies by tissue and they can 
lead to potential changes in cell behaviour (Kleino et al., 2007), along with preferential 
interaction profiles (Kleino et al., 2009; Zhong et al., 2008), it is highly likely that this is a 
form of regulation linked to function. Unfortunately, the full scope of this remains 
unclear. 
The removal of the pro-domain of ADAM15 by the proprotein-convertase furin, controls 
the enzymatic function of the metalloproteinase. Despite furin inhibition preventing 
catalytic function in ADAM15 (Lum et al., 1998), it also inhibits catalytic function in other 
ADAMs too so this is a non-specific form of control. This may be controlled to some 
extent by the interactions of the ICD with certain SH3-containing proteins. Endophilin 
and SH3PX1 have been shown to only bind to pro forms of ADAM15 rather than mature 
forms although whether this has an effect on furin cleavage of ADAM15 is as yet 
unknown (Howard et al., 1999). It is also worth considering that the cleaved pro-domain 
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could potentially act as an inhibitory ligand to mature ADAM15. This is the case with 
ADAM10 but has not been investigated for ADAM15. 
In terms of inhibition as opposed to regulation, TIMPs 2 and 3 have been shown to be 
the main inhibitors of ADAM15 although this inhibition is accomplished in a much less 
efficient manner than the inhibition of MMPs by TIMPs (Maretzky et al., 2009b). It has 
also been shown that recombinant forms of the ADAM15 disintegrin domain (RDD) can 
inhibit functions enacted by ADAM15 through its disintegrin domain (Lucas et al., 2009). 
This includes endothelial cell growth, migration and angiogenesis. This is a potential 
therapeutic strategy for inhibiting ADAM15 in diseases. ADAM15 makes a good 
therapeutic target not only due to its links to disease, especially cancer, but also due to 
the relatively innocuous phenotype of ADAM15 null mice, which are viable through 
development and fertile as adult animals (Bohm et al., 2005). 
 
1.3.4 ADAM15 in non-cancerous disease 
Angiogenesis Related Conditions 
Although ADAM15 plays a role in developmental angiogenesis, it is not essential for 
angiogenesis to occur. However, in response to a synthesised peptide based upon the 
metalloproteinase domain of ADAM15 and VEGF stimulation, endothelial cells have 
exhibited increased proliferation, migration and tube formation which increased overall 
angiogenesis (Raiter et al., 2010). 
Atherosclerosis is a condition of the artery wherein the artery becomes hardened due 
to the development of an atheromatous plaque formed by a build-up of cholesterol and 
macrophages. In the rabbit model for atherosclerosis, the progression of the conditions 
can be reduced by the expression of ADAM15 in a catalytically dependent manner 
(Bultmann et al., 2011). However, endothelial-mediated vasoreactivity is reduced by 
ADAM15 in a catalytically independent manner. This is contradicted by in-vitro studies 
on human atherosclerotic tissue where ADAM15 mRNA and proteins levels were 
elevated and increased further in response to PDGF. Increased expression of αvβ3 and 
α5β1 were linked to increased ADAM15 expression and these have been shown to 
increase platelet interactions (Al-Fakhri et al., 2003; Pelisek et al., 2012). Increased 
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ADAM15 in response to PDGF also initiated increased smooth muscle migration and 
proliferation. Additionally, knockdown of ADAM15 in ApoE-deficient mice led to 
reduction in aortic atherosclerotic lesion size and smooth muscle deposition. Further 
study showed that ADAM15 had a role in barrier dysfunction and monocyte 
transmigration across endothelial cell monolayers in a manner dependent on the 
intracellular domain of ADAM15, although only variant A was used and requires the 
presence of Src and Yes (Sun et al., 2012). It is clear that ADAM15 plays some role in 
atherosclerosis but what that is, and if it varies across species, is yet to be established. 
Psoriasis lesions affect 2% of the population and these lesions form in a pro-angiogenic 
microenvironment. Interaction ability with pro-angiogenic integrins αvβ3 and α5β1 
potentially link ADAM15 to these conditions. Reduced endothelial cell migration in vitro 
and reduced vascularisation and blood flow in mice designed to exhibit reduced blood 
flow in response to a recombinant form of the ADAM15 disintegrin domain has been 
demonstrated and these results were supported by in vivo studies using psoriasis 
positive mice (Zibert et al., 2011). 
Inflammatory Conditions 
In normal intestinal tissue, ADAM15 is expressed in both the pro- and mature forms, 
while in colonic tissue, a previously undescribed post-translational modified form with 
a molecular weight between that of the pro and mature forms is seen, despite normal 
expression in the mRNA (Charrier-Hisamuddin et al., 2007). ADAM15 expression can be 
seen in healthy intestinal cell types including endothelial cells, pericryptic 
myofibroblasts and smooth muscle cells but not the myenteric cells or submuscosae 
(Mosnier et al., 2006). Protein and mRNA levels of ADAM15 are increased in the tissues 
of patients suffering from ulcerative colitis or Crohn’s disease, although the splice 
variants involved have not been assessed. Leukocyte-endothelial cell-cell interactions, 
which are involved in inflammatory pathways, have been demonstrated in endothelial 
cells expressing ADAM15, in a manner dependent on the presence of the RGD sequence 
in the ADAM15 disintegrin-like domain (Charrier-Hisamuddin et al., 2007).  
Similarly, ADAM15 is up-regulated in inflammation and sepsis and mediates endothelial 
hyperpermeability. The microRNA, miR-147b, targets the 3’ UTR of ADAM15, decreasing 
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total and cell surface expression of ADAM15 in endothelial cells (Chatterjee et al., 2014). 
This then reduced LPS-induced barrier dysfunction across endothelial monolayers, 
further underlining an inflammatory role for ADAM15. Further to this, ADAM15 
expression was found in association with pulmonary oedema in mice suffering LPS-
induced inflammatory lung injury with high levels seen in endothelial cells but not in 
neutrophils, despite increased neutrophil transmigration across the endothelial barrier. 
Considered together, this shows that ADAM15 has a role in hyperpermeability and 
neutrophil transmigration in acute inflammatory lung injury (Sun et al., 2013). 
Finally, proteolytic cleavage of TIR-domain-containing adapter-inducing interferon-β 
(TRIF) by ADAM15 removes the ability of TRIF to facilitate Toll-like receptor (TLR) 3 and 
4 signalling and thus reduces activation of the transcription factors NFκB and IFN 
signalling which initiate production of pro-inflammatory cytokine production. This is the 
first time a role for ADAM15 has been seen in TLR signalling (Ahmed et al., 2013).   
Degenerative Joint Conditions 
The link between ADAM15 and osteoarthritis (OA) was first established by the increased 
severity of OA in older mice and accelerated osteoarthritic lesions in ADAM15 null mice 
with male mice affected more severely and earlier than female mice (Bohm et al., 2005). 
This is supported by the increased ADAM15 mRNA and protein in the immortalised 
chondrocyte cell line, T/C28a4, which also demonstrated increased adhesion to type II 
and IV collagen but not fibronectin in an integrin-dependent fashion requiring the RGD 
motif of ADAM15. Additionally, those cells overexpressing ADAM15 showed a decrease 
in caspases 3 and 7 and an increased in the caspase 3 inhibitor, XIAP (Bohm et al., 2010). 
The longer survival rates induced by this in chondrocytes can allow a collective build-up 
of cell damage due to stress which leads to OA and is more damaging for the joint in the 
long term through articular cartilage loss and subchondral bone damage.     
The expression levels of ADAM15 are even more extreme in rheumatoid arthritis (RA) 
across multiple tissue layers in the joint including endothelial cells and immune cell 
filtrates suggesting a role in the recruitment of immune cells to the joint (Bohm et al., 
2001). The ADAM15 substrate, CD23, which functions to recruit non-specific B-cells and 
increase the inflammatory response, is also upregulated in RA in both the cleaved and 
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intact forms (Bonnefoy et al., 1996). Due to the highest levels of expression of ADAM15 
being at the border of the cartilage destruction, it has been suggested that ADAM15 
could be degrading cartilage directly although this has yet to be proven experimentally 
(Bohm et al., 2001). Given the raised angiogenesis observed in RA positive joints, the 
evidence strongly implicates ADAM15 in RA pathology. More recently, RA synovial 
fibroblasts have been shown to avoid apoptosis upon FasL exposure by phosphorylating 
FAK and c-Src in an ADAM15 dependent fashion, indicating ADAM15 as a potential 
target for therapy in rheumatoid arthritis (Bohm et al., 2013). A similar study which 
silenced ADAM15 in human fibroblast-like synoviocytes (FLSs) indicated suppression of 
pro-inflammatory cytokines and chemokines preventing cell migration and invasion via 
inhibition of VEGF-A, MMP1 and MMP3, via LPS stimulation (Gao et al., 2015). Silencing 
ADAM15 in collagen-induced arthritis (CIA) rats reduced the arthritis score and the 
extent of joint damage (Gao et al., 2015) thus supporting the potential of ADAM15 as a 
therapeutic target in rheumatoid arthritis.  
Human Immunodeficiency Virus (HIV) 
The expression of another member of the ADAM family, ADAM10, in CD4+ T 
lymphocytes is required for infection by the more common and virulent HIV-1 strain. 
This is also dependent on the expression of ADAM15 and γ-secretase, which are 
responsible for ADAM10 proteolytic processing, supporting a model whereby the 
processing of ADAM10 releases the ICD which then incorporates with HIV-1 Pre-
Integration Complex (PIC), facilitating nuclear trafficking (Endsley et al., 2014). 
Intrauterine Adhesions 
Intrauterine adhesions are uterine blockages which can develop sporadically and as a 
complication of operative hysteroscopy, caesarean section, normal delivery and 
infections such as tuberculous endometritis, causing infertility, recurrent miscarriages 
and irregular periods. The protein and RNA levels for both ADAM15 and ADAM17 are 
significantly raised in intrauterine tissues, particularly in the most severe forms although 
the specific relevance of this is as yet unclear (Liu et al., 2013).  
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1.3.5 ADAM15 in cancer 
ADAM15 has been shown to have both tumour promoting and tumour inhibiting 
functions depending on the location of the primary tumour. For example, ADAM15 is 
released into the extracellular space within an exosome and those exosomes which are 
rich in ADAM15 have tumour suppressing capabilities across a number of cancerous cell 
lines including MCF-7 (human breast adenocarcinoma), NCI-H460 and A549 (human lung 
carcinoma), MDAH2774 (human ovarian adenocarcinoma) and SK-MEL-28 (human 
melanoma) (Lee et al., 2012). The ectodomain of ADAM15 can be shed from these 
exosomes and, in a similar manner to the ADAM15-rich exosomes, reduced vitronectin-
induced cell migration and activation of the MEK-ERK pathway in MDAH2774 cells (Lee 
et al., 2014). Further examples of the role of ADAM15 in various types of cancer will be 
discussed here although the future focus of this study will be on those interactions 
involved in breast cancer. 
Colon Carcinoma 
Colon carcinoma exhibits reduced ADAM15 in 23% of cases with a corresponding loss of 
differentiation. ADAM15 substrates, E-cadherin and α3β1, are reduced here as they are 
in epithelial-mesenchymal transition (EMT), a process which is deregulated during 
metastasis, increasing the migratory potential of the cancerous cells (Toquet et al., 
2012). 
Primary Melanoma versus Metastatic Melanoma  
Melanomas arise from melanocyte cells in the skin which are responsible for melanin 
production. Primary melanoma has a good survival rate of around 95% when discovered 
early (2011c). Metastatic melanoma, by comparison, has a survival rate of less than 15% 
if the metastases are distant. ADAM15 has been shown to be significantly reduced in 
metastatic melanoma compared to primary melanoma in a manner that can be 
regulated by TGF-β (Ungerer et al., 2010). Where ADAM15 was expressed, migration 
and invasion was reduced, implying that ADAM15 is acting in a tumour suppressor role. 
Although variants A-D are all expressed in melanoma, D is the primary isoform expressed 
although, as there has been no function established for variant D, why this is the case is 
unclear (Ungerer et al., 2010). However, contrary to these findings, later stage 
43 
 
melanoma tumours were smaller in ADAM15 null mice compared to wild type along with 
fewer metastases in the lungs and lymph nodes which implies that ADAM15 is 
contributing to metastasis formation (Schonefuss et al., 2012). This contradiction, and 
thus the role of ADAM15 in melanoma, has yet to be resolved.  
Intra-tumoral electrotransfer of a plasmid encoding the recombinant disintegrin domain 
of ADAM15 (pRDD), into B16F10 melanoma-bearing C57BL/6 mice, induced a significant 
inhibition of tumour growth and, after removal of the primary tumour, an 84% reduction 
of tumour metastasis. Additionally, pRDD decreased cell proliferation in B16F10 primary 
tumours while not affecting normal skin blood flow (Daugimont et al., 2011). 
Prostate Cancer 
Levels of ADAM15 expression have been linked to the progression of metastatic prostate 
cancer as have the loss of a type of structural junctional complex, desmosomes. A key 
component of desmosomes is Dsg-2, a substrate of ADAM15 (Shiina et al., 2005). The 
cleavage of ADAM15 substrates, E-cadherin and N-cadherin has been demonstrated in 
prostate cancer cell lines, reducing cell-cell interaction and encouraging metastasis 
(Lucas and Day, 2009). 
Angiogenesis is vital for tumour growth beyond 1 mm and prostate cancer is no 
exception (Lucas and Day, 2009). As previously discussed, ADAM15 increases 
angiogenesis in a VEGF- and angiopoetin-1-dependent manner but, additionally and 
specifically in prostate cancer, ADAM15 up-regulation increases production of the pro-
angiogenic MMP9 (Bergers et al., 2000). Increased MMP9 has separately been linked to 
increased invasiveness in prostate cancer. 
Finally, when ADAM15 is knocked down in the prostate cancer cell line, PC-3, adhesion 
to laminin, vitronectin and fibronectin is reduced (Lucas and Day, 2009). 
Pancreatic Cancer 
When considering pancreatic ductal adenocarcinoma tissue samples, two proteins, 
ADAM15 and MHC class 1 polypeptide-related sequence B (MICB), were found to be 
expressed at higher levels than in normal pancreatic tissue. MICB is a ligand for the 
NKG2D type II receptor and thus induces a cytolytic response. MICB expression was 
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inversely correlated to ADAM15 expression, with higher ADAM15 expression in the 
more advanced cases of the disease. When ADAM15 was knocked down, the 
concentration of MICB on the cell surface increased and the concentration of soluble, 
cleaved ectodomain form of MICB (sMICB), which has been previously linked to poor 
differentiation and high tumour stage cells, was reduced in the culture supernatants but 
mRNA levels for the protein remained unchanged. It was concluded that ADAM15 was 
involved in the shedding of MICB in PANC-1 cells, thus decreasing MICB NKG1D-
mediated toxicity (Xiaohui Duan, 2013). 
Breast Cancer 
ADAM15 expression levels are significantly raised throughout the progression of breast 
cancer pathogenesis, with the highest levels in the most aggressive tumours (Kuefer et 
al., 2006). Loss of the ADAM15 substrate, E-cadherin, has been used as an indicator of 
poor prognosis in breast cancer, encouraging migration and reducing cell adhesion, and 
the soluble form, sE-cad, inhibits cell aggregation and increases cell invasion. 
Additionally sE-cad can interact with HER2 and HER3, under conditions of growth factor 
deprivation, leading to their dimerisation and initiation of ERK signalling. The 
downstream effects of ERK signalling are increased cell survival, proliferation and 
migration, all of which promote tumour growth. ADAM15, alongside ADAM17, mediates 
another mechanism involving ErbB receptors, that of thrombin-induced EGFR signalling 
(Najy et al., 2008b).  
Recently, a link between the ADAM15 splice variants and prognoses in certain subtypes 
of breast cancer have been described, Variants B and C were more highly expressed in 
breast cancer tissue compared to normal, but A and D levels were unaffected. In a longer 
term study, following up patients over a period of approximately 15 years, those 
patients suffering from node-negative cancer but whose primary tumours expressed 
higher levels of A and B, appeared to have a poorer prognosis whereas the levels of C 
had little difference. By comparison, in those patients suffering from node positive 
cancers, the expression levels of A and B in tumours had no effect on prognosis but 
higher levels of C correlated with an improved prognosis (Zhong et al., 2008), as can be 
seen in figure 1.10. 
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It has been suggested that the preferential interaction profiles of the splice variants with 
proteins that contain SH3 domains could be responsible for the correlation between 
prognosis and expression level. This is further supported by the significant role of some 
of the SH3 domain containing proteins that show such preferential interactions. The 
manner in which these interactions take place will be investigated in this thesis. 
Figure 1.10 Relationship between ADAM15 splice variants expression levels and disease-free survival in 
non-negative and node-positive tumours. The mRNA for each variant was quantified for 229 patients and 
the clinical outcome studied. The cohort was split into <median and > median expression levels and then 
the time after surgery was plotted against disease free survival. Taken from Zhong et al (2008, (Zhong et 
al., 2008)) 
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1.4 SH3 domain containing proteins 
Due to their strong, independent links to breast cancer and their interactions with the 
splice variants of the ICD of ADAM15, three SH3 domain containing proteins have been 
selected for further study here. These are Grb2, Src and Brk.  
 
1.4.1 Growth Factor Receptor-Bound Protein 2 (Grb2) 
Grb2 is a ubiquitously expressed adapter protein consisting of an SH2 domain flanked 
by two SH3 domains, as can be seen in figure 1.11, that is involved in multiple signalling 
transduction pathways and is encoded by the GRB2 gene. Ablation of this gene in mice 
is embryonic lethal at an early stage highlighting roles for the protein in development 
and cell proliferation (Jang et al., 2009). Highly conserved across multiple species, the 
human GRB2 gene and its Drosphilia drk homologue, can be used to replace the sem-5 
gene in Caenorhabditis elegans cell signalling (Tari and Lopez-Berestein, 2001).   
 
Figure 1.11 Structure of Grb2 based on the 
crystal structure pdb 1GRI with N-terminal SH3 
domain in blue, the central SH2 domain in green 
and the C-terminal SH3 domain in red (Maignan 
et al., 1995). 
 
 
 
 
 
Functions of Grb2 
The primary, and most well-known, function of Grb2 is as an adapter protein working to 
bring Son of Sevenless 1(Sos1), a guanine nucleotide exchange factor, and Ras to within 
spatial proximity. This allows GDP-GTP exchange to be undertaken by Sos1, this 
activating Ras (Giubellino et al., 2008). Sos1 and Ras are localised to different regions of 
the cell when Grb2 is lacking. The central SH2 domain of Grb2 interacts with pYXRX 
47 
 
motifs on the intracellular domain of various receptor tyrosine kinases, such as EGFR, 
hepatocyte growth factor receptor (HGFR) and platelet-derived growth factor receptor 
(PDGFR) and with Sos1 via the N-terminal SH3 domain in a 2:1 ratio of Grb2 to Sos1 
(McDonald et al., 2012a). Once activated, Ras signalling is responsible for cell growth, 
proliferation, apoptosis, actin cytoskeleton integrity changes, cell adhesion changes and 
migration, thus making Grb2 influential in cell processes (Tari and Lopez-Berestein, 
2001).  
The SH3 domains of Grb2 can be phosphorylated, the physiological context of which is 
yet to be fully explored. This phosphorylation was required for the inhibitor effect of 
prolactin on EGF signalling to MAPK activation and cell proliferation. Prolactin is a 
differentiation factor in mammary epithelial cells so, if Grb2 is not phosphorylated, 
mammary precursor cells are not capable of differentiation in response to prolactin 
(Haines et al., 2009). 
Grb2 has also been shown to have a role in T and B cell antigen receptor stimulation. In 
thymocytes, which are hematopoietic progenitor cells which differentiate into mature 
lymphocytes, Grb2 regulates T-Cell receptor (TCR) induced activation of MAPKs p38 and 
JNK via control of Lck signalling (Jang et al., 2009). In the absence of Grb2, Lck signalling 
is dramatically reduced although the mechanism by which this control is conducted is 
unclear. Influence over TCR signalling cascades in thymocytes grants Grb2 some 
measure of control over positive and negative cascades that result in cell proliferation, 
differentiation, cytokine production, T-cell development and homeostasis.  
The ability of SH3 domains, such as those in Grb2, to interact with proline-rich motifs is 
employed in the clathrin-dependent internalisation of ADAM12. Ablation of Grb2 
markedly reduces this internalisation thus regulating ADAM12 behaviour in ectodomain 
shedding, cell-adhesion and signalling (Stautz et al., 2012a). 
It has also been shown that dimeric Grb2 will bind to two Fibroblast Growth Factor 
Receptor 2 (FGFR2) molecules, thus forming a 2:2 heterodimer. The proximity generated 
allows FGF binding and the FGFR2 cytoplasmic tail kinase domains to cross-
phosphorylate themselves and cause a conformational shift, thus causing Grb2 
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phosphorylation and release. The FGFR2 kinase domains can then transphosphorylate 
themselves further and initiate downstream signalling (Lin et al., 2012). 
Grb2 in Cancer 
Grb2 has been linked to cancer in many ways, a selection of which will be discussed here. 
On a genetic level, the location of the human grb2 gene, chromosome 17 (q22) is within 
a region known to be highly duplicated in solid tumours and leukaemias. In chronic 
myeloid leukaemia (CML), the oncoprotein, Bcr-Abl, will bind to the SH2 domain of Grb2, 
linking this mutant protein to the Ras pathway, thus initiating cell processes such as 
proliferation, adhesion, apoptosis and migration which are all manipulated during 
cancer development (Huebner et al., 1994). 
The SH2 domain of Grb2 can also bind to FAK, once it has been phosphorylated by Src, 
leading to integrin adhesion and deregulation of E-cadherin (Schlaepfer et al., 1994). The 
subsequent E-cadherin/N-cadherin switch is a hallmark of epithelial-mesenchymal 
transistion which is necessary for cancer progression (Hazan et al., 2004). Repression of 
the ability of the SH2 domain to interact with pYXRX motifs inhibits migration in vitro 
and tumour dissemination in animal models, thus corroborating Grb2 SH2 domain 
involvement. Interacting with FAK also enables FAK to initiate Ras and ERK2 pathways, 
the downstream effects of which include the ability of cells to spread through actin 
cytoskeleton rearrangement (Schlaepfer et al., 1998).  
This is not the only connection of Grb2 to the actin cytoskeleton as it can interact directly 
with the actin filament machinery via a regulator of actin cytoskeleton rearrangement, 
WASp (She et al., 1997). Patients with mutations in WASp possess functional defects in 
their platelets, T and B cell polarisation and the ability of cells to migrate in response to 
external stimuli. Binding of WASp to Grb2, via the SH2 domain, translocates cytosolic 
WASp to the membrane where it can interact with Rac, Cdc45 and EGFR and stimulate 
signalling. When in a heterotrimer with Nck, the complex stabilises actin-nucleating 
complexes, a process which promotes cell migration via lamellipodia (Scaplehorn et al., 
2002). Another heterotrimer including Grb2, that of EGFR-Grb2-PAK1, is also required 
to EGFR-induced lamellipodia formation (Puto et al., 2003). 
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 An important process in the metastasis of solid tumours to secondary locations is the 
process by which cancerous cells exit capillaries (extravasation). Grb2 is associated with 
this process by interactions with L-Selectin (Brenner et al., 1996). Selectins mediate 
adhesion of cancer cells to endothelial cell luminal surfaces, allowing the cells to lodge 
at a secondary location and exit the blood vessel in a process more typically used by 
lymphocytes (Witz, 2006). Increased selectin ligands and upregulation of L-Selectin 
expression have been linked to increased metastasis to the lymph nodes (Qian et al., 
2001).  
In breast cancer, Grb2 is upregulated in several breast cancer cell lines, including MCF-
7, MDA-MB-361 and -435 cells, enhancing Ras signalling to modify behaviour of the cells. 
In primary breast tumours, there is a two fold increase in Grb2 mRNA compared to 
normal breast tissue. The overexpression of Grb2 mRNA is even more pronounced in 
primary breast cancer tissue that express low levels of EGFR, implying that Grb2 
amplifies signalling downstream from the receptor (Kairouz and Daly, 2000).   
Also in breast cancer, Grb2 is required for transforming growth factor β (TGF-β) 
stimulation of EMT and invasion in mammary epithelial cells (MECs). The TGFβ type II 
receptor (TβR-II) is phosphorylated on tyrosine 284 by Src, providing a binding site for 
the SH2 domain of Grb2. Ablation of this interaction impaired stimulation of p38 MAPK 
in MECs but not Smad3 and prevented cells from undergoing EMT or invade synthetic 
basement membranes. In mice models, TβR-II phosphorylation of Y284 is necessary for 
TGFβ stimulation of breast cancer growth and pulmonary metastasis via p38 MAPK 
(Galliher-Beckley and Schiemann, 2008). 
In a final example, lemur tyrosine kinase 3 (LMTK3) –induced CDC45 activation requires 
the interaction of LMTK3 with Grb2. LMTK3 promotes metastasis in breast cancer by 
inducing transcription of genes encoding integrin subunits, leading to an increase in 
actin cytoskeleton remodelling, focal adhesion formation and adhesion to collagen and 
fibronectin in culture (Xu et al., 2014b).   
Grb2 as a therapeutic target 
Due to the diverse links between Grb2 and various forms of cancer, it is unsurprising 
that Grb2 makes a tempting therapeutic target and a number of approaches have been 
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undertaken. The majority of these focus on interfering with the function of the SH2 
domain interacting with RTKs. For example, the general transcription inhibitor, 
actinomycin D prevents the interaction of the Grb2 SH2 domain with Shc and thus 
reducing tumour cell cycle progression (Kim et al., 2005b; Kim et al., 1999). Blocking the 
SH2 domain with recombinant peptide ligands or synthetic small molecules that mimic 
the target binding motif of RTKs has proven to be effective in some cases. Unlike other 
SH2 domains in the Src family, Grb2 preferentially binds to motifs that include an 
arginine at the pY+2 position in the recognition site and that also have a β-bend 
configuration (Kessels et al., 2002) which reduces the cross-reactivity of potential 
therapeutics.  Such antagonists have been shown to potently block HGF-stimulated cell 
motility and matrix invasion along with morphogenetic events required for angiogenesis 
(Atabey et al., 2001). In a murine syngeneic melanoma cell line (B16-F1) metastasis 
model, there was a significant reduction in metastatic burden in the presence of a 
prototypical Grb2 SH2 domain binding antagonist (Giubellino et al., 2007). Also 
recombinant forms of the SH2 domain have been used to competitively inhibit the full 
length Grb2 protein function with regards to RTKs and thus suppressed breast cancer 
cells growth and migration (Yin et al., 2013). 
Due to low affinities between SH3 domains and their target proteins and the strong 
overlap of target proteins for SH3 domains in different proteins, it is more difficult to 
design inhibitors specifically to the SH3 domains of Grb2. However, the function of the 
SH2 domain does require Grb2 to be localised to the membrane edge. This does reduce 
the number of practical targets. Some synthetic peptides have been designed to reduce 
the influence of Grb2 in cancer progression with mixed success although it was possible 
to reduce proliferation of cells in CML. In terms of small molecules, a selection have been 
identified that compatibly interfere with the interaction of the C-terminal SH3 domain 
of Grb2 and Shc with moderate to low affinities. Of those molecules, those based upon 
dihydro-s-thrazine scaffold are the most successful (Simister et al., 2013).   
 As can be see here, Grb2 is an important protein in both healthy and cancerous cells 
and so any interactions with the ADAM15 ICDs could be playing a role in signalling that 
can allow cells to survive apoptosis and cell precipitation and thus are worthy of further 
study.  
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1.4.2 The proto-oncogene, tyrosine kinase Src 
A key protein superfamily in cell signalling is that of the Src family tyrosine kinases. 
Members of this family engage with receptor tyrosine kinases and integrins and are 
involved in signalling via both potential partners. Src, named for the viral counterpart’s 
ability to cause sarcomas in chickens (Src Rous sarcoma virus) is a cytoplasmic tyrosine 
kinase with a length of 536 residues in the human form encoded at the chromosomal 
locus 20q11. It is ubiquitously expressed, with comparative genes across the range of 
metazoan evolution, and contains two phosphorylation sites at tyrosines 419 and 527 
crucial to the activation of the kinase. Beginning at the N-terminus, Src contains a unique 
domain, sometimes called an SH4 domain, an Src Homology 3 (SH3) domain, an SH2 
domain, a proline-rich linker sequence, a tyrosine kinase domain, also known as an SH1 
domain, and a C-terminal tail (Wheeler et al., 2009). The unique (SH4) domain acts as a 
target for myristolation thus targeting it to the cytoplasmic membrane where it is 
anchored by the C-terminal tail. The SH3 and SH2 domains work together to regulate 
the catalytic activity of the tyrosine kinase domain through their ability to interact with 
proline-rich sequences and phosphotyrosine containing short motifs respectively. The 
phosphorylation site at Tyr527 is phosphorylated which then internally interacts with 
the SH2 domain which positions the SH3 domain to interact with the proline-rich linker 
region. This “closed” conformation prevents catalytic activity of the tyrosine kinase 
domain. If Tyr527 is dephosphorylated, the protein “opens” which allows the 
autophosphorylation of Tyr419, activating the kinase and freeing the other domains for 
their functional interactions (Okada and Nakagawa, 1989). This process is illustrated in 
figure 1.12. 
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Figure 1.12 Structural changes during Src activation, A) Inactive Src, held in the “closed” conformation by 
phosphorylated Tyr527 interacting with the SH2 domain allowing the SH3 domain interaction with the 
linker region. B) Dephosphorylation of Tyr527 leads to autophosphorylation of Tyr416, releasing the SH2 
domain and thus the SH3 domain. C) Active Src in the open conformation. Taken from (Elsberger et al., 
2009) 
 
Functions of Src 
The kinase domain of Src catalyses the following reaction: 
MgATP1- + protein –O:H    protein –O:PO32- + MgADP + H+ 
The introduction of a phosphoryl group can activate other signalling proteins and initiate 
signalling with a variety of downstream effects (Roskoski, 2015). Dephosphorylation of 
the C-terminal tyrosine in Src can be achieved by a range of tyrosine phosphatases 
(Alonso et al., 2004) or the requirement for dephosphorylation of Tyr527 can be over-
ridden by phosphorylation of Tyr213 in the SH2 domain, removing the inhibitory effects 
of pTyr527 and allowing activation. This second pathway can be achieved by the 
interaction of the SH2 domain of Src with the intracellular kinase domains of a range of 
receptor tyrosine kinases such as PDGFR, VEGFR, EGFR, HER-2 and -3, mitogen-activated 
protein kinase extracellular signal-regulated kinase -2 and colony-stimulating factor 1 
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receptor, thus allowing external stimuli to initiate internal signalling pathways (Stover 
et al., 1996).  
Due to the wide range of proteins with which Src can interact, along with the variety of 
cell mechanisms which Src can activate, Src has been described as a “signal-transduction 
hub” co-ordinating intracellular responses to extracellular stimuli. Some examples of 
these cell mechanisms can be seen in figure 1.13 and a selection will be discussed here. 
 
Figure 1.13 Examples of the signalling pathways in which Src plays a pivotal role including cell adhesion, 
receptor tyrosine kinase signalling and the Akt pathway leading to downstream events such as 
angiogenesis and inflammation. Taken from (Zhang and Yu, 2012). 
 
Src is able to regulate the cell cycle and proliferation by suppressing regulators such as 
p27KIP1, otherwise known as cyclin-dependent kinase inhibitor 1B, which prevents 
activation of cyclinE-CDK2 or cyclinD-CDK4 complexes, retaining cells in the G1 phase 
and preventing cell division (Riley et al., 2001). Additionally, in normally quiescent cells, 
signalling downstream from Src can induce the expression of cyclins D1, E and A which 
progress cells through the S and G2 phases of cell division. In addition to regulating cell 
proliferation, Src protects cells from apoptosis by activating anti-apoptotic signalling 
proteins such as PI3K and ERK1/2 (Johnson et al., 2000).  
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Cell-cell adherens junctions and cell matrix focal adhesions can also be negatively 
regulated by Src signalling via the redistribution of component proteins including FAK, 
cadherins and catenins (Fincham and Frame, 1998; Sheppard, 2000), thus destabilising 
focal adhesions and the suppression of E-cadherin localisation to adherens junctions 
(Serrels et al., 2009).   
Negative regulation of cell adhesion by Src is complemented by the roles Src plays in the 
promotion of cell migration. Firstly, Src can promote the expression of cortactin through 
interactions with FAK (Kanner et al., 1990). Cortactin promotes migration by recruiting 
Arp2/3 complex proteins to the actin filaments, stabilising nucleation sites for actin 
branching within the cytoskeleton at the leading edge of migrating cells. These form 
invadopodia and facilitate cell migration (Chan et al., 2009; Weaver et al., 2001).   
A final example of the diverse functions of Src is that of angiogenesis. Src can regulate 
VEGF expression via STAT3 thus increasing migration of endothelial cells, mitosis of 
endothelial cells, MMP activity and αvβ3 expression thus creating fenestrations and 
blood vessel lumens and the generation of new blood vessels (Cheranov et al., 2008). 
The interaction of ADAM15 and Src has been shown to be important in conferring the 
ability of ADAM15 to initiate shedding of FGFR2iiib. ADAM15 variants A and B were 
compared for their ability to shed FGFR2iiib (Maretzky et al., 2009a). While Cos7 cells 
transfected with ADAM15 A displayed an increased ability to shed FGFR2iiib when 
compared to a proteolytically inactive mutant, ADAM15 B showed even higher levels of 
shedding ability, despite equal protein expression levels of each variant. This effect was 
confirmed as direct as knocking out ADAM9, which can also shed FGFR2, had no effect. 
The interaction of ADAM15 with Src was shown to be necessary for this shedding to 
occur as inhibiting Src with dasatinib or PPI reduced the ADAM15 B dependent shedding 
of FGFR2 in a dose-dependent manner. When repeated in Src -/- mouse embryonic 
fibroblasts (mEFs) the shedding of FGFR2 was comparable for both ADAM15 variants A 
and B. Also, if tyrosine 735 of ADAM15 B was removed, it was not possible for Src to 
activate ADAM15 mediated shedding. If this tyrosine residue was removed, the 
shedding ability of ADAM15 B was reduced to the levels of ADAM15 A. 
 
55 
 
Src in Cancer 
All of the cell mechanisms in which Src plays a role, as discussed above, are deregulated 
in cancerous cells which heavily implicates Src in the development of cancer. As with the 
functions of Src, these are too varied to discuss in full here but a few examples will be 
considered focusing particularly on the role of Src in breast cancer. 
Elevated Src levels have been observed in glioblastoma (Kleber et al., 2008) and cancers 
of the prostate (Posadas et al., 2009), pancreas (Fu et al., 2006), lung (Mazurenko et al., 
1992) and breast (Verbeek et al., 1996), with some cancers demonstrating increased 
activity of Src with normal protein levels and others demonstrating increased protein 
levels (Cartwright et al., 1989). Higher expression of Src has been correlated with 
malignancy, especially in tumours with a high metastatic potential, with expression 
being inversely correlated with proliferative stage, size and grade of tumour (Boyer et 
al., 2002). For example, increased expression of Src correlates with progression of 
colonic polyps to primary lesions and liver metastases and indicates a poor prognosis in 
colon carcinoma (Talamonti et al., 1993).  
The impact of Src expression on breast cancer has been shown to be varied and 
important. High expression levels of Src have been linked to a poor prognosis for 
patients with metastatic disease. In Src-null mice and cell lines, MAPK signalling is no 
activated in response to estrogen (Kim et al., 2005a). Breast cancer cell lines with 
increased expression of EGFR and Src also exhibit increased phosphorylated Shc, 
activation of MAPK and tumorigenicity compared to those cells that either do not 
overexpress EGFR or only overexpress Src (Biscardi et al., 1998).  Additionally, EGF-
induced DNA synthesis is dependent on the kinase domain of Src being functional in 
some breast cancer cell lines (Wilson et al., 1989).  
The phosphorylation state of Src in tumours also impacts upon the survival of breast 
cancer patients. Patients with high cytoplasmic expression of Src phosphorylated at 
Tyr215 displayed a significant survival advantage compared to those possessing high 
levels of the autophosphorylated, constitutively active, Tyr419 phosphorylated, 
membrane bound Src. This constitutively active form of Src is the form expressed in 
triple negative tumours, those tumours that do not express either the ER, PgR or HER-2 
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receptor and have a significantly poorer prognosis due to a lack of effective treatments 
(Kanomata et al., 2011). 
Finally, Src is used as an independent predictor of disease specific survival of breast 
cancer that has metastasised to the bone (Zhang et al., 2009). Deficient bone 
remodelling is prevalent in Src- null mice leading to osteoporosis (Soriano et al., 1991). 
Osteoclasts with disrupted Src expression suffer from reduced migration leading them 
to be unable to form ruffled membranes. Mice infected with MDA-MB-231 breast cancer 
cells with constitutively active Src suffered from increased osteolytic bone metastases 
(Zhang et al., 2009). 
 Src as a therapeutic target 
Although Src has several functional roles in the promotion of cancer progression, this is 
due to its normal role in a number of pathways commandeered within cancerous cells 
and not due to it being a primary driver of tumourigenesis. It is very rare for mutant 
forms of Src to exist; involvement is primarily due to overexpression or constitutive 
activation rather than mutation. As such, monotherapy targeting of Src is unlikely to be 
successful in treating cancer but it does make Src an appealing target as an auxiliary 
treatment to current therapies (Roskoski, 2015).  
Due to the strong sequence homology within the Src Family Kinases, there are no Src-
specific treatments currently under trial in the clinic, with those drugs being tested 
targeting a range of similar proteins at once. Those already approved for medical use by 
the United States Food and Drug Administration (FDA) are for use in hematologic 
cancers such as chronic myelogenous leukaemia (CML) and acute lymphoblastic 
leukaemia (ALL) and are currently in clinical trials in a number of solid tumours, with the 
exception of vandetanib which has been approved for medullary thyroid carcinoma. 
Such drugs include Bosutinib which targets BCR-Abl, Src, Lyn and Hck, amongst others, 
which is in trials for breast cancer and glioblastoma (Puls et al., 2011). Dasatinib targets 
BCR-Abl, Src, Lck, Fyn, Yes and PDGFR and is in trials for breast cancer and other solid 
tumours along with ALL (Araujo and Logothetis, 2010). Ponatinib targets all Src family 
kinases along with BCR-Abl, PDGFR and VEGFR (Cortes et al., 2013). Saracatinib (Laurie 
et al., 2014) and AZD0424 (Nowak et al., 2007) are more specific, only targeting Src and 
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BCR-Abl and are not yet approved for use but as in trials for a range of solid tumours. All 
of these target the glycine-rich loop, containing a GxGxΦG, which is very mobile and acts 
as a lid to the ATP binding pocket of the kinase domain, and thus act as ATP-competitive 
inhibitors (Johnson et al., 2001). AZD0530 is a selective inhibitor of Src and Abl and 
blocks Src phosphorylation and has been shown to be effective against ER positive 
breast cancer cells in vitro (Herynk et al., 2006). All of these drugs are designed to 
enhance chemosensitivity and complement endocrine therapy.  
These treatments have also been considered as an option for treating triple negative 
breast cancers which are difficult to treat as they exhibit high levels of constitutively 
active Src (Herynk et al., 2006). Similarly, these drugs have shown some potential when 
combined with bisphosphates in patients with breast cancer that has metastasised into 
bone (Zhang et al., 2009).  
Unfortunately, there are no suitable biomarkers with which to identify which tumours 
would benefit from treatment involving specific Src inhibitor therapies. 
 
1.4.3 Breast Tumour Kinase, Brk, also known as Protein-Tyrosine Kinase 6 
(PTK6) 
Brk is a non-receptor tyrosine kinase with an ancestral connection to the Src family 
(D'Aniello et al., 2008). It is encoded by a gene at locus 20q13.3 (Park et al., 1997) 
downstream from promoters sensitive to NFκB and SP1 (Kang et al., 2002). The full 
length 451 amino acid protein has a similar structure to that of Src but lacking the 
myristoylation site, demonstrating a functional divergence from members of the Src 
family kinases such that Brk is a cytoplasmic, rather than membrane-bound, protein and 
containing an SH3 domain, an SH2 domain and a protein kinase domain (Lee et al., 1998). 
It exists in two splice variants, one of which excludes exon 2 of 8 thus removing the SH2 
and protein kinase domains and introducing a novel C-terminal region (Mitchell et al., 
1997). Activation of Brk also follows a similar pathway to that of Src whereby the 
phosphorylated Tyr447 residue binds to the SH2 domain and stabilises interactions 
between a linker region and the SH3 domain, rendering the protein inactive and 
requiring a phosphatase enzyme to activate (Derry et al., 2000). It also contains 
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phosphorylation sites at tyrosines 13, 61, 66, 114, 342 and 351. Tyr342 exists within the 
kinase activation loop and phosphorylation of this residue has been shown to increase 
catalytic activity of the enzyme (Qiu and Miller, 2002). Brk is expressed in healthy, 
differentiated epithelial cells of the intestine (Vasioukhin et al., 1995), skin (Wang et al., 
2005), prostate (Lee et al., 1998) and oral epithelium (Petro et al., 2004). Despite the 
protein’s early links to breast cancer, it is only expressed in cancerous breast tissue. In 
healthy mammary glands and ovary tissue, expression levels of Brk are very low to 
undetectable (Mitchell et al., 1994). 
Functions of Brk 
Brk has been shown to be able to phosphorylate a number of proteins, although some 
have not yet been confirmed to be substrates in vitro. Most of these potential substrates 
are involved in the EGF signalling pathway and include the RNA-binding proteins Sam68, 
SLM-1, SLM-2 and PSF, the transcription factors STAT3 and STAT5a/b and signalling 
proteins p190RhoGAP, paxillin, Akt, IRS-4, BKS/STAP1 and KAP3A (Ostrander et al., 
2010). These substrates link Brk to multiple downstream mechanisms, the most 
prominent of which include epithelial cell differentiation, migration and apoptosis.  
In the skin and intestinal tissues, Brk functions as an inducer of cellular differentiation in 
both normal and cancerous cells. Increased levels have been observed in differentiating, 
non-dividing epithelial cells. In human and mouse keratinocytes, differentiation was 
induced by Brk expression and was required for expression of Keratin 10 and filaggrin, 
epidermal differentiation markers (Vasioukhin and Tyner, 1997; Wang et al., 2005). Brk 
is also required for the transcriptional activity of STAT3 and STAT5a/b via their 
phosphorylation on Y705 and Y694/699 respectively which can, in turn, promote 
differentiation (Liu et al., 2006; Weaver and Silva, 2007).  
Activation of Rac1 signalling has also been linked to Brk expression (Chen et al., 2004). 
Phosphorylation of the substrate paxillin at tyrosines 31 and 118 creates binding sites 
for CrkII can activate cellular migration via Rac1 signalling particularly in skin cell lines 
and breast cancer cell lines (Petit et al., 2000). Heregulin (HRG)-induced Rac1 activity is 
dependent on Brk expression as is HRG induced activation of p38MAPK and ERK5 
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(Ostrander et al., 2007). In mouse embryonic fibroblasts (MEFs), EGF induction of Brk is 
required for migration and proliferation (Shen et al., 2008). 
Brk in Cancer 
Despite low to undetectable levels of Brk in normal mammary tissue, Brk is highly 
expressed in 60 % of breast tumours and breast cancer cell lines (Mitchell et al., 1994) 
and in 86 % of invasive ductal breast cancer (Ostrander et al., 2007). It is also 
overexpressed in ovarian tumours despite no expression in normal ovary cells 
(Schmandt et al., 2006). Increased levels have additionally been documented in primary 
and metastasised colon tumours, head and neck squamous cell carcinoma, prostate 
tumours, B- and T- cell lymphomas and prostate tumours. Gene expression of Brk is also 
increased in lung, bladder, pancreatic and gastric cancers but the functions here are yet 
to be established (Brauer and Tyner, 2010).  
In U2OS human osteosarcoma cells, overexpression of Brk increases phosphorylation of 
PSF, thus reducing its RNA-binding ability, altering the subcellular location of PSF and 
inducing S-phase cell cycle arrest and reducing proliferation (Lukong et al., 2009). This is 
counter to the effect of overexpression of Brk in breast cancer, where proliferation is 
reinitiated in response by inducing expression of Cyclin E and reducing p27 and a 
transformed phenotype develops (Xiang et al., 2008).  
In addition to reducing proliferation in breast cancer, Brk plays a role in migration of 
tumour cells. T47D and MDA-MB231 breast cancer cell lines required Brk expression for 
a migratory response to EGF and heregulin-β1 in a kinase independent fashion (Castro 
and Lange, 2010). In BT20 cells, migration in transwell assays was induced by 
phosphorylation of KAP3A by constitutively active Brk (Lukong and Richard, 2008). 
Another Brk substrate, STAT5, encourages a proliferative signal in breast cancer cell 
lines.  
Mutation of Brk is relatively unusual in cancerous tissues. No specific mutations have 
ever been established in breast cancer (Mitchell et al., 1997). Some mutations have been 
found in RT-4 bladder and SW900 lung cancer cells lines and in 2.5 % of melanomas 
(Prickett et al., 2009; Ruhe et al., 2007). More common is gene amplification and 
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polysomy of chromosome 20 although the PTK6 gene is amplified to a much lower 
extent than that of ErbB2 (Aubele et al., 2009).  
Brk as a therapeutic target 
Due to the widely increased expression in such a large proportion of breast cancer cells, 
Brk is an attractive target for therapy, particularly as a cooperative partner in therapy. 
Altered sensitivity to targeted therapy correlates with Brk expression (Xiang et al., 2008). 
Inhibition of Brk expression leads to a 50 % suppression of proliferation in breast cancer 
cells in vitro (Harvey and Crompton, 2004). If this could be adapted to delay growth of 
secondary tumours that arise after primary treatment, it could lead to a significant 
improvement in patient prognosis.  
Currently, the primary focus of tyrosine kinase inhibitory drugs are small molecule 
inhibitors. An example of this is STI571 which targets a range of tyrosine kinases 
including Abl, Arg, Kit, PDGFR and BCR-Abl and is surprisingly well tolerated given its 
diverse inhibitory capabilities (Druker, 2002). Unfortunately, not all Brk function is 
kinase dependent. In fact, kinase inactivity in Brk in T47D cells actually promoted 
proliferation thus demonstrating that this may not be the most effective path in Brk 
inhibition (Harvey and Crompton, 2003).  
Alternatively, regulated protein-protein interactions are pivotal to Brk activities via its 
SH2 and SH3 domains. An example of this is the kinase-independent interaction with 
Sam68 (Src-associated substrate in mitosis of 68kDa), also known as KHDRBS1 (KH 
domain containing, RNA binding, signal transduction associated 1). Sam68 is an RNA 
binding protein with roles in post-translational regulation whose overexpression leads 
to a reduced tumour burden and lower metastasis. Brk inhibits Sam68 via 
phosphorylation and the interaction requires the SH2 and SH3 domains (Derry et al., 
2000). Blocking these domains could be a more successful path in the inhibition of Brk. 
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1.5 Nuclear Magnetic Resonance (NMR) 
Nuclear magnetic resonance (NMR) spectroscopy is used to study the structure of 
molecules by capitalising on a physical phenomenon whereby nuclei in a magnetic field 
can absorb and then re-emit electromagnetic energy, radiofrequency in the case of 
NMR. At equilibrium magnetisation, the nuclei will either align with the field, at low 
energy, or against the field at high energy (Hore, 1995a). The initial splitting of these 
energy states generated by the application of the magnetic field is known as the Nuclear 
Zeeman Effect (Levitt, 2009d). The NMR signal is generated by the perturbation of the 
nuclei from the ground state to a higher energy state via the application of a 
radiofrequency pulse and the electromagnetic radiation released as the nuclei relaxes 
to the ground state (Hore, 1995a). NMR requires the use of nuclei with a half-integer 
spin quantum number. Examples of such nuclei include 1H, 15N and 13C. As the 15N and 
13C isotopes account for such small percentages of the naturally occurring forms of these 
elements, any recombinant proteins produced for study by NMR must be isotopically 
labelled with magnetically active isotopes in order to be detected by NMR (Levitt, 
2009c).  
1.5.1 A Simple Pulse Sequence 
In order to perturb the nuclei into a high energy state, radiofrequency pulses are applied 
to the sample. A pulse sequence can be thought of as the program that is used by the 
spectrometer to describe when to apply a pulse, at which frequency, the length of the 
pulse, the length of time delays and the detection time. A simple pulse sequence 
combines a series of pulses with time delays (Levitt, 2009b), a schematic diagram of 
which can be seen in figure 1.14. Initially there is a delay during which equilibrium 
magnetisation is reached which is known as the relaxation delay and indicated in the 
figure as tr. A radiofrequency pulse, close to the appropriate resonant frequency of that 
nucleus, is then applied in order to disturb the population equilibrium magnetisation 
away from the ground state into a high energy state. A free induction decay, FID, which 
is the fluctuating signal generated by the relaxation of the nuclei to their ground state, 
is generated and acquired during the acquisition time, tacq. This sequence is repeated 
many times over and the resulting FIDs are added together. This is called time averaging 
and increases the signal-to-noise ratio (Becker, 1999). As the signal is consistent, the 
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accumulation of the signal is much stronger than that of the cumulative noise, which is 
random and adds together very slowly. Thus the difference between the signal and noise 
is increased and the signal is more obvious. 
 
Figure 1.14 A basic pulse sequence and the resulting FID acquired. 
 
Now that an FID has been acquired, conversion to a useable spectrum is required. The 
acquired FID is first digitised by the spectrometer software, in this case Topspin. The 
signal is sampled as regular time intervals and the size of the signal is stored. These 
digital points from the FID are then submitted to a fourier transformation. This 
mathematical process multiples the FID by cosine waves of different frequencies. The 
net area under the resulting curve calculated is the height of the peak at that 
wavelength. This is repeated for all frequencies across an appropriate range. If there is 
no net area under the curve then there is no peak at that frequency (Keeler, 2006). This 
results in a spectrum with peaks given in terms of frequency. As these frequencies will 
vary depending on the size of the magnetic field and the radiofrequency of the 
spectrometer used, to allow comparison of data from different spectrometers, the 
chemical shift scale is used. An example of the type of spectrum produced by a one-
dimensional 1H NMR experiment is shown in figure 1.15. 
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Figure 1.15 1H spectrum of unlabelled C-terminal SH3 domain of Grb2. Each peak represents nuclei in a 
different environment thus giving a specific chemical shift. 
 
1.5.2 Chemical Shift  
If atoms were bare nuclei, each nuclear isotope type would give rise to a single narrow 
peak reflecting the resonant frequency of that isotope in that magnetic field. However, 
electrons are magnetic particles and thus bring about a local magnetic field which can 
add or subtract from the external magnetic field (Levitt, 2009a). This can affect the local 
environment of the nucleus in question and thus change the chemical shift of a peak for 
that nucleus in a diamagnetic material. Additionally, if a molecule is considered, the 
presence of other magnetic spins within the same molecule and their magnetisation also 
contribute to the local magnetic field and affect the emitted frequency of the nuclei 
relaxing to ground state. As such, nuclear magnetic signals can reveal the electronic and 
nuclear environment of the observed spins. The emitted frequency of a given nucleus is 
proportional to the local value of the magnetic field, thus depends on the location of a 
nucleus in the molecule and the details of the local electronic structure and is referred 
to as the chemical shift, δ (Hore, 1995b). Due to this being field dependent, the 
frequency value for a chemical shift will depend on the spectrometer used to detect it. 
In order to remove field dependency from the spectrum, an alternative scale, which uses 
the difference in the frequencies of the peak in question and that of a reference nucleus 
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(which has a very consistent chemical shift) thus normalising the scale and is quoted in 
parts per million. The equation used to calculate the chemical shift, δ, using this scale is 
as follows: 
𝛿 = 106
(𝜈−𝜈𝑟𝑒𝑓)
𝜈𝑟𝑒𝑓
    (Equation 1) 
Where ν is the frequency of the sample nucleus and νref is the frequency of the reference 
nucleus in that field (Hore, 1995b). 
 
1.5.3 Two-Dimensional Pulse Sequences 
Two-dimensional pulse sequences, such as that used in heteronuclear single-quantum 
coherence (HSQC) experiments in this thesis, follow a general scheme as shown in figure 
1.16 (Keeler, 2006). The sample magnetisation is allowed to reach thermal equilibrium 
before a preparation phase, during which the sample is excited by one or more pulses. 
An evolution time, t1, follows, during which the magnetisation is allowed to evolve prior 
to a mixing time containing further pulses. Finally the signal is recorded as a function of 
the second time variable, t2. 
A two-dimensional data set involves repeating the pulse sequence with increasing 
values of t1 and recording the FIDs as a function of t2 for each value of t1.  
 
 
Figure 1.16 General schematic of two dimensional NMR experiments. Adapted from Understanding NMR 
Spectroscopy, James Keeler, Lecture 7, 2004 (Keeler, 2006). 
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The pulse sequence for the HSQC, as can be seen in figure 1.17, is a complicated two-
dimensional pulse sequence which can be used for studying large molecules such as 
proteins. The pulse sequence has been divided into three periods and affects the two 
spins (I and S) which are bonded to each other. Period A is the preparation stage for this 
pulse sequence where magnetisation is transferred from the I nucleus to the S nucleus. 
Period B is the evolution time and includes a pulse applied exclusively to the I nucleus in 
order to refocus its offset meaning that only the offset of the S nucleus affects the 
evolution of the coupling. Then in Period C, the mixing time, the magnetisation is 
transferred back from the S spin back to the I spin where it is then detected (Keeler, 
2006). A two-dimensional Fourier transform is then applied to the acquired FIDs.  
 
Figure 1.17 Example of a HSQC pulse sequence divided into three periods. Adapted from Understanding 
NMR Spectroscopy, James Keeler, Lecture 7, 2004 (Keeler, 2006). 
 
As t1 is incrementally increased with each repetition of the HSQC pulse sequence, an FID 
for each increment is acquired in t2 but these are each slightly out of phase with each 
other. If each t2 FID is individually Fourier transformed, the peaks calculated would have 
the same chemical shift but vary in intensity and whether they are positive or negative. 
A schematic of this effect is shown in figure 1.18. The amplitude of the resonance signal 
varies periodically as a function of t1 and this amplitude also have a frequency. When 
this frequency is Fourier transformed, the subsequent chemical shift is for the second 
dimension (Levitt, 2009e).  In the case of the HSQC pulse sequence above, the Fourier 
transforms of the t2 FIDs calculate the chemical shift in the I dimension as it is this 
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nucleus on which magnetisation is detected. The chemical shift of the S dimension is 
calculated from the frequency of the I dimension signal variation for the chemical shift 
in question, representing the evolution of coupling during the t1 period on the S nucleus. 
In the case of the proteins, I is the 1H nuclei and S is the 15N nuclei. 
 
Figure 1.18 Fourier transformed peaks for a given chemical shift calculated from the t2 FIDs from a HSQC. 
The frequency of the amplitude variation of these peaks is Fourier transformed to give the other 
dimension of the two-dimensional spectra. This second dimension is a function of t1 (Levitt, 2009e).  
 
The [1H-15N]-HSQC experiments conducted in this thesis will give rise to a peak for every 
NH bond within the sample. In the case of a protein, most of these peaks will correspond 
to the NH bond within the backbone of the peptide chain for each amino acid in the 
chain. There are some exceptions to this. For example, proline residues within a peptide 
chain do not have an NH bond to detect. Additionally, some peaks on the spectrum will 
account for the NH bonds that exist within the side chains of certain amino acids such 
as tryptophan and glutamine. As the chemical shift of a peak is dependent on the 
environment of the nuclei in question, these spectra can be considered a “fingerprint” 
of the protein in question. 
 
1.5.4 Triple Resonance Experiments 
The triple resonance experiments discussed here work in a similar fashion to two-
dimensional HSQC experiments by transferring magnetisation between nuclei via 
covalent bonds such that structural information can be determined. The two 
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experiments used within this thesis are the HNCACB and the CBCACONH which can be 
used along with HSQC spectra to assign the backbone of a protein. 
Triple resonance experiments are possible due to the large single bond heteronuclear 
couplings between carbon, nitrogen and hydrogen residues within a protein meaning 
magnetisation transfer times are shorter and there are fewer losses due to relaxation. 
Also, the chemical shift of Cα nucleus and that of the CO nucleus within a peptide 
backbone are sufficiently different for it to be possible to manipulate their 
magnetisation independently (Ikura et al., 1990).  
The nomenclature for triple resonance experiments indicates the magnetisation 
pathway. For example, when considering the current residue, i, and the previous 
residue, i-1, the HNCACB experiment follows the transfer of magnetisation from the 1HN 
through the 15NH through the 13Cα to the 1Hα and 1Hβ and back again to the 1HN for 
detection. Transfer can occur through the 13Cαi-1 to both the 15Ni-1 and 15Ni (Grzesiek and 
Bax, 1992b). Thus for each NH chemical shift, there will be signal for the Cαi, Cαi-1, Cβi 
and Cβi-1 but, as the Cα and Cβ chemical shifts evolve simultaneously, they exist in the 
same dimension. Figure 1.19 B shows a similar schematic for the CBCACONH 
experiment. This experiment begins with the 1Hα and 1Hβ of the i-1 residue transferring 
their magnetisation energy to the appropriate 13C (Grzesiek and Bax, 1992a). But from 
here, the magnetisation is transferred to the CO. The magnetisation is transferred 
through this carbon to the 15Ni and then the 1HNi residue for detection. Thus the shifts 
for the Cα and Cβ residues from the i-1 residue are viewed from the i perspective.  
 
Figure 1.19 A) Schematic of the magnetisation transfer pathway for the CBCANH experiment, an analog 
of the HNCACB, which correlates the same atoms. B) Schematic of the magnetisation transfer pathway 
for the CβCαCONH experiment (Highman, 2012).  
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 As such, the HNCACB will have peaks for the 13Cα and 13Cβ nuclei from the perspective 
of the 15NHi and 15NHi-1. For each nitrogen and hydrogen shift, there will be 4 peaks in 
the carbon dimension (apart from glycine residues which have no Cβ and proline which 
will have no shift at all as they have no 1HN to be detected through). The CBCACONH 
spectrum will have 13Cα and 13Cβ peaks from the perspective of 15NHi-1 only. When these 
are overlaid, those peaks which appear in both the HNCACB and CBCACONH are those 
for the 13Cα and 13Cβ from the i-1 residue and those that only appear in the HNCACB are 
those for the i residue (Highman, 2012).  
 
Figure 1.20 Three strips showing the overlaid spectra of a HNCACB and a CBCACONH at the same hydrogen 
and carbon chemical shifts but with different nitrogen shifts. The positive Cβ peaks in the HNCACB are 
shown in red and the negative Cα in purple. The CBCACONH peaks are showing in green. Adapted from 
Protein NMR: A Practical Guide, (Highman, 2012).  
 
Given that the carbon chemical shifts for the Cα and Cβ nuclei for each amino acid are 
characteristic within a certain range (with some limitations), it is possible to deduce the 
type of amino acid the peaks in a given strip represent. Those Cα and Cβ peaks within a 
strip that are present on both HNCACB and CBCACONH spectra correspond to the 
previous residue to i. If Cα and Cβ peaks with the same carbon chemical shifts from the 
initial strip, but different hydrogen and nitrogen shifts, can be found only on the 
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HNCACB, these peaks in the new strip will correspond to the i-1 amino acid but now this 
residue can be considered as i. These amino acids are connected within a peptide 
sequence and the type of amino acid of this second residue can be deduced as before 
as can be seen in figure 1.20. Once a small chain of connected residues has been 
established, this can be linked to the amino acid sequence of the protein in question and 
the specific residue of that type can be assigned (Highman, 2012). This system can be 
used in tandem with [1H-15N]-HSQC experiments to assign the backbone of a protein.  
 
1.5.5 Using NMR Titrations to Study Protein-Protein Interactions 
As discussed in 1.5.3, the chemical shift of an NH peak in a HSQC spectrum is dependent 
on the environment of the nuclei within that bond and is affected by other nuclei within 
the environment of the nitrogen and hydrogen in question. So, if this environment is 
changed, the chemical shift for the NH bond on the HSQC spectrum will also change. The 
environment of the nuclei can be changed in in several ways, for example, if the 
conformation of the protein changed and new local bonds are formed (Williamson, 
2013). Here, this principle will be used to study which residues from one protein are 
involved in an interaction with another protein. When a second protein is introduced, 
those residues most affected by any interaction will find their environment changed and 
thus their chemical shifts will change as the concentration of the ligand protein increases 
until the interaction is fully saturated at which point the chemical shift will settle. An 
example of this can be seen in figure 1.21 (Garner et al., 2011). The magnitude of the 
peak movement can be quantified and used to establish which residues are involved in 
any interaction which can be mapped onto a model of the protein. 
This also profits from the requirement for half integer spin quantum number isotopes 
for detection by NMR. If both proteins were detectable via NMR, peaks accounting for 
the increasing concentration of the ligand protein would appear on the spectrum 
making reliable assignment much more difficult. However, if the target protein is 
isotopically labelled and the ligand protein is not, only the target protein will be detected 
during the titration. This means that the effect of the increasing concentration of the 
ligand protein will be observed but the actual ligand protein itself will not (Williamson, 
2013). In order to produce a full model, the titration would be repeated but with the 
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previous ligand protein now isotopically labelled and the previous target protein 
undetectable.  
Figure 1.21 Example of chemical shift perturbations in a [1H-15N]-HSQC showing 15N labelled ubiquitin in 
green and again in the presence of the unlabelled Znf216 A20 domain at a ratio of 1:1 in red. Highlighted 
are the residues which are perturbed to the greatest extent by the interaction. Taken from (Garner et al., 
2011).  
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1.6 Aims of this Project 
 
As discussed in this chapter, the ADAM15 splice variants have been linked to different 
prognoses in early stage breast cancer. This reasons for this are unclear but this could 
be due to the ADAM15 splice variant intracellular domains interacting with various SH3 
domain containing proteins in a preferential manner. Several of these SH3 domain 
containing proteins have been independently linked to breast cancer disease 
progression and so these provide a potential mechanism for the influence of the 
ADAM15 splice variants on breast cancer development.  
To this end, this project will investigate the interactions of the ADAM15 ICDs with the 
SH3 domains of Grb2, Src and Brk in order to attempt to establish the source of the 
preferential binding and potentially the biological relevance of these interactions. This 
will be achieved by pull down assay and NMR spectroscopy. This will require the 
optimisation of the purifications of the SH3 domains, altering the ADAM15 ICD fusion 
tag in order to retain solubility and tumbling rate for NMR and the optimisation of the 
purification of the ADAM15 ICDs. NMR spectroscopy titrations will be used to attempt 
to establish the binding interfaces and any variation is the interaction pattern or 
intensity between the SH3 domains and the various ADAM15 ICDs. 
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Chapter 2: Materials and Methods 
 
2.1 Materials 
Table 2.1 lists the suppliers for the chemicals used in this thesis. 
Table 2.1 Suppliers for the chemicals used in this thesis. 
Reagent/Chemical Source
Tryptone Fisher Scientific (BP9726-5)
Yeast Extract Oxoid (LP0021)
NaCl Fisher Scientific (BP358-212)
Agar Bacteriological Oxoid (LP0011)
Ampicillin sodium Formedium (AMP100)
Kanamycin Monosulphate Formedium (KAN0025)
Chloramphenicol Fisher Bioreagents (10255203)
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Sigma-Aldritch (I6758-5G)
Na2HPO4 Sigma-Aldritch (255793)
NaH2PO4.7H20 Sigma-Aldritch (S9638)
KH2PO4 Fisher Scientific (P285)
NH4Cl Fisher Scientific (A661)
MgSO4 Fisher Scientific (M65)
CaCl2 Fisher Scientific (C614)
FeSO4.7H20 Acros Organic (201390051)
13C glucose Sigma-Aldritch (389374)
glucose Fisher Scientific (10141520)
15N NH4Cl Sigma-Aldritch (299251)
KCl Fisher Bioreagents (BP366)
Tris base Fisher Scientific (BP152)
Sodium Dodecyl sulphate (SDS) Fisher Bioreagents (BPE166-5)
beta-mercaptoethanol Gibco (21985-023)
Bromophenol Blue Sigma-Aldritch (B0126)
Instant Blue Stain Expedeon (ISB1L)
Methanol Fisher Scientific (A412)
Glacial cetic acid Fisher Scientific (A38SI)
Coomassie Brilliant Blue R250 ThermoScientific (20278)
PonceauS Electran (44083)
Bovine Serum Albumin (BSA) Fisher Scientific (BPE9701)
Polysorbate 20 (Tween-20) Promega ( H5151)
HEPES Fisher Bioreagents (BP310)
L-glutathione reduced Sigma-Aldritch (G4251)
Tetramethylethylenediamine (TEMED) ThermoScientific (17919)
Ammonium Persulphate Sigma-Aldritch (A3678)
Human alpha thrombin Enzyme Research Laboratories (HT 1002a)
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldritch (P7626)
Factor Xa Qiagen (33223)
Urea Fisher Scientific (BP169)
Imidazole Fisher Bioreagents (BP30550)
D2O Sigma-Aldritch (151882)
DSS ThermoScientific (PI-21555 )
NaN3 Fisher Chemical (S227I)
73 
 
2.2 Cell Culture 
2.2.1 Cell Culture of MCF-7 cells 
MCF-7 breast cancer cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 
media (with added L-glutamine) (Gibco) with 10% FCS (foetal calf serum) (Hyclone) with 
1000 units/ml penicillin and 1000 ug/ml streptomycin (Gibco). These were grown in 75 
cm2 tissue culture grade flasks at 37 °C with 5% (v/v) CO2. Twice a week, cells were 
passaged once they had reached 80-90% confluency using 0.25% Trypsin-EDTA (Gibco). 
 
2.2.2 MCF-7 Cell Lysis Protocol 
MCF-7 cells were cultured as above in 10 cm2 cell culture petri dishes for 5 days until 
they reached 90% confluency and numbered approximately 2 x 106 cells. The media was 
removed and the cells washed with 1 x PBS (phosphate-buffered saline: 137 mM NaCl, 
2.7 mM HCl, 2 mM KH2PO4, 10 mM Na2HPO4 pH7.4) followed by the addition of 1.5 ml 
of NP-40 buffer (50 mM Tris.HCl pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 10% glycerol, 1% 
NP-40 (Roche Applied Science) and 1 x protease inhibitors (Roche Applied Science). The 
cells were incubated on ice for 5 minutes, scraped from the surface, and incubated on 
ice for 2 further minutes. The suspended cells were pipetted into 1.5 ml eppendorf tubes 
and incubated on ice for a further 5 minutes. After micro-centrifugation at 14000 rpm 
for 15 minutes at 4 °C, the supernatant was kept on ice for further use and the pellet 
discarded. 
 
2.3 Bacterial Cell Cultures for Protein Purification 
 GST-tagged ADAM15 A-C constructs were generated by Dr Zaruhi Poghosyan (Zhong et 
al., 2008). GST-tagged ADAM15 D and E constructs were generated by Dr Christian Roghi 
(unpublished). These constructs were within a pGEX-5X1 plasmid with resistance to 
ampicillin. All GB1-tagged constructs were generated via the introduction of restriction 
sites at the end of the genes by Polymerase Chain Reaction (PCR), digestion of the gene 
from the pGEX-5X1 vector and ligation into the new vector using T4 ligase. These 
constructs were within a pSK-Duet01 plasmid with resistance to kanamycin (Iwai et al., 
2006), a plasmid map of which can be seen in figure 2.1. 
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Figure 2.1 Plasmid map for the vector pSKDuet01 as provided by (Iwai et al., 2006) highlighting restriction 
sites and the location of the His tag (upstream from the GB1 tag) and the site of the kanamycin resistance 
gene. 
 
2.3.1 Transformation of Bacterial Cells 
Due to the presence of human specific codons in the ADAM15 ICD sequence, a variant 
of BL21 (DE3) cells, Rosetta 2 (Merck Millipore) or an alternative variant, Codon + RP 
(Agilent Technologies), were used for any culture or transformation involving these 
constructs. Then 200 μl of calcium-competent Rosetta 2 cells were incubated, on ice for 
30 minutes with 2 μl plasmid DNA. The cells were heat shocked at 42 °C for 60 seconds 
in a water bath and returned to ice for 10 minutes and then 800 μl of 2YT broth (10 g 
tryptone, 10 g yeast extract and 5 g NaCl in 1 L water and autoclaved) was added and 
the cells were incubated for 1 hour at 37 °C, then microcentrifuged at 14,000 rpm for 1 
minute. Next 800 μl of the supernatant was removed, the cell pellet was resuspended 
in the remaining supernatant and this was plated on 2YT agar plates (2YT as previously 
with 15 g agar per litre) containing the appropriate antibiotic for the plasmid (ampicillin 
at 100 μg/ml for GST-tagged constructs and kanamycin at 50 μg/ml for GB1-tagged 
constructs) and coated with chloramphenicol at 35 μg/ml. The chloramphenicol was 
necessary to retain the Rosetta 2 plasmid which allows the translation of human specific 
codons. The plates were incubated overnight at 37 °C. The SH3 domain constructs were 
75 
 
transformed using a similar protocol but into BL21 (DE3) cells and were selected for 
using 100 µg/ml ampicillin. 
 
2.3.2 Protein Expression in 2YT 
Bacteria were transformed as described and a colony from the transformation was used 
to inoculate 100 ml 2YT containing kanamycin, or ampicillin, and chloramphenicol at 
working concentrations described previously. The culture was incubated overnight at 37 
°C, shaking at 200 rpm. This saturated culture was then added to 900 ml 2YT with 
kanamycin, or ampicillin, and chloramphenicol and incubated at 37 °C until the OD 
reached 0.6-0.8. At this point, the cultures were induced with 0.1 mM IPTG and returned 
to incubation for 4 hours, unless stated otherwise. After incubation, the cultures were 
centrifuged at 5000 rpm (Beckman rotor JLA 9.1000) for 15 minutes at 4 °C. The 
supernatant was discarded and the pellets were either frozen at -70 °C for further use 
or resuspended in 30ml of the correct buffer for the purification to follow, in the 
presence of protease inhibitors (Roche Applied Science EDTA-free protease inhibitor 
cocktail tablets). Once resuspended, the cells were sonicated using a Sonics Vibracell 
130 watt, 20 kHz sonicator for 2 minutes with an amplitude of 80%. This was repeated 
a further four times with 5 minute incubations on ice before each repetition. The lysate 
was clarified by centrifugation at 12000 x g 4 °C for 20 minutes (Beckman rotor JA 12). 
The pellet was discarded. Cultures for pull downs were performed as above but using 
500 ml 2YT rather than 1000 ml. 
 
2.3.3 Protein Expression in Minimal Media 
Bacteria were transformed as described and a colony from the transformation was used 
to inoculate 10 ml 2YT containing kanamycin, or ampicillin (and chloramphenicol if 
required) at the working concentrations described previously. The culture was 
incubated overnight at 37 °C, shaking at 200 rpm. The following morning, 8 ml of this 
culture was added to 100 ml enhanced MEM (6 g Na2HPO4, 3 g KH2PO4, 0.5 g NaCl, 1 g 
NH4Cl, adjusted to pH 7.2 and autoclaved, then added 13.33 ml 30% glucose, 1 ml 2 M 
MgSO4, 100 µl 100 mM CaCl2, 500 µl 20 mM FeSO4, 1 ml 1000x micronutrients solution, 
10 ml MEM Vitamin Solution 100x (Sigma)). This culture was incubated at 37 °C until it 
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was saturated; approximately 2 hours. The cells were collected by centrifugation in a 
sterile centrifuge flask at 5000 rpm (Beckman rotor JLA 16.250) for 10 minutes at 25 °C. 
The supernatant was discarded and the cells were resuspended in 10 ml fresh enhanced 
minimal media and added to the main 1000 ml MEM culture (if labelled protein is 
required, use 15N labelled NH4Cl or 13C labelled glucose). The culture was incubated at 
37 °C until an OD of 06.-0.8 had been achieved. The production of the protein in question 
was then induced with 0.1 mM IPTG. The cells were incubated at 37 °C for 4 hours, 
except for Brk and ADAM15 B which were incubated at 28 °C overnight. The cells were 
harvested by centrifugation at 5000 rpm (Beckman rotor JLA 9.1000) for 15 minutes at 
4 °C and the pellets were either frozen at -70 °C for further use or resuspended in 30ml 
of the correct buffer for the purification to follow, in the presence of protease inhibitors 
(Roche Applied Science EDTA-free protease inhibitor cocktail tablets). Once 
resuspended, the cells were sonicated for 2 minutes for four repetitions at 80% 
amplitude using a 130 watt, 20 kHz Sonics Vibracell with 5 minute ice incubations 
between each repetition. The lysate was clarified by centrifugation at 12000 x g 4 °C for 
20 minutes (Beckman rotor JA 12). The pellet was discarded. 
 
2.4 Protein Concentration Determination 
2.4.1 BCA Assays 
BCA assays rely on the change in valence state of copper in the presence of a protein in 
an alkaline environment. The protein chelates Cu2+ and reduces it to Cu1+. This then 
interacts with bicinchoninic acid (BCA) and generates a dark purple colour which absorbs 
at 562 nm in a linear correlation with protein concentration. Standards of bovine serum 
albumin (BSA) as provided by the BCA protein assay kit from Pierce Protein Research 
Products were made with concentrations of 2000, 1000, 500, 250, 125, 62.5 and 31.25 
µg/ml. Samples of MCF-7 lysate were diluted 1/5 and 1/10 with ddH2O and 20 µl of each 
sample and the standards was pipetted into the wells of a 96 well plate. A blank water 
sample was included and each sample was pipetted in duplicate. The BCA solution was 
made using 10 ml Solution A and 200 µl Solution B from the kit. Finally, 200 µl of this 
solution was added to each well and the plate was incubated for 30 minutes at 37 °C. 
After measuring the absorbance at 562 nm using a plate reader, the standards were 
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used to generate a standard curve from which the concentration of the MCF-7 lysate 
was calculated. 
 
2.4.2 Bradford assay 
This assay is based upon the interaction of Coomassie Brilliant Blue G-250 with proteins 
in a 1:1 fashion. The unbound form of Coomassie Brilliant Blue is dark red whereas the 
bound version is blue and absorbs at 595 nm. The increasing absorbance is proportional 
to the protein concentration. Standards were made as for the BCA assay and 5 µl of each 
was pipetted, in duplicate, into a 96 well plate, along with a water control. To each well, 
5 µl of blank affinity sepharose beads were added then 5 µl samples of sepharose bound 
to protein were pipetted into wells in duplicate and 5 µl water added to compensate for 
volume. Next, 250 µl Bradford Solution was added and the plate was incubated at room 
temperature for 5 minutes. After detection at 595 nm, the standards were used to 
generate a standard curve and, from this, the concentration of the protein bound to the 
sepharose was calculated as required for the pull down experiments. 
 
2.4.3 Beer-Lambert Law 
When calculating the amount of pure protein, the Beer-Lambert method was also used. 
The absorbance of the protein sample was taken at 280 nm (compared to a blank of the 
same buffer) and the Beer-Lambert law used to calculate the concentration. The 
extinction coefficients used were calculated based upon the amino acid sequence of the 
protein involved using the ProtParam Tool by ExPASy Bioinformatics Resource Portal 
(Gasteiger E., 2005). The Beer-Lambert Law equation is as follows: 
𝐴 = 𝜀𝑐𝑙     (Equation 1) 
Where A is the absorbance, ε is the extinction coefficient of the protein, c is the 
concentration of the protein and l is the path length of the sample. 
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2.5 Pull Downs 
2.5.1 GST-ADAM15 ICD Affinity Pull Downs 
GST-tagged ADAM15 ICDs, along with a GST tag control, were expressed in Codon + RP 
cells as described above. After sonication, the bacterial cell lysate (40ml) was incubated 
with 1 ml (500 μl beads in suspension) of glutathione sepharose slurry (Generon), which 
had been pre-equilibrated into 1 x PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.8 mM KH2PO4 pH 7.2) with protease inhibitors (Roche Applied Science EDTA-free mini 
protease inhibitor cocktail tablets) by washing 3 times with centrifugation at 1300 x g 
for 3 minutes. The slurry of beads and lysate was incubated at 4 °C overnight on a rocker 
and then the beads were collected by centrifugation at 1300 x g for 3 minutes. Once the 
beads were resuspended in 500 μl 1 x PBS with protease inhibitors, they were kept on 
ice. 
The concentrations of protein bound to the beads and total protein in the MCF-7 lysate, 
generated as described above, were determined by Bradford assay and BCA Assay 
respectively. 30 μg/ml of ADAM15 ICD bound to beads was added to MCF-7 lysate at 
1 mg/ml and mixed on a rotator at 4 °C for 1 hour. The beads were collected by 
centrifugation at 13,000 x g for 2 minutes at 4 °C and the supernatant removed and kept 
on ice. After the beads were washed as previously, with each wash kept on ice, they 
were resuspended in 100 μl SDS loading buffer (0.312 M Tris pH 6.8, 10% SDS, 25% β-
mercaptoethanol, 0.05% Bromophenol Blue) and 100 μl water and heated for 10 
minutes at 100 °C. These were then frozen at -20 °C.  
 
2.5.2 GST-SH3 Domain Affinity Pull Downs 
Each SH3 domain, along with a GST tag control, was expressed in a bacterial cell culture 
as described above. Once sonicated, the bacterial cell lysate (12 ml) was incubated with 
1 ml (500 µl beads in suspension) of glutathione sepharose beads (Generon). The beads 
had been pre-equilibrated into 1 x PBS by washing 3 times with centrifugation at 1300 x 
g for 3 minutes. The lysate and beads slurry were incubated at 4 °C on a rotator 
overnight, then centrifuged at 1300 x g for 3 minutes. The supernatant was removed 
and the beads were washed 3 times with 1 ml 1 x PBS and protease inhibitors by 
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centrifugation at 1300 x g for 3 minutes. The beads were then resuspended in 500 µl 
PBS with protease inhibitors and kept on ice. The concentration of protein on the beads 
was established by Bradford assay. The beads were then incubated with 1 ml bacterial 
cell lysate from Rosetta 2 cells that were over-expressing a GB1-ADAM15 variant. These 
cell lysates were generated as described above. After incubation for 1 hour at 4 °C on a 
rotator, this slurry was centrifuged at 1300 x g and the supernatant removed and kept 
on ice. The beads were washed as previously, with each wash kept on ice. Finally, the 
beads were resuspended in 100 µl SDS loading buffer and 100 µl water. This was heated 
to 100 °C for 10 minutes and frozen at -20 °C.  
 
2.5.3 His-GB1 Affinity Pull Downs 
These pull downs were achieved with the same protocol as for the GST affinity with 
some small changes. The initial incubation of the bacterial cell lysate with the beads 
involves an incubation of 1 hour rather than overnight. The beads used were Ni 
sepharose (Generon) which interact with the poly-His tag at the N-terminus of the GB1 
tag. Once the concentration of protein on the beads had been established by Bradford 
assay and a 10 cm2 dish of MCF-7 cells had been lysed per ADAM15 construct, the 
concentration of the protein in the MCF-7 lysate was established by BCA Assay. This was 
equalised to 1 ml of 1000 µg of MCF-7 protein per construct and aliquoted. 
Approximately 20 µl of beads was added to each 1 ml aliquot of MCF-7 lysate for each 
ADAM15 construct. The volume of beads required was adjusted for the concentration 
of ADAM15 on the beads based upon the results of the Bradford assay. After incubation 
for 1 hour at 4 °C on a rotator, this was centrifuged at 1300 x g and the supernatant 
removed and kept on ice. The beads were washed as previously, with each wash kept 
on ice, with one of the washes including 10 mM imidazole to remove any non-specific 
interactions of proteins from the bacteria or MCF-7 cells. 
 
2.5.4 IgG Affinity Pull Downs 
This protocol also followed a similar protocol to that of the His-GB1 affinity pull downs, 
again with a few differences. The IgG sepharose beads (Generon) were incubated with 
the bacterial cell lysate for 1 hour, as for the His-GB1 affinity. After washing, some beads 
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were then incubated with MCF-7 lysate, as for the His-GB1 affinity pull down. The beads 
were washed as previously and the beads resuspended in SDS loading buffer, heated to 
100 °C and frozen as previously.  
 
Once the pull down samples were prepared, they were separated by SDS gel 
electrophoresis. One gel was stained with Instant Blue stain in order to confirm the 
presence of ADAM15 constructs and that they were intact. The other was used for 
Western blotting in order to detect whether or not selected proteins were pulled down 
by the ADAM15 ICD. 
 
2.6 SDS PAGE Gel Electrophoresis 
Samples were prepared by dilution with SDS loading buffer and heated for 10 minutes 
at 100 °C. After microcentrifugation at 14,000 rpm for 1 minute, the desired volume was 
loaded onto a poly-acrylamide gel and separated at 180 V until the dye band had 
reached the bottom of the gel. The gel was then stained with either Instant Blue 
(Expedeon) or fixed with 10% v/v acetic acid for 30 minutes, stained for 1 hour in 
Coomassie Brilliant Blue stain (1% Coomassie Brilliant Blue R250, 20% v/v Methanol. 
10% v/v Acetic acid) and destained overnight in 10% v/v acetic acid and 50% v/v 
Methanol.  
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The gels were made as described in table 2.2: 
 Resolving Gel (ml) Stacking Gel 
(ml) 
 10% 12% 15% 5% 
dH2O 5 4.2 3 2.43 
Acrylamide 4 4.8 6 0.5 
Gel Buffer 2 3 3 1 
10% w/v APS 0.072 0.072 0.072 0.072 
TEMED 0.014 0.014 0.014 0.007 
 
Table 2.2 SDS-PAGE gel protocol. The table shows the volumes of each solution required to make each gel 
in millilitres. The gel buffers used were appropriate to the gel being made. For example, when making the 
resolving gel, the resolving gel buffer was used (181.5 g/l Tris, HCl pH 8.8, 4 g/l SDS in a 4 x stock solution) 
and for stacking gels, the stacking buffer was used (60.5 g/l Tris.HCl pH 6.8, 4 g/l SDS in a 4 x stock solution). 
All resolving gels used the same 5 % acrylamide stacking gel.  
 
The acrylamide used to make the gels is manufactured by Protogel (30 % w/v 
acrylamide, 0.8 % w/v bis-acrylamide stock solution 37.5:1) 
 
2.7 Western blotting 
Protein from the poly-acrylamide gel was transferred onto nitrocellulose membrane (GE 
Healthcare Amersham Hybond-ECL) via wet transfer at 25 V for 1 hour and 30 minutes. 
The membrane was temporarily stained with Ponceau Red in order to highlight proteins 
bands in order that the membrane could be cut to size. Once the Ponceau Red had been 
rinsed away with water, the membrane was blocked with 5% BSA in 1 x TBS (Tris 
Buffered Saline: 150 mM NaCl, 2 mM KCl, 25 mM Tris pH 7.4) with 0.1% Tween-20 for 1 
hour. The membrane was then incubated overnight at 4 °C in the same BSA/TBS solution 
containing the primary antibody at a dilution of 1:1000. The antibody used for detecting 
Src was #2108 by Cell Signalling and the antibody used for detecting Grb2 was #3972, 
also from Cell Signalling. The antibody for detecting the poly-His tag was #2365 by Cell 
Signalling. After this incubation, the membrane was washed 3 times in 1 x TBS with 0.1 
% Tween-20 for 10 minutes at room temperature with gentle shaking. Incubation with 
the secondary antibody was for 1 hour at room temperature with the same BSA/TBS 
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buffer as for the primary with gentle shaking. The secondary antibody used was goat 
anti-rabbit polyclonal HRP-linked immunoglobulin (Dako Denmark) for all primaries as 
they were all rabbit monoclonals. After incubation with the secondary antibody, the 
membrane was washed as previously. Finally, the membrane was developed with Pierce 
Protein Research ECL Western blotting Substrate. This membrane was imaged using a 
FujiFilm Intelligent Dark Box LAS-3000. 
 
2.8 SH3 Domain Purification 
2.8.1 GST Affinity Purification of Fusion Proteins 
BL21 (DE3) cells were transformed with the appropriate plasmid for the desired SH3 
domain. The SH3 domains of Grb2 and that of Src were expressed from pGEX-2T 
plasmids and the SH3 domain of Brk was expressed from a pGEX-3X plasmid. All plasmids 
contained resistance to ampicillin. If unlabelled protein was required, the cells were 
cultured as in the 2YT culture method described; labelled protein was produced using 
the Minimal Media protocol. After harvesting, the cells were resuspended in 30 ml of 
the appropriate buffer for the SH3 domain with protease inhibitors. For Grb2C/N and 
Src, this was 20 mM sodium phosphate, 0.15 M NaCl pH 7.2 (hereafter known as SPB or 
sodium phosphate buffer) and for Brk, this was 25 mM HEPES, 0.1 M NaCl pH 7.0. The 
cells were sonicated as described above and incubated on ice for 30 minutes. The lysate 
was clarified with centrifugation as previously. The pellet was discarded. Meanwhile, the 
glutathione sepharose beads (Generon) were equilibrated into the appropriate buffer 
by washing with ~ 40 ml water and 5 column volumes (CV) of buffer. The column volume 
used was 4 ml. Once the lysate had been clarified by centrifugation, it was syringe 
filtered through a 0.45 µm membrane and the beads were added to the lysate. The 
beads and lysate were incubated together overnight on a rotator at 4 °C or for 1 hour at 
4 °C in the case of Brk. Next, the lysate-beads mix was returned to the PD-10 column 
and the flow through was collected. The beads are washed 4 times with 10 ml buffer 
and each wash flow through was collected. The protein was eluted with 5 times 2 CV 
buffer with 300 mM glutathione. Each elution was collected separately. Gel samples 
were taken (20 µl), to which SDS loading buffer was added (20 µl) and they were then 
heated to 100 °C for 10 minutes and run on 15% SDS PAGE gels as described above. The 
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fractions shown to be containing the desired SH3 domain were kept on ice or frozen at 
-20 °C for further use. 
 
2.8.2 Thrombin Digestion 
The constructs for the C-terminal domain of Grb2 (known here as Grb2C), the N-terminal 
domain of Grb2 (known here as Grb2N) and the SH3 domain of Src contained a thrombin 
cleavage site (LVPRGSAMV) between the GST tag and the SH3 domain construct allowing 
the removal of the GST tag. The relevant fractions from the GST affinity column were 
combined and the amount of desired protein present was calculated using the Beer-
Lambert method as described previously. In order to establish how many units (based 
upon the activity) of thrombin was required to completely digest 1 mg of protein during 
the first purification, 1 ml of sample was incubated overnight with varying numbers of 
thrombin units per mg protein either at room temperature or at 4 °C. It was established 
that 5 units of thrombin would completely digest 1 mg Grb2C overnight at room 
temperature whereas 3 units was insufficient and 7 units was wasteful. For all further 
reactions, 5 units of thrombin was used per mg desired protein. Based upon the 
recommended resuspension of thrombin by the manufacturers (HT 1002a, lot 398L, 
Enzyme Research Laboratories), 1 unit of thrombin equates to 0.092 µl of solution. The 
required volume of thrombin was added to the sample and incubated overnight at room 
temperature. After incubation for approximately 16 hours, sample was run on a 15% 
SDS-PAGE gel as described above to confirm complete digestion. Upon confirmation, the 
digestion was ended by the application of 1 mM PMSF (phenylmethanesulphonyl 
fluoride). Following similar optimisation, Grb2N required 7.5 units of thrombin per 1 mg 
of protein and the Src SH3 domain required 5 units of thrombin. 
 
2.8.3 Factor Xa Digestion 
Unlike the other SH3 domains studied here, the GST tag was fused to Brk with a linker 
region containing a Factor Xa cleavage motif (IEGR). As with thrombin digestions, the 
amount of enzyme required to digest 1 mg of Brk SH3 domain was optimised and it was 
found that 7.5 units of Factor Xa is required to digest 1 mg of protein overnight at 37 °C. 
The fractions shown by SDS-PAGE to contain the GST tagged Brk were combined and the 
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protein concentration calculated using the Beer-Lambert law and thus the number of 
units of Factor Xa required was determined. This was incubated with the protein sample 
overnight at 37 °C and a sample taken the following morning and run on a 15% SDS-
PAGE gel. Upon confirmation of complete digestion, the digestion was stopped using 
PMSF as above. 
 
2.8.4 Spin Concentration of Protein Samples 
Spin concentration is the process by which the volume of a sample is reduced by 
centrifugation through a membrane with a specific molecular weight pore size while 
maintaining the protein amount, reducing the volume and thus increasing the 
concentration. Samples were spin concentrated at 4000 x g at 4 °C until the desired 
volume was achieved. The concentrators used for all proteins, other than the Brk SH3 
domain, were Vivaspin 6 or 20 (Sartorius), dependent on initial volume, with a molecular 
weight membrane cut off of 5000. In the case of Brk, Amicon Ultra-15 were used due to 
the Brk SH3 domain adhering to the polyethersulfone (PES) membrane of the Vivaspin 
concentrators. The Amicon concentrators use a cellulose membrane instead. The 
samples were centrifuged in 45-60 minute runs until the desired volume was achieved.           
 
2.8.5 Size Exclusion Chromatography for SH3 domain purification 
Samples were concentrated down to a volume of 2.5 ml and loaded onto a SuperdexTM 
75 (GE Healthcare) 330ml gel filtration column, pre-equilibrated with the appropriate 
buffer. This was run with a flow rate of 1 ml/min and 10 ml fractions were collected. 
20 µl gel samples were taken and treated as previously and separated with a 15% SDS-
PAGE gel as described previously. Once the fractions containing the SH3 domain, and 
not the GST tag, were identified in this manner, they were combined and the protein 
concentration calculated using the Beer-Lambert technique. The fractions were then 
dialysed into the appropriate NMR buffer using a dialysis membrane of MW limit 3000 
over the weekend at 4 °C. This was not necessary for the Brk SH3 domain as spectra 
were collected in the same HEPES buffer used during purification. Finally, the protein 
sample was concentrated to approximately 2 mM and frozen at -20 °C until used as an 
NMR sample. 
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2.9 ADAM15 ICD Purification 
2.9.1 Nickel Affinity Purification 
Rosetta 2 cells were transformed as described above and cultured following the 2YT 
protocol. After harvesting, the pellet was resuspended with 50 mM sodium phosphate, 
300 mM NaCl, 8 M urea (unless stated otherwise) pH 7.4 (hereafter known as IMAC 
buffer) with protease inhibitors (Roche Applied Science EDTA-free protease inhibitor 
cocktail tablets). The cells were sonicated as described and incubated on ice for 30 
minutes. The lysate was then clarified by centrifugation and filtering as previously 
described. The nickel sepharose gravity column (Ni-NTA sepharose, Generon) was 
equilibrated into IMAC buffer and the clarified lysate was applied to the column and the 
flow through collected. This step was repeated so that the lysate passed over the beads 
twice. The beads were then washed twice with 2 CV of IMAC buffer, with each wash 
collected separated. Next, the beads were washed with increasing concentrations of 
imidazole in IMAC buffer.  These concentrations of imidazole were 50 mM, 75 mM, 
100 mM, 150 mM, 200 mM and 500 mM unless otherwise stated. These washes were 
collected separately and gel samples were made from each elution as described 
previously. Those fractions containing the protein of interest were then dialysed into 
IMAC buffer in order to remove the imidazole and urea. The samples were then frozen 
at -20 °C until further use.  
 
2.9.2 Size Exclusion Chromatography for ADAM15 Purification 
The removal of impurities remaining after Ni-NTA Affinity purification was attempted 
using size exclusion chromatography. The protocol for this was the same as for SH3 
domain purification described previously but with the column pre-equilibrated into 
IMAC buffer (without urea) prior to use. 
 
2.9.3 Talon Affinity Purification  
As an alternative to Ni-NTA affinity purification, Talon (® GE Healthcare) affinity 
purification was attempted. This works under the same principle as Ni-NTA affinity but 
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uses Co2+ as the affinity ion. This has been shown to interact with poly-histidine tags 
with a higher specificity than Ni-NTA affinity and so was attempted to try to avoid the 
impurities which remained after Ni-NTA affinity. The lysate was prepared as previously, 
using a 2YT culture of the variant in question and sonicated and clarified as previously. 
The column and Äkta was pre-equilibrated into IMAC buffer with 8 M urea. The sample 
was loaded onto the 1 ml Talon column at 1 ml/min and then the column was washed 
with 20 cv of IMAC buffer in order to achieve a stable baseline. The protein was eluted 
with a gradient over 20 cv at 1 ml/min with the concentration of imidazole increasing 
over that gradient from 0 mM to a final concentration of 300 mM. Fractions of 1 ml were 
collected and gel samples prepared. Those fractions containing the protein were 
identified using a 15 % SDS PAGE gel and dialysed into IMAC buffer to remove the 
imidazole and urea. After dialysis, the sample was frozen at -20 °C until further use.  
 
2.10 Nuclear Magnetic Resonance  
2.10.1 NMR Sample Preparation 
All samples for NMR were concentrated using Vivaspin spin concentrators as above, 
having already been dialysed into the appropriate buffer (50 mM sodium phosphate, 
100 mM NaCl pH 7.5 for Grb2C, 50 mM Tris.HCl, 100 mM NaCl pH 8.0 for Grb2N and 
100 mM sodium phosphate, 100 mM NaCl pH 6.0 for the Src SH3 domain) until a volume 
of ~0.4 ml was achieved. Brk was studied in the same HEPES buffer as it was purified in 
and ADAM15 B was dialysed into the same buffer as used for the Src SH3 domain. The 
sample was transferred by pipette to a 1.5 ml eppendorf and made up to 0.5 ml with 
flow through from the concentration (i.e. the same buffer). The samples had been made 
to have a final concentration of 1 mM. To each sample, 50 µl D2O, 10 µl DSS and 10 µl 
NaN3 were added and the samples were transferred to 5 mm NMR tubes (PP535, 
Wilmad® or Norell® S-5-600-7).  
 
2.10.2 NMR Data Acquisition 
Spectra were acquired using a Bruker Avance I 500 MHz spectrometer with a 1H 
operating frequency of 499.6853512 MHz. This spectrometer uses a 5 mm inverse triple 
resonance (HCN) z-gradient probe. All spectra were acquired at 298 K. The spectra 
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acquired for backbone assignments were 15N HSQC, 13C HSQC, HNCαCβ and CβCαCONH. 
Spectral parameters are shown in Table 2.3.  
 
Table 2.3 Acquisition Parameters for NMR experiments at 500 MHz obtained 
Experiment 
Number of 
Scans 
Complex Points Spectral Width (Hz) 
1H 15N 13C 1H 15N 13C  
15N HSQC 16 1024 128  -  7507.587 1772.345  -  
HNCaCb 32 1024 128 32 6510.417 9425.719 1822.984 
CbCaCONH 32 1024 61 32 6510.417 9425.719 1822.984 
15N HSQC 
(long titration 
data points) 120-240 1024 64  -  7507.507 1772.345  -  
13C HSQC * 32 512  -  64 10416.67  -  33332.08 
* indicates that this experiment was acquired using the 800 MHz spectrometer 
 
The 13C HSQC was acquired at 298 K using a Bruker Avance III 800 MHz spectrometers 
with a 1H operating frequency of 800.2337599 MHz. This spectrometer uses a triple 
resonance inverse TXI probe with z- gradients.  
 
2.10.3 NMR Spectral Processing 
The NMRPipe software package (Delaglio et al., 1995) was used to zero-fill, linear 
predict, Fourier transform and phase all spectra acquired. The DSS standard in each 
sample was used to reference the respective proton, 13C and 15N chemical shifts using a 
script written in house by Dr James Tolchard.  
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2.10.4 Backbone Assignments 
Backbone assignments for Grb2C were provided by Prof John E. Ladbury via BMRB entry 
18748 (Lin et al., 2012). These were used to assign most residues using the CCPNmr 
analysis software package (Vranken et al., 2005). Any remaining assignments were made 
by using the i, i-1 connectivities observed with the HNCαCβ and CβCαCONH spectra. 
Backbone assignments for Grb2N were provided by Michael Wittekind et al (Wittekind 
et al., 1997), for Src by Hongtao Yu et al (Yu et al., 1993) and for Brk by Sunggeon Ko et 
al (Ko et al., 2009). 
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2.10.5 Titration Spreadsheets 
Samples A and B were prepared as indicated in the spreadsheets. Intermediate data 
points were achieved by the removal of the indicated volume from A and replacing with 
the same volume of B. 
Titrations with Grb2C 
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Titrations with Src 
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Titrations with Brk 
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Chapter 3: Studying the ADAM15 Intracellular Domains 
 
3.1 Introduction 
As discussed in chapter 1, the ADAM15 intracellular domain is encoded by exons 18-23 
of the ADAM15 gene with the splice variants involving exons 19-22 (Kleino et al., 2007). 
As shown in figure 3.1, ADAM15 A is missing exons 20 and 21 and is 97 residues long, 
whereas ADAM15 B is missing exon 21 and is 122 residues long. ADAM15 C is the longest 
ICD variant, at 145 residues long, as it includes all potential exons and thus all of the 
potential proline-rich regions that the gene translates to. ADAM15 D includes a 
frameshift at tyrosine 735 which is encoded for at the end of exon 18 and thus has no 
polyproline regions(Poghosyan, 2001). Additionally, exons 19-21 and 23 are spliced out 
of this variant rendering ADAM15 D as the shortest variant at only 56 residues. Finally, 
ADAM15 E excludes exon 20 and is 121 residues in total. The potential proline-rich 
regions available here include potential binding sites for SH3 domains whereby the 
ΦPpΦP motif (where Φ is a hydrophobic residue and p can be a proline) folds into the 
hydrophobic cleft of the SH3 domain and specificity is provided by the residues 
surrounding the motif (Kaneko et al., 2008). Due to the variations in behaviour displayed 
by cells overexpressing each ICD (Zhong et al., 2008), along with the correlation to 
differing prognoses in breast cancer patients (Zhong et al., 2008), and the prospective 
specificity of each ICD with different SH3 domains (Kärkkäinen et al., 2006; Kleino et al., 
2009; Zhong et al., 2008), it is of value to study how these splice variants behave with 
regards to their interactions with SH3 domains.  
Figure 3.1 Schematic showing the ADAM15 splicing locations and the proline-rich regions that they are translated to. 
Adapted from Zhong et al (Zhong et al., 2008). 
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Due to the high proportion of glycine, arginine, proline, serine, glutamine and glutamic 
acid residues within all of the ADAM15 ICDs, it has been predicted that the proteins are 
intrinsically disordered and lack consistent secondary structure. Although this renders 
NMR studies of the proteins more difficult, as intrinsically disordered residues have 
amide 1H chemical shifts between 8.0 and 8.5 ppm leading to overlapping peaks which 
can be more difficult to assign, it has been achieved in the past (Kosol et al., 2013). Any 
potential NMR studies are, however, complicated by the high number of proline 
residues present as these do not contain an N-H bond when in a peptide chain and so 
do not have a peak on a standard [1H-15N]-HSQC spectrum. When the importance of the 
proline residues with regards to interactions with any SH3 domains is considered, this is 
a significant hindrance although alternative pulse sequences can be used here instead. 
Additional problems arise due to the insolubility of the recombinant ICDs when not 
fusion-tagged to a more soluble protein as established by a previous summer project 
student in the lab, Alex Carey-Hulyer.  
 
3.2 Interactions of the SH3 domain-containing proteins with GST-tagged 
ADAM15 ICDs via GST Affinity Pull Down Assay 
Previously it has been shown by pull down assay that the ADAM15 ICD variants interact 
preferentially with different proteins that contain SH3-domains (Poghosyan, 2001). In 
these studies, the MDA-MB-435 cell line was used to provide the endogenous SH3 
domain proteins. To confirm that these results could be reproduced in the breast cancer 
MCF-7 cell line, these experiments were repeated. Since the publication of the previous 
pull down studies, it has also been shown that FAK can act as an intermediary in 
interactions between ADAM15 A and some SH3 domain containing proteins (Fried et al., 
2012) providing additional reasons for repetition of the assay, as FAK is present in MCF-
7 cells but not in MDA-MB-435 cells. Finally, there has been some debate as to the 
lineage of MDA-MB-435 cells recently due to their expression of melanocyte-specific 
markers along with the expected breast cell-specific markers. As other aggressive breast 
cancer cell line have shown similar expression profiles, it has been suggested that these 
lines did originate from breast tumours but have experienced some lineage infidelity 
(Sellappan et al., 2004).  
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A Bicinchoninic acid (BCA) assay was initially used to establish the total protein 
concentration of the MCF-7 cell lysate but unfortunately, the presence of the sepharose 
beads interfered with the reaction involved, rendering it not suitable. The Bradford 
assayAssay was chosen for this purpose as it is not sensitive to the presence of 
sepharose. Additionally, the first anti-Src antibody used was later discovered to be 
specific for an epitope of Src that is conserved across many members of the Src 
homology family including Lyn and Hck which are of a similar molecular weight to Src 
and thus could be contributing to the results for Src on a Western blot.  
 
 
Figure 3.2 SH3 domain-containing proteins pulled down from MCF-7 cell lysate by recombinant GST fusion 
ADAM15 ICD variants. Glutathione sepharose beads with no covalently bound protein was presented as 
a negative control. GST fusion ADAM15 ICD variants used as bait proteins as indicated. GST bound to 
sepharose without an ADAM15 ICD was used to indicate a lack of interaction between the tag and the 
SH3 domains directly. Src and Grb2 were detectable at endogenous levels from the MCF-7 lysate. 
A) Western blots probing for Src or Grb2. B) Equal loading of proteins confirmed by Coomassie Blue 
stained SDS-PAGE poly-acrylamide gels. 
 
Both Src and Grb2 were equally pulled down by all of the ADAM15 ICDs, as seen in figure 
3.2 which is, in the case of ADAM15 B and C, consistent with the results achieved in 
previous publications using MDA-MB-435 cells. However, Src was shown to interact with 
ADAM15 A here which is contrary to previous studies. This difference could be due to 
the presence of FAK in the lysate of MCF-7 cells acting as an intermediate in the 
interaction. These results are also consistent with data collected by Dr Christian Roghi 
through in cell localisation studies using proximity ligation studies (personal 
communication). Although this difference occurs, it is clear that the MCF-7 cells show a 
similar pattern of interactions to previous research and are of a more reliable breast 
cancer lineage so are suitable for continued use here. 
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3.3 Test Purifications of Recombinant GB1 Fusion Proteins 
As mentioned in section 3.1, the ADAM15 ICDs were found to be insoluble when the GST 
fusion tag, intended for purification purposes, was removed. Unfortunately, retaining 
the GST fusion tag for use in the later NMR studies was not feasible due to the large size 
of the final fusion proteins having too large a molecular weight and slow tumbling time 
to be practical. For this reason, the fusion tag used for purification purposes needed to 
be of a size small enough to be retained for the NMR titrations later. Due to its small size 
and consistent, clear [1H-15N]-HSQC spectrum, the immunoglobulin binding domain 1 of 
Protein G from group C and G Streptococcal bacteria (GB1) was chosen (Sommer et al., 
2012; Xu et al., 2014a). A vector, based upon pRSFDuet from Novagen, was purchased 
and contained DnaE N-intein with a His-GB1 fusion tag. This was called pSKDuet01 and 
was produced by Hideo Iwai et al (Iwai et al., 2006) and provided an N-terminal GB1 tag 
for solubility purposes and an associated His tag for purification purposes. The DnaE N-
intein gene was removed using restriction sites for BamHI and HindIII which were also 
introduced to the 5’ and 3’ ends of the genes for the ADAM15 ICDs by polymerase chain 
reaction (PCR). The ADAM15 ICD genes were ligated into the pSKDuet01 and validated 
by sequencing. This vector was then transformed into Codon + RP cells for protein 
expression tests.   
 
Figure 3.3 SDS-PAGE gel electrophoresis of a time course test expression of each of the GB1-tagged 
ADAM15 ICDs in Codon + RP bacterial cells.  
 
A time course expression test, shown in figure 3.3, was conducted using E.coli Codon + 
RP (Agilent Technologies) at 37 °C over 5 hours. Human specific codons are used in these 
genes; and therefore they required adapted bacterial strains, such as Codon + RP, for 
successful expression. All the ADAM15 ICDs expressed well at 37 °C and expression 
continued over time so there was no evidence of toxic over-expression if incubated for 
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too long. Test purification via nickel affinity chromatography was possible due to the 
poly-histidine tag but the low concentration of the eluted bands for all the ICDs 
compared to the concentration of the proteins seen in the Codon + RP lysate, 
demonstrated a need for further optimisation of the purification protocol. However 
weak, this test experiment did prove that the His-GB1 tagged ADAM15 ICDs do bind to 
Ni sepharose which was capitalised on for future purifications and in further pull down 
assays. 
 
3.4 Interactions of the SH3 domain-containing proteins with GB1-tagged 
ADAM15 ICDs via His Affinity Pull Down Assay 
The GST-based pull down assay was repeated using the newly made His-GB1 fusion 
ADAM15 ICDs to study the interactions of ADAM15 D and E, which were not available as 
GST fusion proteins previously, and to confirm that the GB1 tag did not affect the 
interactions of the ADAM15 ICDs with SH3 domain-containing proteins. Ni-NTA 
sepharose was used to bind to the His tag of the new fusion proteins, as in the test 
purification, and the concentration of ADAM15 ICD bound to the sepharose beads was 
determined by Bradford assay as previously, prior to their exposure to MCF-7 cell lysate. 
Unfortunately, test pull down assays using GB1 tagged ADAM15 B and D as bait proteins, 
showed that there was a strong interaction between the SH3 domain-containing 
proteins and the Ni-NTA sepharose beads directly. In the case of Brk and Grb2, the beads 
actually led to the apparent enrichment of the SH3 protein compared to the 
concentration of the proteins in the MCF-7 lysate as seen in figure 3.4 A. The presence 
of the GB1 tag or GB1-ADAM15 B or D actually inhibited the interaction of the SH3 
domain-containing proteins with the Ni sepharose beads in certain cases. It was not 
possible to confirm a lack of interference from the GB1 tag in any interaction from this 
study in advance of later NMR titrations due to the non-specific binding seen. However, 
one possible explanation is that this non-specific binding could be between the Ni2+ ions 
on the sepharose beads rather than the sepharose beads themselves. If this was the 
case, the GB1-ADAM15 bait protein would need to saturate all the available Ni2+ ions on 
the sepharose, so that any SH3 domain-containing protein pulled down by this mixture 
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could be guaranted to have been pulled down by the bait protein. Figure 3.4 B attempts 
to resolve this issue by introducing a second negative control of sepharose beads that 
had been entirely stripped of Ni2+ ions by exposure to EDTA prior to pre-equilibration 
into the appropriate buffer as with the other sepharose samples.  
 
Figure 3.4 A) Western blot of the test pull down of Src, Grb2 and Brk by GB1 tagged ADAM15 B and D 
including a Ni sepharose negative control and the MCF-7 cell lysate to confirm the presence of 
endogenous protein. B) Western blot of the test pull down of Src and Brk by GB1 tagged ADAM15 B and 
D with two negative controls; Ni sepharose beads that have been stripped of Ni2+ and the Ni sepharose 
that is not bound to any bait protein as in A. 
 
This control showed no interaction with either Src or Brk which confirms that the 
interactions between the SH3 domain-containing proteins with the negative sepharose 
control were via the Ni2+ ions and not the sepharose beads themselves. While this did 
imply that any interaction was between the ADAM15 ICD bait proteins and the SH3 
domain-containing proteins rather than any non-specific interaction, it introduced a lack 
of reliability to the experiment. The Bradford assay results did confirm that the 
concentration of ADAM15 ICD bait proteins bound to the Ni-NTA sepharose was at least 
equal to the potential binding capacity of the sepharose as provided by manufacturer 
but this value is theoretical and so saturation of the Ni2+ ions could not be guaranteed. 
An alternative technique would need to be attempted in order to confirm that the GB1 
A 
B 
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tag does not affect the interactions of the ADAM15 ICDs with proteins containing SH3 
domains.  
 
3.5 Interactions of the SH3 domain-containing proteins with GB1-tagged 
ADAM15 ICDs via IgG Affinity Pull Down Assays 
As mentioned above, the GB1 tag is derived from the immunoglobulin binding domain 
1 of Protein G from group C and G Streptococcal bacteria and is capable of interacting 
with IgG molecules. As such, sepharose coated in IgG molecules can be used in place of 
Ni2+ sepharose. IgG is a complex, multi-chain, folded protein (Vidarsson et al., 2014) and 
not a small molecule or simple protein, requiring very specific conditions to function. 
While these properties had the potential to be prohibitive, it was hoped that this 
technique would eradicate the non-specific interactions seen in section 3.4.  
On experimentation with this more sensitive technique, it became clear that success 
would be mixed as seen in figure 3.5. When probing for Src, the protein was shown to 
be present in the MCF-7 lysate and pulled down by ADAM15 B. Src was not pulled down 
by ADAM15 D or the GB1 tag, although there was a larger protein pulled down by both 
to which the anti-Src antibody interacts. Src has significant sequence identity with many 
other members of the Src homology family and this band may be one of these. 
Unfortunately here, the anti-Brk antibody (ICR-100 (Kamalati et al., 1996)) did not detect 
any Brk and only non-specific sensitivity to the antibody was seen.  
However, the major issue presented was in the case of Grb2. There was significant 
interference with the signal from the anti-Grb2 antibody and a positive signal in all lanes. 
Potentially, there could have been a direct interaction between the IgG molecules and 
the Grb2 protein which would explain Grb2 being pulled down by both the ADAM15 D 
ICD, which should not be able to interact at all with SH3 domains as it lacks any proline 
rich regions, and by the GB1 tag and the IgG sepharose which had not been exposed to 
any bait protein. It was unlikely that the SH3 domain-containing proteins were binding 
directly to the sepharose beads as the IgG is conjugated to the same type of sepharose 
as the Ni-NTA sepharose used in section 3.4. In that figure, the SH3 domain-containing 
proteins were not pulled down by unconjugated sepharose beads. An alternative 
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explanation is that the Grb2 antibody was sensitive to one of the protein chains of the 
IgG molecule. When making the SDS-PAGE gel samples, the sepharose beads, having 
been washed and being conjugated to IgG – GB1-ADAM15 ICD – Grb2, were heated to 
100 °C to remove the proteins from the beads. The sample was loaded from this 
supernatant which means that the loaded sample included denatured IgG protein 
chains. The light chains of IgG have a molecular weight of approximately 25 kDa, similar 
to Grb2 and thus could potentially have been interfering with the signal here. This 
interference rendered this pull down assay technique impractical in confirming that the 
biological interactions seen in previous pull down studies were unaffected by altering 
the fusion tag on each ADAM15 ICD from GST to GB1.  
 
Figure 3.5 Western blots probing for the SH3 domain-containing proteins pulled down by ADAM15 B or D 
by the trial IgG pull downs. The top panel has been probed for Src, the middle panel for Brk and the bottom 
panel for Grb2. From the left: a positive control of the MCF-7 lysate, results for those proteins pulled down 
by ADAM15 B, D and the GB1 tag and finally the negative control of the IgG sepharose conjugated to no 
bait ADAM15 ICD protein. 
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3.6 Interactions of the recombinant SH3 domains with the GB1-tagged 
ADAM15 ICDs 
All studies involved recombinant forms of the ADAM15 ICDs and endogenous, full length 
forms of the SH3 domain-containing proteins. However, the full length versions of these 
ADAM15-interactors are too large for practical use in NMR titration experiments. The 
molecular tumbling of proteins in the spectrometer lead to microscopic changes in the 
local magnetic fields which affect the rate at which nuclei in the high energy state return 
to the low energy state. Larger molecules tumble much slower and thus return to 
population equilibrium more quickly and the FID signal decays much more quickly until 
it is difficult to detect. The viable limit of sensitivity of the NMR experiments to be used 
here is approximately 25-30 kDa (Keeler, 2006) and both Src and Brk surpass this in their 
full length forms. Although Grb2 would be small enough to study alone, interactions 
with the ADAM15 ICDs would increase the overall molecular mass and reduce the 
tumbling to an undetectable rate. Additionally, Grb2 contains two SH3 domains and they 
could compete with each other in vitro. As such, recombinant proteins accounting for 
each individual SH3 domain and the recombinant GB1-ADAM15 ICD proteins were used 
in NMR titration studies of the interactions. In order to confirm that it is indeed the SH3 
domains of the signalling proteins that are responsible for the previous pull down 
interactions observed, a similar pull down assay was used which also served to establish 
that the recombinant domains behave similarly to the full length endogenous proteins. 
In this experiment, instead of using MCF-7 breast cancer cell lysate, lysates of bacterial 
cells which were overexpressing the recombinant target protein were incubated with 
the sepharose. Given the issues of specificity encountered in section 3.5, the SH3 
domains were employed as the bait proteins in this pull down assay and the His-GB1-
ADAM15 ICDs were detected by Western blot. This removed interactions of potential 
non-specific bacterial bait proteins competing with the recombinant SH3 domains for 
the Ni-NTA sepharose. As no antibody against either the GB1 tag or any of the ADAM15 
ICDs available, the membrane was probed using a poly-His specific antibody.  
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As can be seen in figure 3.6 A, there was some non-specific interaction observed 
between the GST tag control with each of the GB1-ADAM15 ICDs. This did not present a 
significant problem with regards to future NMR titrations however as the GST fusion tag 
was used to purify the SH3 domains and will have been cleaved and removed prior to 
acquisition of the NMR experiments. In this case, the level of interaction seen between 
the GST fusion tag and the GB1-ADAM15 ICDs can be viewed as a background level for 
that GB1-ADAM15 ICD being detected. The same can be said for any direct interaction 
seen with the glutathione sepharose beads and the GB1-ADAM15 ICD, as the beads were 
not present in the titrations.  
 
Figure 3.6 A) Western blots showing the ADAM15 ICDs pulled down by each of the recombinant GST-tagged SH3 
domain including a GST negative control, a non-baited sepharose negative control and a positive Codon + RP (C+RP) 
lysate sample, along with a GB1 negative control in the top panel. B) Summary table of the interactions seen in A. 
Results are respresentative for three biological replicates. 
 
A 
B 
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GB1-ADAM15 A appeared to be pulled down equally by Brk and the N-terminal SH3 
domain of Grb2 (Grb2N), less so by the C-terminal SH3 domain of Grb2 (Grb2C) and even 
less so again by Src. In fact, the band representing the relative amount of ADAM15 A 
pulled down by the Src SH3 domain was barely more intense than that of the 
background level seen with GST. This weak interaction was potentially due to the high 
concentrations used in this experiment compared to the endogenous levels relevant in 
previous studies here such as figure 3.2. GB1-ADAM15 B was pulled down equally by all 
the SH3 domains investigated here which agreed with previous studies (Zhong et al., 
2008). GB1-ADAM15 C was pulled down by the SH3 domain of Brk, Grb2C and Grb2N 
with equal intensity but the interaction observed with the Src SH3 domain was minimal 
compared to the background level. This was not dissimilar to the results seen in the GST 
pull down assays where little Grb2 was pulled down by GST-ADAM15 C (see figure 3.2). 
GB1-ADAM15 D was only marginally pulled down by any of the SH3 domains which 
confirmed expectations as the ADAM15 D ICD does not contain any motifs previously 
described as capable of interaction with SH3 domains. Any interaction seen could also 
potentially be due to the relatively high concentrations used in this type of assay 
compared to endogenous levels of these proteins. Finally, ADAM15 E interacted equally 
with all the SH3 domains available as did ADAM15 B. Importantly, the GB1 tag alone did 
not interact with any of the SH3 domains. This was crucial for the NMR titrations as the 
GB1 tag would be present as a fusion tag on the ADAM15 ICDs during the experiments 
in order to maintain solubility of these recombinant proteins. 
This experiment confirmed that the recombinant forms of the GB1-ADAM15 ICDs and 
the SH3 domains did interact with each other in vitro ensuring the viability of the 
planned NMR titrations. 
 
3.7 Optimisation of the Purification of the ADAM15 ICD variants 
3.7.1 Purification of His-GB1 tagged ADAM15 ICDs by Ni Affinity 
As the recombinant ADAM15 ICDs have a poly-histidine tag, in addition to the GB1 tag, 
initial purification was performed via Ni affinity. As can be seen in figure 3.7 A, two 
proteins of similar molecular weight were eluted at different imidazole concentrations 
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during purification of GB1-ADAM15 B; more specifically, one protein of approximately 
25 kDa was eluted at 50 mM imidazole and then a slightly larger protein was eluted 
between 100 mM and 300 mM imidazole. When the GB1 tag is analysed by SDS PAGE, 
it appears to have a molecular weight of approximately 13 kDa despite having an actual 
molecular weight of 8.4 kDa. Combined with the molecular weight of the ADAM15 B of 
12.8 kDa, the GB1-ADAM15 B recombinant protein could appear to be slightly larger 
than its actual molecular weight on a polyacrylamide gel. Due to this, it was not 
immediately clear as to which of the eluted proteins with the approximate molecular 
weight of 25 kDa was that of GB1-ADAM15 B. If one of the eluted proteins was a 
bacterial protein endogenous to the Codon + RP cells used to express the protein rather 
than that of the desired GB1-ADAM15 B, this protein should be present when purifying 
other ADAM15 ICDs. To this end, the purification of GB1-ADAM15 D was attempted as 
the combined molecular weight of GB1-ADAM15 D is only 14.6 kDa and so, even with 
the apparent inflation of the molecular weight of the GB1 tag on polyacrylamide gels, it 
would be clear which elutions contained the desired recombinant protein. As can be 
seen in figure 3.7 B, GB1-ADAM15 D was eluted by imidazole concentrations between 
100 mM and 300 mM which demonstrated that the protein eluted at 50 mM imidazole 
was likely a bacterial protein interacting with the Ni-NTA sepharose and as such the 
elutions at 50 mM imidazole were not taken forward to later stages of the purification 
protocol. 
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Figure 3.7 A) SDS PAGE gel electrophoresis of Ni Affinity purification of GB1-ADAM15 B with the protein 
eluting when exposed to more than 100 mM imidazole. B) SDS PAGE gel electrophoresis of Ni Affinity 
purification of GB1-ADAM15 D with the protein eluting when exposed to more than 100 mM imidazole. 
C) Chromatogram of size exclusion chromatography purification of GB1-ADAM15 B. D) SDS PAGE gel 
electrophoresis of fraction from the size exclusion chromatography purification of GB1-ADAM15 B. 
 
Subsequently to the Ni affinity purification, removal of the large protein of 
approximately 50 kDa, along with the small contaminants eluted with the GB1-ADAM15 
B, was attempted by size exclusion chromatography. As can be seen in the 
chromatogram in figure 3.7 C and the subsequent SDS PAGE gel in D, the similar size of 
the smaller contaminants were too close to that of the desired GB1-ADAM15 B and they 
could not be separated this way.  
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3.7.2 Purification of the His-GB1 tagged ADAM15 ICDs by Ion Exchange 
Chromatography 
 As size exclusion chromatography had been unable to remove the small contaminant 
proteins from the GB1-ADAM15 B, ion exchange chromatography was attempted. The 
fractions from the Ni affinity purification were combined and dialysed into either 50 mM 
sodium acetate pH 5 or 100 mM sodium acetate pH 5. Unfortunately, after 48 hours of 
dialysis, a precipitate had formed in both samples. Figure 3.8 A shows a gel of the sample 
prior to dialysis in acetate buffer and from the supernatants of the samples from after 
dialysis and it is clear that it is indeed the GB1-ADAM15 B protein that has been 
precipitating, ruling out the use of these buffers.  
 
3.7.3 Purification of the His-GB1 tagged ADAM15 ICDs by Ni affinity in the 
presence of 6 M Urea 
A disadvantage of using Ni affinity for purification purposes, as opposed to GST affinity 
for example, is that the affinity of the Ni2+ ions for polyhistidine tags is not as specific as 
other techniques. Ni affinity columns can potentially interact with any protein exhibiting 
a sufficient localised negative charge, at the pH used. This could account for the 
contaminant proteins that were eluted at similar imidazole concentrations to the 
desired GB1-ADAM15 ICD. Denaturation of all the proteins present would reduce the 
likelihood of localised negative charge and thus avoid non-specific interactions whereas 
the sequential nature of the polyHis-tag will still retain its localised charge and so the 
cluster is not reliant on correct folding. To achieve denaturation, 6 M urea was added to 
all the buffers involved in the Ni affinity purification. 
As can be seen in figure 3.8 B, the addition of urea was successful in the removal the 
larger, 50 kDa protein from the elutions at high imidazole concentrations but did little 
to reduce the presence of the smaller contaminants from the same elutions as the 
desired GB1-ADAM15 B. Also shown in figure 3.8 B is a sample of the eluted GB1-
ADAM15 B with the urea removed to confirm that it was not degraded by exposure to 
high concentrations of urea. Although the contamination issues where not entirely 
solved by the presence of urea, this did go some way to aid the purity of the final sample 
and so was used for all future Ni affinity purifications of the GB1-ADAM15 ICDs. 
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Figure 3.8 A) SDS PAGE gel electrophoresis of GB1-ADAM15 B sample before and after dialysis into acetate 
buffer. The protein has precipitated due to exposure to sodium acetate solutions. B) SDS PAGE gel 
electrophoresis of fractions from the Ni Affinity purification of GB1-ADAM15 B in the presence of 6 M 
urea along with a gel of the sample after dialysis to remove the urea to confirm the protein had not 
degraded. The protein eluted at concentrations of more than 100 mM imidazole as previously. C) SDS 
PAGE gel electrophoresis of the fractions from the Talon™ purification of GB1-ADAM15 B. The 
concentration of imidazole that caused protein elution was 75 mM. D) SDS PAGE gel electrophoresis of 
the fractions from the Ni affinity purification of the same expression of GB1-ADAM15 B. E) SDS PAGE gel 
electrophoresis of the fractions from the Ni Affinity purification of GB1-ADAM15 B at 4 °C after a shorter, 
3 hour induction. 
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3.7.4 Purification of the GB1-ADAM15 ICDs via alternative protocols utilising 
the His-tag 
While nickel ions are the ion of choice for use in purifications of His-tagged proteins, due 
to their strong affinity even at low protein concentrations, other ions, including cobalt 
can also be used. Cobalt has six coordination sites, like nickel, but has a lower affinity for 
His-tags, especially if the His-tag is not fully exposed or if the protein concentration is 
lower. The benefit here is that this means that there are fewer non-specific interactions 
with the Co sepharose (Jiang et al., 2004). A lower concentration may not be ideal but 
samples purified this way are often less contaminated.  
In order to compare the efficacy of Ni affinity compared to Co affinity, the pellet from a 
1 L culture was split in half and one half purified by each technique using the same 
buffers and both in the presence of urea. The cobalt sepharose used here was Talon™ 
(GE Healthcare) and it was used with the Äkta purification system. The results of this 
column can be seen in figure 3.8 C and the Ni affinity purification of the same expression 
in D. Unfortunately, using Co affinity did not reduce the contaminants of smaller size any 
more effectively than Ni affinity. This implied that the bands seen on the gels are not 
non-specific contaminants but either degraded or truncated forms of the desired GB1-
ADAM15 ICD that retains the N-terminal His-tag. 
 
3.7.5 Ni Affinity Purification of GB1-ADAM15 B at low temperature with a 
shorter induction culture 
It is possible that the small contaminant bands are in fact degraded or truncated forms 
of the desired GB1-ADAM15 ICD and therefore modifications to the culture and 
purification were considered. The induction length of the culture was reduced from 
4 hours to 3 hours to avoid a toxic response from the bacterial cells to the high 
concentrations of the GB1-ADAM15 ICD and the Ni affinity purification was conducted 
at 4 °C to reduce degradation, the results of which can be seen in figure 3.8 E. However, 
these steps did not reduce the level of degraded protein bands. Further optimisation 
was therefore required. 
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3.7.6 Low Temperature Culture of GB1-ADAM15 B 
An effective method for reducing in-cell degradation or truncation is to induce 
production of the desired protein at a lower temperature for a longer time. Rather than 
induce the bacteria to produce GB1-ADAM15 B at 37 °C for 4 hours, the cells were 
induced at 28 °C overnight which slows protein production, allowing the bacterial 
ribosomes to respond to clusters of rare codon tRNAs or to cope with any rare codon 
tRNAs which are still at a relatively low copy number, despite the use of specialised cells 
equipped with extra copies of rare codons. Potential protein misfolding is also reduced 
in long, cool inductions. The results of the subsequent Ni affinity purification can be seen 
in figure 3.9 A and show that the degradation/truncation issue had been significantly 
reduced but not entirely resolved and thus further modifications to the purification 
protocol were required. 
 
Figure 3.9 A) SDS PAGE gel electrophoresis of NI affinity purification of GB1-ADAM15 B expressed at 28 
°C overnight in Codon + RP cells. B) SDS PAGE gel electrophoresis of Ni affinity purification of small scale 
expression of GB1-ADAM15 expressed in Codon + RP cells at 28 °C overnight. C) SDS PAGE gel 
electrophoresis of Ni affinity purification of small scale expression of GB1-ADAM15 B expressed in Rosetta 
2 cells at 28 °C overnight. D) SDS PAGE gel electrophoresis of Ni affinity of purification of GB1-ADAM15 B 
expressed in large scale, 28 °C overnight culture in Rosetta 2 cells. 
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3.7.7 Comparison of Expression of GB1-ADAM15 ICDs in Codon + RP cells and 
Rosetta 2 cells 
If the issue seen here was not degradation but truncation, this could be due to the rare 
codons required for the translation of the GB1-ADAM15 ICDs. The Codon + RP cells used 
to express the GB1-ADAM15 ICDs thus far have extra copies of the argU and proL codons 
but lack extra copies of either ileY or leuW codons. As all of these rare codons are 
required for the expression of the ADAM15 ICDs, an alternative cell line which contains 
extra copies of all of these codons was evaluated. The Rosetta 2 cell line, another 
variation on the BL21 (DE3) cell line, containing all of the rare codons required was 
trialled. Small scale cultures of both the Rosetta 2 and Codon + RP cell lines were grown 
and GB1-ADAM15 B expressed in both. Ni affinity purifications from these cultures can 
be seen in figure 3.8 B and C and the purification from the Rosetta 2 cell culture 
demonstrated fewer of the small contaminant proteins than that of the Codon + RP cells 
although they were not removed entirely.  
 
3.7.8 Large Scale Culture and Purification of GB1-ADAM15 B using Rosetta 2 
cells 
As the small scale production of the GB1-ADAM15 ICDs using Rosetta 2 cells produced 
fewer contaminants than that of Codon + RP cells, and the low temperature overnight 
culture generated fewer contaminants in Codon + RP cells, the next stage of 
optimisation was to combine these and attempt production of GB1-ADAM15 B in 
Rosetta 2 cells at low temperature overnight. The results of the Ni affinity purification 
of that culture can be seen in figure 3.9 D and showed a significant reduction in the 
contaminant bands compared to previous purifications and this improvement was seen 
in the case of all the GB1-ADAM15 ICDs. Ideally, NMR experiments would use proteins 
of the highest purity possible as NMR spectra represent the net behaviour of the nuclei 
generating a given chemical shift. This was not possible here but the purity level 
demonstrated was enough to attempt NMR experiments and was pure enough to act as 
the ligand protein in a titration experiment. 
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3.8 Nuclear Magnetic Resonance Studies of GB1-ADAM15 B 
As it had proven difficult to purify the ADAM15 ICDs to the preferred level of purity 
required for NMR studies, it was decided that the interactions between the ADAM15 
ICDs and the SH3 domains should initially be studied from the perspective of the SH3 
domains. There are assignments available for all of the SH3 domains being studied here 
(Lin et al., 2012; Wittekind et al., 1997; Yu et al., 1993) which will be covered in later 
chapters. Additionally, the high number of proline residues present in the ADAM15 ICDs, 
which are likely to be directly relevant to any potential interaction, would require the 
use of less common NMR pulse sequences for detection from the ADAM15 ICD 
perspective. 
Single labelled, 15N GB1-ADAM15 B was produced using the optimised protocol 
described above. A [1H-15N]-HSQC was acquired for this to establish how much the 
contaminants affect the spectrum of the protein, which can be seen in figure 3.10.  
 
Figure 3.10 [1H-15N]-HSQC of 15N labelled GB1-ADAM15 B 
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The spectrum for GB1-ADAM15 B proved to be better resolved than expected. The high 
level of contaminants with potentially similar sequences to the GB1-ADAM15 ICD, with 
several potential versions of the same residue in slightly different environments due to 
variable truncation, had the potential to present a significant level of interference. 
Sufficient concentrations of the truncated proteins would add to the signal of residues 
unaffected by the truncation while providing new peaks for those that are affected. 
However, this was not seen here. The level of purity attained was enough to overcome 
this and presented a clear spectrum. The majority of the peaks are positioned between 
8.0 ppm and 8.5 ppm in the 1H dimension which is consistent with amino acids residing 
in regions of disorder in proteins (Uversky, 2011). This is likely to represent the majority 
of the residues from the ADAM15 B ICD. The peaks spread out through the rest of the 
spectrum correlate strongly with the published spectrum of the GB1 tag (Sun et al., 
2005).  
 
3.9 Conclusions and Discussion 
It has already been shown in a number of studies that the ADAM15 ICDs interact with 
proteins that contain SH3 domains (Zhong et al., 2008). It has also been shown that the 
proline-rich regions play a large part in those interactions (Kleino et al., 2009). This 
chapter attempted to validate these studies and ensure that alterations, necessary for 
the planned NMR experiments, do not affect those results.   
Previously used as a model of metastatic breast cancer, the MDA-MB-435 cell line is now 
suspected to have been cross-contaminated with the M14 melanoma cell line (Rae et 
al., 2007) and expresses markers for both breast cancer and melanoma. Here, it was 
demonstrated that the interaction profile previously observed in this melanoma line 
could be reproduced in the breast cancer cell line, MCF-7. This would suggest that the 
interactions of the ADAM15 ICD with intracellular proteins that contain an SH3 domain 
are not restricted by tissue type and thus could potentially have a function beyond that 
of cancerous disease. Since ADAM15 has also been heavily implicated in inflammatory 
conditions such as arthritis and in atherosclerosis (Bohm et al., 2013; Sun et al., 2012), 
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any interactions observed throughout this thesis could have an impact in such 
conditions beyond breast cancer.   
Previously, the interactions of ADAM15 variants D and E have not been discussed. 
Although the interactions viewed here are using recombinant domains rather than full 
length endogenous proteins, these have the potential to have a biological function. 
ADAM15 D did not interact with Src or Brk as expected, due to the lack of proline-rich 
motifs with which to bind to canonical SH3 domains. The lack of interaction partners 
discovered for ADAM15 D does not explain why this variant is the most widely expressed 
variant across a wide selection of healthy tissues, after that of ADAM15 A (Kleino et al., 
2007). However, it did interact at the low level with the N-terminal SH3 domain of Grb2. 
This was unexpected and may go some way to completing the functional roles of the 
ADAM15 D variant.  
The interaction profile of ADAM15 E was very similar to that of ADAM15 B. In previous 
studies it was not possible to differentiate between expression of the ADAM15 E and 
ADAM15 B variants due to their very similar molecular weight and sequence length 
(Kleino et al., 2007). There is only one polyproline region differing between these two 
variants. Although the biological function of each of the variants remains unclear, it is 
intriguing that these two variants behave in such a redundant manner.   
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In summary, this chapter has shown that: 
 MCF-7 breast cancer cells displayed a similar interaction profile to that of MDA-
MB-435 cells. 
 Expression and purification of the newly GB1-tagged ADAM15 ICDs was possible. 
 Ni affinity based pull down assays were not possible due to non-specific 
interactions of the SH3 domain-containing proteins with the Ni ions. 
 IgG affinity based pull down assays were problematic due to the interference of 
the IgG light chain with the Grb2 antibody. 
 Src was not pulled down from MCF-7 cell lysate by GB1-tagged ADAM15 D. 
 Recombinant SH3 domains from Grb2, Src and Brk do interact with the GB1-
tagged ADAM15 ICDs but did not interact with the GB1 tag alone. 
 Production of the GB1-tagged ADAM15 ICD was optimised to use Rosetta 2 cells 
for expression and purification by Ni affinity in the presence of urea. 
 NMR studies of GB1-tagged ADAM15 B are possible but due to the existence of 
backbone assignments for the SH3 domains and high proline concentration in 
the ADAM15 ICDs, the titrations were studied from the perspective of the SH3 
domains primarily. 
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Chapter 4: Interactions of Grb2 with ADAM15 ICDs 
 
4.1 Introduction 
Growth factor receptor-bound protein 2 (Grb2) is 217 residues long and contains an N-
terminal SH3 domain from residues 1-58, a central SH2 domain from residues 60-152 
and a C-terminal SH3 domain from residues 156-215 (Uniprot ID: P62993 (Magrane and 
Consortium, 2011)). The SH2 domain binds to tyrosine phosphorylated sequences 
containing the motif pY-X-N-X where X is a hydrophobic residue, most commonly valine 
(Vidal et al., 2001). Both the N-terminal and C-terminal SH3 domains have been shown 
to interact with proline-rich regions (Simon and Schreiber, 1995). For example, the N-
terminal SH3 domain (Grb2N) interacts with Ras-guanine exchange factor SOS and the 
C-terminal SH3 domain (Grb2C) interacts with proline-rich motifs such as those which 
contain the motif P-X-I/L/V-D/N-R-X-X-K-P (Berry et al., 2002; Simon and Schreiber, 
1995).  
Both SH3 domains will be considered as potential interaction partners in this chapter, 
using recombinant proteins for each specific domain. Both Grb2N and Grb2C follow the 
general structural pattern for SH3 domains. Both Grb2N and Grb2C contain 8 β-strands, 
an n-Src loop, a RT loop, a distal loop and an α-turn as shown in Figure 4.1.  
 
 
Figure 4.1 A) The NMR structure of Grb2C based on the pdb 1GFC (Kohda et al., 1994). B) The structure of 
Grb2N based on the pdb 3GBQ (Wittekind et al., 1997). Highlighted on each are the standard features of 
an SH3 domain, the n-Src loop, the RT loop, the distal loop and the α-turn. 
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As shown previously, Grb2 has been shown to interact with ADAM15 variants A-C in 
various published studies (Kärkkäinen et al., 2006; Zhong et al., 2008). The previous 
chapter has shown that ADAM15 E can also bind to Grb2 but ADAM15 D does not. 
However, as there are two SH3 domains present in full length Grb2, it is not known which 
domain is involved in the ADAM15 interactions and this will be addressed here. Grb2C 
was chosen to be studied first due to the full 1H, 15N and α and β 13C assignments having 
been published along with the PDB structure used here (1GFC (Kohda et al., 1994)) and 
an article demonstrated that the Grb2C was responsible for the interaction with the 
cytoplasmic domain of FGFR2 Bii and that the Grb2N acted to dimerise with the parallel 
domain of second Grb2 molecule (Lin et al., 2012). 
Due to the purification issues described in the previous chapter and the high number of 
prolines present in the ADAM15 ICDs, the interactions will be studied from the 
perspective of the SH3 domains. The ADAM15 ICDs were purified as discussed and 
dialysed into the appropriate NMR buffer for the labelled SH3 domain in question. 
 
4.2 Optimisation of the Purification of Grb2C 
During the optimisation of the pull downs, the DNA sequence of the Grb2C was 
confirmed and the expression was optimised in BL21 (DE3) cells. This construct has a 
GST fusion tag and, after cell lysis by sonication and clarification by centrifugation, 
glutathione sepharose was used to extract the fusion protein from the lysate. This was 
eluted with 300 mM reduced glutathione and the fractions containing eluted protein 
were combined, once identified by gel electrophoresis shown in figure 4.2 A. As 
previously discussed, the GST tag is too cumbersome for NMR spectroscopy (Zhou and 
Wagner, 2010) and so it was removed from the Grb2C construct via thrombin digestion. 
This was optimised by digesting 1 ml of the protein overnight at either room 
temperature or at 4 °C with either 1.5, 3, 5 or 7.5 units of thrombin per mg of protein. 
The results were analysed by gel electrophoresis, shown in figure 4.2 B, and 5 units of 
thrombin per mg of protein was used for further purification. Once the thrombin 
reaction was stopped with 100 mM PMSF, separation of the GST tag was initially 
attempted via the use of a second glutathione sepharose column. Unfortunately, as 
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shown in the figure 4.2 C, this failed to remove all of the tag. The flow through sample 
which contained Grb2C with some remaining GST tag was concentrated by 
centrifugation to a volume of less than 3 ml and then the GST tag was separated from 
the Grb2C protein by size exclusion chromatography, using the same SPB buffer, as 
previously used for the glutathione affinity column, with a flow rate of 1 ml/min. The 
resulting chromatogram is shown in figure 4.2 E with the SDS-PAGE gel of the peaks 
shown in figure 4.2 D. As size exclusion chromatography was more successful at 
removing the tag, the second glutathione sepharose column was omitted from further 
purification attempts and size exclusion chromatography was used to remove all of the 
tag in a single step. Finally, the sample was dialysed into Grb2C NMR buffer and 
concentrated to 2 mM. 
In order to confirm that the purification of the protein yielded folded protein, a one 
dimensional 1H NMR experiment was acquired. The presence of a peak (highlighted in 
red in Figure 4.3) with a chemical shift lower than 0 ppm indicated that a methyl group 
was shielded from the magnetisation by the electron cloud of a ring in an aromatic 
residue.  In order for this to be possible, the protein must have been folded in such a 
way as to bring these two functional groups in close proximity in the hydrophobic core. 
Also, there were peaks in the high ppm region additional to the characteristic 
tryptophan residue peaks, further confirming that the protein was produced and folded 
correctly as such peaks would only occur due to protein folding.  
Based on the success of producing unlabelled Grb2C, 15N and 15N, 13C labelled versions 
of the protein were generated using the same protocol, without the second GST affinity 
column. 
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Figure 4.2 A) The first GST affinity column performed. The band eluted in elution 1, at 300 mM glutathione, 
is GST-Grb2C. B) Optimisation of thrombin cleavage of the tag from Grb2C. Thrombin as used in the 
indicated amount (from 1.5 units to 7 units per milligram of protein) and temperatures (4 °C or room 
temperature) C) The second GST affinity column attempted. The Grb2C should be in the flow through with 
all GST retained until the elutions. D) SDS PAGE gel of the fractions from the size exclusion column with 
those fractions from peak 3 containing the desired Grb2C. E) Chromatogram of this size exclusion column 
with three clear peaks.  
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Figure 4.3 1H NMR spectra of unlabelled Grb2C. The red square highlights a hydroxyl group with a ppm 
shift of less than 0 indicates that it is shielded from magnetisation by its proximity to an aromatic ring. 
The green box highlights peaks characteristic of tryptophan residues along with additional peaks 
characteristic of a folded protein. 
 
4.3 Assignment of Grb2C backbone using NMR 
Using the 13C, 15N labelled recombinant protein produced above, HSQC, HNCACB and 
CBCACONH spectra were collected using the 500 MHz spectrometer. Using the 1H, 13C 
and 15N assignments from Chi-Chuan Lin et al (Lin et al., 2012), 76% of the backbone of 
Grb2C was assigned with the exception of the proline residues and 1Gly, 2Ser, 3Ala, 5Val, 
8Gln, 50His, 51Gly, 65Asn, 66Arg and 67Asn. The assignments are shown in figure 4.4. 
 
4.4 Titrations of Grb2C with the cytoplasmic domains of ADAM15 
Although it was not possible to purify the ADAM15 cytoplasmic domains to a sufficient 
level in order to begin structural analysis, due to in cell degradation of the protein during 
expression, it was possible to purify the ADAM15 ICDs to a suitable degree in order to 
use them as the ligand protein in a titration experiment. As NMR data uses the net signal 
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produced, small signals caused by low level contaminants of the ligand protein will be 
negligible in comparison to the overall signal caused by the effects of the ligand. 
 
Figure 4.4 shows the 1H, 15N HSQC spectrum of the Grb2C SH3 domain with peak assignments 
 
As long as a clear majority of the ligand sample is the full length ADAM15 cytoplasmic 
domain construct, the effects seen in the spectrum for GrbC2C will be those caused by 
the main ADAM15 ICD construct and not the contaminants.  
In order to study the interaction of Grb2C with each ADAM15 ICD, two NMR samples 
were made. For each titration, sample A contained 0.5 mM 15N Grb2C in NMR buffer. 
Sample B contained 0.5 mM 15N Grb2C and 1.5 mM ADAM15 ICD in NMR buffer. HSQC 
experiments were acquired for both samples and these represent the first and last data 
points for a titration. The intermediate data points were collected by transferring a small 
volume of sample B into sample A, increasing the concentration of ADAM15 ICD in 
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sample A while maintaining the Grb2C concentration. Those peaks that are affected by 
any interaction between the two proteins will appear to “move” across the spectra. This 
is called the chemical shift perturbation (CSP) and it was calculated for each peak using 
the following equation: 
 CSP (Δppm) = √(𝛥𝛿𝐻𝑁)2 + (𝛥𝛿𝑁 ∗ 0.15)2     (Equation 2) 
Where 0.15 is a scaling factor to compensate for the difference in ppm scale for 15N 
compared to 1H and Δδ is the change in chemical shift (Takahashi et al., 2000). 
Firstly, a titration of 15N Grb2C with the unlabelled GB1 tag was conducted as a control 
and to establish a baseline. As can be seen in Figure 4.5, there was negligible 
perturbation of peaks when the GB1 tag was added thus confirming that any chemical 
shift perturbations seen in further titrations with each ADAM15 ICD would be 
attributable to the ADAM15 ICD in question and not the presence of the GB1 tag.    
Despite being minimal, the chemical shift perturbations caused by the presence of the 
GB1 tag were subtracted from the CSPs caused by each GB1-tagged ADAM15 ICD prior 
to further analysis. All the ADAM15 IDs, other than variant D, showed some interaction 
with the Grb2C SH3 domain, with perturbations of Grb2C residues 22Glu, 44Trp and 
56Phe common to all of the interactions. In figure 4.6, the quantification of the 
perturbations caused by ADAM15 A, shown in figure 4.6 B, were calculated from the 
spectra in figure 4.6 A. Other residues affected by the presence of the variant A ICD 
include 13Gln, 18Phe and 55Met, though to a significantly lower extent.  
The perturbations caused by the presence of ADAM15 B include 22Glu, 44Trp and 
56Phe, as for the other ICD interactions, but 58Arg was also affected here. Unlike in the 
case of ADAM15 A, 13Gln was not affected at all by the presence of ADAM15 B, whereas 
19Asp was. Residues 18Phe and 55Met were perturbed to a similar extent here as in the 
interaction of Grb2C with ADAM15 A. This can be seen in Figure 4.7 B.  
In Figure 4.8, the effect of the introduction of ADAM15 C on the chemical shift of the 
residues of Grb2C can be seen. As in the cases of ADAM15 A and B, residues 22Glu, 
44Trp, 56Phe and 58Arg were shifted most dramatically by the introduction of ADAM15 
C but by a smaller margin than was the case for the previous ADAM15 ICDs. Unlike the 
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introduction of ADAM15 A or B, 13Gln, 18Phe and 55Met were either unaffected 
entirely or shifted by a less than 0.02. In this case, only the residues mentioned above 
and 17Asp, 19Asp and 46Lys were shifted by more than 0.02. 
As can be seen in Figure 4.9, the chemical shift perturbations of the residues of Grb2C 
caused by the presence of ADAM15 D were negligible. The largest shift observed was 
for residue 22Glu but this was still only 0.015. This is consistent with predictions that 
ADAM15 D would not interact with the SH3 domains as it lacks proline-rich motifs. 
Finally, Figure 4.10 shows the results for the titration of Grb2C with ADAM15 E. As for 
the titrations with ADAM15 A-C, residue 22Glu, 44Trp and 56Phe of Grb2C were the 
most affected by the introduction of ADAM15 E. Additionally, 12Val, 13Gln, 15Leu, 
17Asp, 19Asp, 45Trp, 55Met, 58Arg and 59Asn show significant movement upon 
interaction with ADAM15 E. 
Additionally, it is important to note that as the concentration of each ADAM15 ICD 
increased in the titration sample, a precipitate formed. This happened in all cases, 
except for ADAM15 D, once the ratio of Grb2C to ADAM15 was above 1:1.5. However in 
the cases of ADAM15 B and E, this occurred at lower concentrations of ADAM15 than 
for ADAM15 A and C, beginning at concentrations of 0.5 mM: 0.5 mM in the cases of 
variants B and E and at 0.5 mM: 0.75 mM for variants A and C. As the intensity of the 
peaks for Grb2C decreased dramatically once the precipitate started to form, it can be 
argued that the concentration of 15N Grb2C in solution was reducing as the 
concentration of ADAM15 ICD increases. Additionally, peak broadening in an indicator 
of intermediate exchange whereby the exchange rate between the bound and unbound 
forms of the protein is of the same order as the frequency difference and thus the 
chemical shift of the peak is an average based upon the time spent in the unbound form 
with a lower intensity. This sort of exchange can also be seen when there are multi-
binding events occurring such as non-specific interactions due to the high 
concentrations of the proteins present in the sample (Kovrigin, 2012). Thus the 
interactions of the SH3 domain with the ADAM15 ICD causes aggregation and 
precipitation in vitro. 
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Figure 4.5 A) [1H-15N]-HSQC spectra for the 15N Grb2C SH3 domain by itself (navy blue), in the presence of 
0.5 mM GB1 tag (cyan) and in the presence of 1.5 mM GB1 tag (green) and the intermediates in 
intermediate shades as indicated in the key. The concentration of 15N Grb2C SH3 domain was 0.5 mM in 
all spectra. B) Chemical shift perturbations caused by the presence of the GB1 tag on the spectrum of the 
Grb2C SH3 domain at 0.5 mM of each protein. 
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Figure 4.6 A) [1H-15N]-HSQC spectra for the 15N Grb2C SH3 domain by itself (navy blue), in the presence of 
0.5 mM ADAM15 A (cyan) and in the presence of 1.5 mM ADAM15 A (green) and the intermediates in 
intermediate shades as indicated in the key. The concentration of 15N Grb2C SH3 domain was 0.5 mM in 
all spectra and intermediate concentrations are also shown. B) Chemical shift perturbations caused by the 
presence of the ADAM15 A on the spectrum of the Grb2C SH3 domain at 0.5 mM of each protein. 
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Figure 4.7 A) [1H-15N]-HSQC spectra for the 15N Grb2C SH3 domain by itself (navy blue), in the presence of 
0.5 mM ADAM15 B (cyan) and in the presence of 1.5 mM ADAM15 B (green) and the intermediates in 
intermediate shades as indicated in the key. The concentration of 15N Grb2C SH3 domain was 0.5 mM in 
all spectra and intermediate concentrations are also shown. B) Chemical shift perturbations caused by the 
presence of the ADAM15 B on the spectrum of the Grb2C SH3 domain at 0.5 mM of each protein. 
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Figure 4.8 A) [1H-15N]-HSQC spectra for the 15N Grb2C SH3 domain by itself (navy blue), in the presence of 
0.5 mM ADAM15 C (cyan) and in the presence of 1.5 mM ADAM15 C (green) and the intermediates in 
intermediate shades as indicated in the key. The concentration of 15N Grb2C SH3 domain was 0.5 mM in 
all spectra and intermediate concentrations are also shown. B) Chemical shift perturbations caused by the 
presence of the ADAM15 C on the spectrum of the Grb2C SH3 domain at 0.5 mM of each protein.  
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Figure 4.9 A) [1H-15N]-HSQC spectra for the 15N Grb2C SH3 domain by itself (navy blue), in the presence of 
0.5 mM ADAM15 D (cyan) and in the presence of 1.5 mM ADAM15 D (green) and the intermediates in 
intermediate shades as indicated in the key. The concentration of 15N Grb2C SH3 domain was 0.5 mM in 
all spectra and intermediate concentrations were also shown. B) Chemical shift perturbations caused by 
the presence of the ADAM15 D on the spectrum of the Grb2C SH3 domain at 0.5 mM of each protein. 
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Figure 4.10 A) [1H-15N]-HSQC spectra for the 15N Grb2C SH3 domain by itself (navy blue), in the presence 
of 0.5 mM ADAM15 E (cyan) and in the presence of 1.5 mM ADAM15 E (green) and the intermediates in 
intermediate shades as indicated in the key. The concentration of 15N Grb2C SH3 domain was 0.5 mM in 
all spectra and intermediate concentrations were also shown. B) Chemical shift perturbations caused by 
the presence of the ADAM15 E on the spectrum of the Grb2C SH3 domain at 0.5 mM of each protein. 
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4.5 Comparison of the CSPs of Grb2C caused by each ADAM15 ICD 
When the results of the Grb2C-ADAM15 ICD titrations were compared, as shown in 
Figure 4.12, the differences in CSP intensity were emphasised. When considering only 
those residues with a CSP above the average + 2x standard deviation, residues 22Glu, 
44Trp and 56Phe were consistently affected although there was some variation in the 
intensity of the CSP, particularly in the case of 22Glu which ranges from a CSP of 0.07 
when in the presence of ADAM15 E to ~0.045 in the presence of the other ICDs. The 
residue 13Gln was affected by the presence of ADAM15 A and E but not any of the 
others. The titrations of ADAM15 B and C followed very similar patterns with 58Arg also 
displaying shifts larger than the average + 2 standard deviations. However, the CSPs 
caused by ADAM15 B were consistently slightly larger than those caused by ADAM15 C 
which implies a slightly tighter interaction. Larger chemical shift perturbations correlate 
with stronger binding affinities, although the exact proportion of the relationship 
between these depends on the proteins involved (Williamson, 2013). ADAM15 E caused 
significantly larger chemical shift perturbations over the whole of the Grb2C SH3 domain 
which also strongly implies that the interaction between these two proteins is tighter 
than for the other ICDs.   
In Figure 4.13, the chemical shift perturbations have been mapped onto the structure of 
Grb2C, as shown in Figure 4.1A. Mapped were those residues which exhibit the greatest 
chemical shift perturbation when the appropriate ADAM15 ICD is introduced. 
The models make it very clear that the interaction interface between Grb2C and all of 
the ADAM15 ICDs, except D, are consistent with the many of the same key residues 
involved in all of the interactions albeit to differing extents. This implies two things: 
firstly, there is variation in the binding intensities of the each of the ADAM15 ICDs with 
Grb2C based upon the intensity of the chemical shift perturbations of those residues 
involved. This was supported by the rate of precipitation of the protein in the NMR tube 
during the titrations. As the concentration of the ADAM15 ICDs was increased, a 
precipitate began to form. This likely occurred at a lower concentration of ADAM15 B 
and E likely due to their binding more tightly to Grb2C than the other ADAM15 ICDs. 
Unfortunately, it was not possible to measure the dissociation constant by NMR as the 
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reaction did not saturate before precipitation began. It is likely that non-specific 
interactions aided earlier precipitation.  
Secondly, it is clear that the same face of the SH3 domain is involved in all of the 
interactions which suggests that those ICDs which interact with Grb2C (ADAM15 A, B, C 
and E) do so in a similar manner. A common element between each ICD must be 
involved. Studying the sequences of the ADAM15 ICDs, shown in Figure 4.11, there were 
only two characteristics common in all of the Grb2C-interacting ADAM15 ICDs and thus 
potential motifs involved in the interaction investigated here. 
  
Figure 4.11 The sequence alignment of the ADAM15 ICDs A-E with the proline-rich regions highlighted 
and the GRTK/RSPK motifs underlined. 
 
The three proline-rich regions common to all the ADAM15 ICDs, except D for the case of 
this discussion, were regions P1, P4 and P5. Any of these could be responsible for the 
interactions, individually or in combination. Additionally, it has been demonstrated 
previously that the C-terminal SH3 domain of Grb2 can interact with proteins that 
contain the motif RGTK (Simister et al., 2013). This alternative sequence is present in all 
the ADAM15 ICDs as well and will be further investigated. 
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Figure 4.12 Chemical Shift Perturbations of Grb2C caused by each of the ADAM15 ICDs. Also highlighted 
were the average CSP across all five titrations, the average + standard deviation and the average + 2x 
standard deviation. 
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Figure 4.13 Chemical Shift Perturbations caused by each ADAM15 ICD mapped on to the structure of 
Grb2C (1GFC) where the darkest shading indicates the CSPs above average + 2x standard deviation, the 
middle shading for those CSPs above average + standard deviation and the lightest shading for CSPs above 
average. Grey residues were unaffected or shifted by less than the average CSP. The model on the left 
and the central model show the same perspective of the protein; the right model was rotated 180°.  
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4.6 Titration of 15N Grb2C with mutated ADAM15 B 
To determine whether the interaction of the ADAM15 ICDs with the C-terminal SH3 
domain of Grb2 required one of the proline-rich motifs 1, 4 and 5 of the ICDs or the 
alternative RGTK sequence, the RGTK sequence was mutated in the ICD of ADAM15 B 
and the titration with 15N Grb2C was repeated. The mutated gene was synthesised by 
GenScript in order to include the BamHI and HindIII restriction sites which were used 
when generating the previous GB1-tagged ADAM15 ICD constructs. This allowed the 
gene to be ligated into the pSKDuet01 vector thus  GB1-tagging the mutant (Iwai et al., 
2006). No further optimisation of the purification was required. The mutant, henceforth 
known as ADAM15 BM, included the altered RGTK motif, now an AGTA sequence, which 
should have removed any interaction present if this was the motif required. 
As with the titration with ADAM15 B, protein began to precipitate at a ratio of 1:1. 
Additionally, the same residues of Grb2C that exhibited movement in the presence of 
ADAM15 B still exhibited movement in the presence of ADAM15 BM as can be seen in 
figure 4.14. In fact, those residues affected by the presence of the ADAM15 B ICD were 
affected more so in the presence of ADAM15 BM. Removal of the RGTK motif did not 
reduce the ability of the B variant ICD to interact with the Grb2C SH3 domain thus 
confirming that the alternative RGTK motif was not necessary here.  
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Figure 4.14 A) [1H-15N]-HSQC spectra for the 15N Grb2C SH3 domain by itself (navy blue), in the presence 
of 0.5 mM ADAM15 BM (cyan) and in the presence of 1.5 mM ADAM15 BM (green) and the intermediates 
in intermediate shades as indicated in the key. The concentration of 15N Grb2C SH3 domain was 0.5 mM 
in all spectra and intermediate concentrations were also shown. B) Chemical shift perturbations caused 
by the presence of the ADAM15 BM on the spectrum of the Grb2C SH3 domain at 0.5 mM of each protein 
alongside those for the CSPs caused by ADAM15 B. 
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4.7 Optimisation of the purification of Grb2N 
The purification of Grb2N was attempted using the same protocol as for Grb2C, as they 
were both GST fusion tagged. After clarification of the bacterial lysate, the GST-tagged 
protein was purified by glutathione sepharose and eluted with 300 mM reduced 
glutathione in SPB pH 7.2, as can be seen in Figure 4.15 A. Thrombin digestion was 
optimised to 7.5 units as can be seen in Figure 4.15 B. Finally, the GST tag and Grb2N 
were separated by size exclusion chromatography. The purified protein was then 
dialysed into 50 mM sodium phosphate, 100 mM sodium chloride pH 6.0, the buffer 
used when acquiring the assignments (Wittekind et al., 1997). A selection of NMR 
experiments including [1H-15N] HSQC, HNCACB and CBCACONH were acquired. With the 
aid of a summer project student, Sam Walpole, it was possible to assign the majority of 
the backbone of Grb2N as shown in Figure 4.16 A (Wittekind et al., 1997).  
However, as has been highlighted in Figure 4.16 B, there were several residues for which 
there were two peaks appearing on the HSQC spectrum. The corresponding peaks in the 
HNCACB and CBCACONH spectra for the HSQC peaks, were equally duplicated. There 
are two possible explanations for this. Firstly, it has been shown that Grb2N dimerises 
with itself in vitro and in vivo (Lin et al., 2012). Secondly, it could be that Grb2N exists in 
two forms here, a full folded form and a partially, or entirely, unfolded form. Half of the 
duplicated peaks reside between 8.0 ppm and 8.5 ppm in the 1H dimension which is 
characteristic of unfolded residues making the second explanation more likely here 
(Kosol et al., 2013).  
In order to improve folding in future experiments, the purification protocol was altered 
to include an incubation step in the presence of 8 M urea and 1 mM DTT for 4-5 hours 
at 25 °C after the size exclusion step. The urea was removed by dialysis but the DTT 
concentration was maintained in order to prevent possible dimerisation of the Grb2N 
with itself. The urea incubation was intended to unfold all the protein in the sample and 
allow it to refold as the urea was removed. However, this did not improve the peak 
duplication in the HSQC.  
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Figure 4.15 A) Glutathione sepharose purification of GST-tagged Grb2N. B) Thrombin digestion 
optimisation to remove GST tag. C) SDS PAGE gel of peaks from the size exclusion separation of GST and 
Grb2N. D) Chromatogram of the size exclusion column. 
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Figure 4.16 A) [1H-15N] HSQC of Grb2N showing backbone assignments. B) [1H-15N] HSQC highlighting 
those peaks which were duplicated. Peaks highlighted with red assignments are located in positions 
expected from residues within a folded region. The peaks highlighted with green assignments are for the 
same residues but residing within a region which implies disordered residues. 
A 
B 
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Based upon the purification technique from a different Grb2N publication (Wittekind et 
al., 1997), the purification was repeated but in 50 mM Tris.HCl pH 8.0 rather than SPB. 
When the sample was separated by size exclusion chromatography, a small shoulder 
appeared on one of the peaks as shown in Figure 4.17 B. When a sample of each fraction 
was analysed by SDS PAGE gel electrophoresis (Figure 4.17 A), both the shoulder and 
the main peak appeared to contain Grb2N, although to a much smaller extent in the 
shoulder. In order to investigate whether this shoulder represented a partially unfolded 
version of the SH3 domain, each fraction was concentrated separately and [1H-15N] 
HSQC were collected for each. Figure 4.17 C shows these spectra overlaid with an 
example of the HSQC prior to the Tris.HCl purification. Although there were some 
differences between the spectra, neither set of the duplicated peaks is removed entirely, 
confirming that the current purification protocol was not specific enough to separate 
the folded and unfolded forms of Grb2N. 
Finally, ion exchange chromatography was attempted in order to try to purify only the 
folded form of Grb2N as this technique had been used in the purification of the domain 
in previous publications. Unfortunately, the chromatogram and subsequent SDS PAGE 
gel electrophoresis, shown in Figure 4.18, show that this technique was also unable to 
separate the folded and unfolded forms of this protein nor remove the cleaved GST tag. 
 
4.9 Conclusions and Discussion 
This chapter has discussed the interactions of the scaffolding protein, Grb2, with the 
splice variant intracellular domains of ADAM15. Initially the results demonstrated that, 
in the case of the C-terminal SH3 domain of Grb2 and given that the interactions 
observed were not dependent on the RGTK motif, one of proline-rich region 1, 4 or 5, 
from the ADAM15 ICDs is responsible and thus follows a more traditional interaction 
pathway. Unfortunately, it is not possible to say which exactly region is responsible here 
or if multiple polyproline region cooperate to facilitate binding without further mutation 
studies. However, previous truncation studies using ADAM15 A, have shown that the N-
terminal proline-rich region (proline-rich region 1), inhibited interaction with full length 
Grb2, although this was relaxed upon phosphorylation of the ADAM15 A ICD 
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(Poghosyan, 2001). Pull down studies showed that proline-rich region 4, which is the 
second motif of ADAM15 A, held considerable importance for interactions with 
endogenous Grb2, as removal of this motif dramatically reduced the amount of Grb2 
pulled down from breast cancer cell lysate. Mutants with the final proline-rich region, 
P5, removed, showed some reduced interaction but not to the same extent as when P4 
was removed (Poghosyan, 2001). Combining this with the NMR data discussed in this 
chapter, it is highly likely that P4 is the primary proline-rich region of the ADAM15 ICDs 
involved in the interaction with Grb2C.  
Unfortunately, the inability to produce entirely folded Grb2N presented a number of 
issues with regards to collecting titration data to study the interaction of the ADAM15 
ICDs. Although the peak intensity of the duplicated peaks implies that the proportions 
of unfolded and folded were fairly equal, it would not be possible to quantifiably study 
any potential interaction exhibited. Additionally, there may have been some interaction 
between the ADAM15 ICDs and the unfolded protein which would render the results 
unreliable. This means it was not possible to study the potential interactions between 
Grb2N and the ADAM15 ICDs despite it being shown by pull down in chapter 3 that 
Grb2N had the ability to interact with the ADAM15 ICDs, apart from variant D. This is 
disappointing as it means it was not possible to entirely confirm which SH3 domain from 
Grb2 provides the primary mechanism of interaction with ADAM15 in a biological 
setting.  
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Figure 4.17 A) SDS PAGE gel electrophoresis of the size exclusion chromatography column. B) 
Chromatogram of the size exclusion chromatography column showing the shoulder on peak 2. C) [1H-15N] 
HSQC spectra of 15N Grb2N. The blue spectrum is an example of Grb2N using the previous purification 
protocol. In purple is the spectrum of the main peak containing Grb2N from the size exclusion column and 
the green spectrum shows the protein purified from the shoulder of this peak. 
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Figure 4.18 A) SDS PAGE gel electrophoresis of the fractions from the anion exchange chromatography. 
B) Chromatogram of the anion exchange chromatography. 
 
In a biological setting, the N-terminal SH3 domain is responsible for the primary function 
of Grb2, namely interactions with Son of Sevenless (SoS) (McDonald et al., 2012a), the 
guanine nucleotide exchange factor responsible for GTP hydrolysis of Ras, thus initiating 
the MAPK cascade. This relies upon recruitment of Grb2 by phosphorylated Receptor 
Tyrosine Kinases (pRTKs) by the central SH2 domain (Belov and Mohammadi, 2012). By 
contrast, the C-terminal SH3 domain interacts with Gab1, via the non-canonical RxxK 
motif (McDonald et al., 2012b), and to proteins such as mutant Huntingtin (Baksi et al., 
2014) and UVRAG (Roy et al., 2014). It is currently unclear as to how the interaction of 
Grb2 with ADAM15 plays a role in cell function. However, Grb2 has been shown to be 
required for FGF7 (also known as Keratinocyte Growth Factor) induced motility in MCF-
7 breast cancer cells via the activation of ERK 1/2 (Zang et al., 2004). It has also been 
shown that ADAM15 increases migration and proliferation in breast cancer in an ERK 
1/2 phosphorylation dependent manner (Sun et al., 2010) so there could potentially be 
crossover in these pathways. As mentioned previously, Grb2 inhibits FGFR2 until the 
introduction of a growth factor, such as FGF7, at which point, the conformational change 
in FGFR2 leads to the cross-phosphorylation of Grb2 and subsequent release thus 
activating FGFR2 (Lin et al., 2012). ADAM15 B has also been shown to shed a splice 
variant of FGFR2, specifically FGFR2iiib, in an apparently Src dependent manner 
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(Maretzky et al., 2009b). ADAM15 B expression is linked to more aggressive forms of 
node negative breast cancer (Zhong et al., 2008). Although it is unclear precisely how 
the interaction of Grb2 and ADAM15 is relevant to their biological functions, there is 
significant overlap of pathways in which both proteins are involved and even greater 
correlation of the phenotypic behaviour of breast cancer cells exposed to high levels of 
these proteins, which lends credence to their connected role in breast cancer 
progression and is likely reliant upon the P4 region of the ADAM15 ICD. 
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In summary, this chapter has shown that: 
 Purification of the Grb2C domain was optimised. 
 The backbone of 13C, 15N Grb2C was assigned. 
 Titrations of the 15N Grb2C domain with the ADAM15 ICDs demonstrated a 
consistent binding interface including 22Glu, 44Trp and 56Phe; 
o Also 13Gln in the presence of ADAM15 A and E; 
o Also 58Arg in the presence of ADAM15 B and C; 
o Larger CSPs imply a stronger interaction with ADAM15 E. 
 ADAM15 D does not interact with 15N Grb2C. 
 Non-specific interactions between the ADAM15 ICDs and 15N Grb2C caused 
protein aggregation and precipitation at higher concentrations. 
 A proposed RXXK motif was not responsible for any interaction observed. 
 Highly likely that the polyproline region 4 of the ADAM15 ICDs is responsible for 
the observed interactions with 15N Grb2C. 
 Grb2N proved difficult to purify due to partially folded and unfolded states; 
o Exposure to urea did not aid refolding; 
o Size exclusion could not separate the folded and unfolded forms; 
o Ion exchange chromatography was unsuccessful despite success in 
previous publications. 
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Chapter 5: Interactions of Src and Brk with the ICDs of ADAM15  
 
5.1 Introduction to Src 
The human protein tyrosine kinase Src is 536 residues long and contains, starting from 
the N-terminus, a long unfolded region, an SH3 domain, a SH2 domain, a proline-rich 
linker sequence, a tyrosine kinase domain and a C-terminal tail (Wheeler et al., 2009). 
The SH3 and SH2 domains work together to regulate the catalytic activity of the tyrosine 
kinase domain through their ability to interact with proline-rich sequences and 
phosphotyrosine containing short motifs respectively. The SH3 domain of Src follows the 
same structural pattern as other SH3 domains (Saksela and Permi, 2012). It contains five 
β-strands, a RT loop, a distal loop, an n-Src loop and a short α-turn as shown in figure 
5.1 (Yu et al., 1993). 
 
 
 
 
 
 
Figure 5.1 Structure of the SH3 domain of Src (1SRL (Yu et al., 1993)) with the RT loop, the distal loop, the 
n-Src loop and the α-turn highlighted. 
 
Src has been shown previously to interact with the ICDs of ADAM 15 variants B and C 
but not with variant A (Zhong et al., 2008). This was reinforced in the data presented in 
chapter 3.  In this chapter, each ADAM15 ICD was titrated into the SH3 domain of Src 
and the interaction studied by HSQC NMR experiments.  
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5.2 Purification of the Src SH3 domain 
As our construct for the Src SH3 domain has a GST fusion tag, the protocol used was 
based upon the same principles as for the purification of Grb2C as can be seen in figure 
5.2. Affinity purification was used to separate the protein from the cell lysate. After 
enzymatic digestion with thrombin to remove the GST fusion tag, these were separated 
using size exclusion chromatography. The concentrated sample was stored at -20 °C. 
 
Figure 5.2 SDS PAGE gels for the purification of the Src SH3 domain. A) Glutathione sepharose column 
fractions with the GST-Src SH3 domain eluted at 300 mM glutathione in elution 1. B) Thrombin digestion 
optimisation with various thrombin amounts at room temperature. C) Akta chromatogram for the size 
exclusion showing 3 peaks D) SDS PAGE gel of the fractions of the size exclusion column with the peaks 
from which they originated highlighted. Peak 1 contained the GST fusion tag, peak 2 the Src SH3 domain 
and peak 3 containing no protein. 
 
5.3 Assignment of Src SH3 domain 
In order to assign the backbone of the Src SH3 domain, 13C-, 15N-labelled recombinant 
protein was produced as described above. HSQC, HNCαCβ and CβCαCONH spectra were 
acquired. Along with 1H and 15N assignments from Yu and colleagues (Yu et al., 1993), 
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these were used to assign the full 1H, 15N, 13Cα and 13Cβ of the Src SH3 domain with the 
exception of Gly1, Ser2, Pro55 and Pro61 (13Cα and 13Cβ assigned for Pro55 and 61). The 
successfully assigned peaks are shown on a HSQC spectrum in figure 5.3. 
 
Figure 5.3 1H, 15N HSQC spectrum of the Src SH3 domain with peak assignments 
 
5.4 Titrations of Src SH3 domain with the cytoplasmic domains of 
ADAM15 
As with the titrations of the Grb2C with the ADAM15 ICDs, two NMR samples were made 
for each titration with sample A containing 0.5 mM 15N Src SH3 domain and sample B 
containing 0.5 mM 15N Src SH3 domain and 1.5 mM of the appropriate ADAM15 ICD. 
After acquiring HSQC spectra for these data points, small volumes were removed from 
sample A and replaced with the same volume from sample B which maintained the 
concentration of the labelled Src SH3 domain while providing intermediate 
concentrations of the ADAM15 ICD. In order to ensure that all the chemical shift 
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perturbations observed are exclusively due to the interaction of the Src SH3 domain with 
the ADAM15 ICD involved, the SH3 domain was also titrated with the GB1 tag. The small 
chemical shift perturbations (CSPs) caused by the presence of the tag were subtracted 
from further titration CSPs when the ADAM15 ICDs were involved.  
As shown in figure 5.4 A, there were very small changes between the spectrum for 
0.5 mM Src SH3 alone and the spectrum for 0.5 mM Src SH3 in the presence of 0.5 mM 
GB1 tag. These were quantified using the same calculation for chemical shift 
perturbation as for Grb2C as shown below: 
CSP (Δppm) = √(𝛥𝛿𝐻𝑁)2 + (𝛥𝛿𝑁 ∗ 0.15)2   (Equation 2) 
The CSPs caused by the presence of the GB1 tag are shown in figure 5.4 B.  
As can be seen in figure 5.5 A, several peaks in the spectrum for the 15N Src SH3 domain 
undergo chemical shift perturbations indicating that there is an interaction between the 
ADAM15 A ICD and the Src SH3 domain. The chemical shift perturbations observed at a 
ratio of 0.5 mM Src SH3 to 0.5 mM ADAM15 A (with the CSPs caused by the GB1 tag 
subtracted) are lower than those observed for the interaction of Grb2C with ADAM15 A 
and do not follow the usual pattern of interaction shown by the Src SH3 domain with 
other proline-rich motifs. The biggest movements displayed are 17Arg, 20Thr, 53Tyr, 
54Ile and 57Asn.  
Unlabelled ADAM15 B was titrated into 0.5 mM 15N Src SH3 to a final concentration of 
1.5 mM ADAM15 B as previously. The spectra for this titration can be seen in figure 5.6 
A with the chemical shift perturbations shown in figure 5.6 B. The shifts caused by the 
presence of ADAM15 B were much greater than those caused by ADAM15 A with some 
CSPs caused by ADAM15 B being more than double those caused by ADAM15 A. 
Although the reaction does not saturate at these concentrations, larger chemical shift 
perturbations implied a tighter interaction between the Src SH3 domain and ADAM15 B 
than with ADAM15 A. The residues most affected by the interaction are 17Arg, 19Glu, 
22Leu, 36Thr, 40Trp, 41Trp, 53Tyr and 57Asn.  
The spectra for the titration of 15N Src with ADAM15 C are shown in figure 5.7 A and the 
quantification of the chemical shift perturbations are shown in B. The CSPs here are 
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lower than those caused by ADAM15 B but still much higher than for the interaction 
with ADAM15 A. The residues most involved in the interaction are 17Arg, 19Glu, 36Thr, 
40Trp, 56Ser and 57Asn. This interaction follows a similar pattern to that of the 
interaction of the Src SH3 domain with ADAM15 B. 
ADAM15 D was titrated into 0.5 mM 15N Src SH3 domain to a final concentration of 
1.5 mM and observed by HSQC as for the previous titrations which can be seen in figure 
5.8 A. There were very few changes between the spectra for 0.5 mM Src SH3 domain 
alone and in the presence of 0.5 mM ADAM15 D and any peak movements observed 
were very small in comparison to those caused by the other ADAM15 ICDs, even 
ADAM15 A. This would imply that ADAM15 D does not interact with the SH3 domain of 
Src. This is expected since ADAM15 D does not contain any proline-rich motifs and the 
Src SH3 domain has not been shown to interact with any other motifs.  
Figure 5.9 A shows the chemical shift perturbations of the 15N Src SH3 domain caused 
by the presence of ADAM15 E, with the quantification of these shown in B. A similar 
pattern of peak movements to those caused by ADAM15 B and C can be observed, 
implying that there is a similar interaction, although these were smaller than those of 
ADAM15 B. The residues most affected are 17Arg, 19Glu, 22Leu, 36Thr, 40Trp, 41Trp, 
53Tyr, 56Ser and 57Asn. 
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Figure 5.4 A) 1H, 15N HSQC spectra for the 15N Src SH3 domain by itself (navy blue), in the presence of 0.5 
mM GB1 tag (cyan) and in the presence of 1.5 mM GB1 tag (green). Concentration of the Src SH3 domain 
was 0.5 mM in all spectra. B) Chemical shift perturbations caused by the presence of GB1 tag on the 
spectrum of the Src SH3 domain at 0.5 mM of each protein.  
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Figure 5.5 A) 1H, 15N HSQC spectra for the 15N Src SH3 domain by itself (navy blue), in the presence of 0.5 
mM ADAM15 A (cyan) and in the presence of 1.5 mM ADAM15 A (green) and the intermediates in 
intermediate shades as indicated in the key. Concentration of the Src SH3 domain was 0.5 mM in all 
spectra. B) Chemical shift perturbations caused by the presence of ADAM15 A on the spectrum of the Src 
SH3 domain at 0.5 mM of each protein.  
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Figure 5.6  A) 1H, 15N HSQC spectra for the 15N Src SH3 domain by itself (navy blue), in the presence of 0.5 
mM ADAM15 B (cyan) and in the presence of 1.5 mM ADAM15 B (green) and the intermediates in 
intermediate shades as indicated in the key. Concentration of the Src SH3 domain was 0.5 mM in all 
spectra. B) Chemical shift perturbations caused by the presence of ADAM15 B on the spectrum of the Src 
SH3 domain at 0.5 mM of each protein.  
156 
 
 
Figure 5.7 A) 1H, 15N HSQC spectra for the 15N Src SH3 domain by itself (navy blue), in the presence of 0.5 
mM ADAM15 C (cyan) and in the presence of 1.5 mM ADAM15 C (green) and the intermediates in 
intermediate shades as indicated in the key. Concentration of the Src SH3 domain was 0.5 mM in all 
spectra. B) Chemical shift perturbations caused by the presence of ADAM15 C on the spectrum of the Src 
SH3 domain at 0.5 mM of each protein.  
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Figure 5.8 A) 1H, 15N HSQC spectra for the 15N Src SH3 domain by itself (navy blue), in the presence of 0.5 
mM ADAM15 D (cyan) and in the presence of 1.5 mM ADAM15 D (green) and the intermediates in 
intermediate shades as indicated in the key. Concentration of the Src SH3 domain was 0.5 mM in all 
spectra. B) Chemical shift perturbations caused by the presence of ADAM15 D on the spectrum of the Src 
SH3 domain at 0.5 mM of each protein.  
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Figure 5.9 A) 1H, 15N HSQC spectra for the 15N Src SH3 domain by itself (navy blue), in the presence of 0.5 
mM ADAM15 E (cyan) and in the presence of 1.5 mM ADAM15 E (green) and the intermediates in 
intermediate shades as indicated in the key. Concentration of the Src SH3 domain was 0.5 mM in all 
spectra. B) Chemical shift perturbations caused by the presence of ADAM15 E on the spectrum of the Src 
SH3 domain at 0.5 mM of each protein.  
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5.5 Comparison of the Binding Interface of the Src SH3 domain with 
different ADAM15 ICDs 
In order to compare directly the effects of the interaction of each ADAM15 ICD with the 
Src SH3 domain, the chemical shift perturbations caused by each ICD (with the CSPs for 
GB1 subtracted) were combined onto one graph, shown in figure 5.10. The average CSP 
for all the titrations was calculated and are shown, along with the average plus the 
standard deviation and the average plus half of the standard deviation. These limits 
were used to define the boundaries mapped onto the structure of the Src SH3 domains 
seen in figure 5.11, with those residues with CSPs that were greater than the average 
plus the standard deviation highlighted in the darkest colour, with progressively lighter 
colours for the other boundaries. Those values below average are not significantly 
affected by the interactions.  
From this analysis, it is even clearer that ADAM15 D does not interact with the Src SH3 
domain. Only two residues of the Src SH3 domain display movements large enough to 
be above average when in the presence of ADAM15 D and, when the CSPs caused by 
ADAM5 D are removed from the average calculation, the average value shifts up and no 
ADAM 15 D caused shifts reach this value. It is likely that there is no interaction between 
ADAM15 D and the Src SH3 domain due to ADAM15 D’s lack of any proline-rich motifs. 
The chemical shift perturbations caused by ADAM15 B, C and E are all fairly similar in 
their magnitude and follow an almost identical pattern in terms of which residues are 
involved in the interactions. This would imply that they all interact with the Src SH3 
domain through a consistent motif across all three ADAM15 ICDs. When compared to 
those resides shown to be involved in other interactions of the Src SH3 domain, 
highlighted in figure 5.10 with green boxes (Sparks et al., 1994), there are strong 
correlations, especially at residues 17Arg, 21Asp, 40Trp and 56Ser – 58Tyr. Although 
residues 12Try – 15Glu from the RT loop have been shown to be involved in previous 
studies, they are not here with the possible exception of 14Tyr to a small extent. 
Residues 16Ser – 22Leu are involved and this string of amino acids also reside on the RT 
loop of the domain. This means that the interface displayed here is consistent with those 
seen in the literature and also involves the α-turn portion of the protein. 
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Figure 5.10 Chemical shift perturbations caused by each ADAM15 ICD, with those caused by ADAM15 A 
in orange, B in blue, C in red, D in green and E in purple, on the Src SH3 domain. The residues highlighted 
in green boxes have been shown to be involved in the interaction of the domain with other proline-rich 
motifs. Also highlighted are some structural features of the domain. 
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Figure 5.11 Chemical shift perturbations caused by each ADAM ICD, displayed on the 3D structure of the 
Src SH3 domain (PDB code 1SRL (Yu et al., 1993)). The darkest colour for each indicates those CSPs larger 
than the average plus the standard deviation. The middle colour indicates the residues with a CSP higher 
than the average plus half of the standard deviation and the lightest colour shows those residues with 
CSPs above average.  
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Unfortunately, as with the titrations of Grb2C, the interactions between the Src SH3 
domain and the ADAM15 ICDs do not saturate even at the highest concentrations 
involved. As the ADAM15 ICDs precipitate at more than 1.5-2 mM, it was not possible 
to increase the final concentrations of the titration to saturate the binding and calculate 
the Kd accurately. However, as discussed in chapter 4, the larger chemical shift 
perturbations are an indicator of a tighter interaction as they represent interactions that 
are closer to the saturation chemical shift (Williamson, 2013). In this case, that would 
be those caused by ADAM15 B, by a significant margin. The CSPs caused by ADAM15 C 
and E are extremely similar in magnitude which would imply they have bind to the Src 
SH3 domain with a similar strength.  
 
5.6 Introduction to Brk 
Breast tumour kinase, Brk, (also known as Protein-Tyrosine Kinase 6, PTK6) is a non-
receptor tyrosine kinase in a similar, but distinct, family to that of the Src family of 
tyrosine kinases. It contains an SH3 domain from residues 11-72, an SH2 domain from 
residues 78-170 and a protein kinase domain from residues 191-445 (Lee et al., 1998). 
The myristolation site required for the Src family kinases to be membrane-bound is not 
included in Brk thus allowing it to exist as a cytoplasmic protein. As discussed in 
chapter 1, Brk exists in two splice variants, with one variant excluding exon 2 creating a 
unique C-terminal region but both variants include the SH3 domain (Mitchell et al., 
1997). Dephosphorylation of Tyr 447 is required for release of the SH2 domain and 
destabilisation of interactions between the SH3 domain and the linker domain, which 
maintains the “closed”, inactive conformation of Brk, in order to active the “open” 
conformation of the enzyme (Qiu and Miller, 2002). This is an activation pathway that 
Brk shared with Src. The linker region of Brk contains a type II polyproline helix with the 
sequence HEPEPLPHW which sits within the hydrophobic pocket of the SH3 domain 
when Brk is in the “closed” conformation consisting of Phe19, Trp44, Pro63 and Tyr66 
which follows the canonical interaction of SH3 domains with polyproline motifs (Ko et 
al., 2009). The SH3 domain has also been shown to interact with the P424XXP427 sequence 
within the C-terminal region of Akt and thus contributes to the regulation of the 
phosphorylation and activation of Akt (Zheng et al., 2010). 
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The structure of the Brk SH3 domain follows a similar structural arrangement as the 
other SH3 domains discussed in this thesis with the exception of the α-turn which is 
missing here and is shown in figure 5.12 (Ko et al., 2009). 
 
Figure 5.12 Structure of the SH3 domain of Brk (2KGT (Ko et al., 2009)) with the RT loop, n-Src loop and 
distal loop highlighted. This SH3 domain lacks the α-turn.  
 
 
5.7 Optimisation of the purification of the Brk SH3 domain 
As with the other SH3 domains studied in this thesis, the Brk SH3 domain had a GST 
fusion tag for purification purposes. As can be seen in figure 5.13, a small scale 
expression test of the Brk SH3 domain demonstrated that the protein could be 
expressed well in BL21 (DE3) cells for up to 3 hours at 37 °C but that the protein began 
to degrade in-cell when induced for longer than this and so initial investigations began 
with the comparison of the expression of the recombinant domain at either 37 °C for 
3 hours of at 28 °C overnight in order to gain the maximum expression and minimum 
degradation. These can be seen in figure 5.14 A and B. Expression was significantly 
higher in the culture that had been induced at 28 °C overnight and so this culture 
technique was used in all further purifications.  
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Figure 5.13 Test expression of the Brk SH3 domain in BL21 (DE3) cells with induction for the indicated 
times at 37 °C. 
 
Unlike the other SH3 domains studied, the linker region between the GST fusion tag and 
the Brk SH3 domain was sensitive to digestion by the enzyme Factor Xa, rather than 
thrombin. Optimisation of the digestion was undertaken by the incubation of 1 mg of 
the recombinant fusion protein with either 1, 3, 5, 7.5 or 10 units of Factor Xa at 25 °C 
overnight. The results of this can be seen in figure 5.14 C and 7.5 units per mg protein 
was selected for future use in the purification process. The digested protein sample was 
then concentrated to approximately 2.5 ml and then loaded onto the gel filtration 
column in order to separate the now cleaved GST fusion tag from the Brk SH3 domain. 
Unfortunately, as can be seen in figure 5.14 D, separation was unsuccessful and a large 
portion of the Brk SH3 domain has been lost while the amount of GST fusion tag appears 
to have remained the same. It was suggested that this could be due to the recombinant 
SH3 domain sticking to the membrane of the spin concentrator used to reduce the 
sample volume after digestion to a more suitable volume for size exclusion 
chromatography. The membrane in the Vivaspin spin concentrators used previously is 
made from polyethersulfone (PES). While this is usually a suitable membrane material 
for use in spin concentrators, a small number of proteins will bind to this membrane and 
very little will be released by washing of the membrane when the concentrated sample 
is removed. In order to confirm if this is indeed an issue, another digested sample was 
concentrated for size exclusion using a spin concentrator with a cellulose rather than 
PES membrane. Once concentrated, a sample was studied by SDS PAGE gel 
165 
 
electrophoresis to confirm that the protein was still present and not bound to the 
membrane. This can be seen in figure 5.15, and due to the success seen here, the Amicon 
Ultra-15 spin concentrators were used whenever the volume of the Brk SH3 domain 
required reducing in future purifications. When this sample was separated by size 
exclusion chromatography, separation was significantly improved and no further Brk 
was lost during this stage of purification.  
 
Figure 5.14 SDS PAGE gel electrophoresis of A) Glutathione sepharose purification of GST-fusion Brk SH3 
domain expressed at 37 °C for 3 hours. B) Glutathione sepharose purification of GST-fusion Brk SH3 
domain expressed at 28 °C overnight. C) Optimisation of the digestion of the GST fusion tag from the Brk 
SH3 domain by Factor Xa using varied amounts of the enzyme as indicated at 25 °C overnight. D) First 
failed separation of cleaved GST fusion tag from the Brk SH3 domain by size exclusion chromatography. 
 
Unfortunately, when expression of the Brk SH3 domain was attempted with 13C and 15N 
labelling, the expression was significantly reduced compared to unlabelled expression. 
While some reduction in expression is expected due to the use of minimal media in order 
to limit the sources of these isotopes to only the labelled forms provided causing a 
harsher environment for the bacterial cells to grow in, reductions of this level were 
unexpected. Unfortunately, due to time restraints, it was not possible to confirm exactly 
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what was causing this poor expression in minimal media and so NMR experiments were 
conducted using a lower concentration of labelled SH3 domain than in previous studies.  
 
Figure 5.15 SDS PAGE gel electrophoresis of the concentrated digested sample of GST fusion tag and Brk 
SH3 domain concentrated using an Amicon Ultra-15 spin concentrator with a cellulose membrane. 
 
5.8 Assignment of the Brk SH3 domain backbone 
Recombinant Brk SH3 domain, labelled with 13C and 15N isotopes, was purified. HSQC, 
HNCACB and CBCACONH experiments spectra were acquired using the 500 MHz 
spectrometer. Along with the 1H and 15N assignments from Lee and Sunggeon (Ko et al., 
2009), it was possible to assign 65% of the recombinant Brk SH3 domain. This included 
the sequence of the entire Brk SH3 domain but did not include the extensions included 
in the protein construct that arise from the linker region between the domain and the 
GST fusion tag at the N-terminus and the vector sequence at the C-terminus of the 
desired SH3 domain. These extra residues within the recombinant protein are predicted 
to be disordered, using PONDR Disorder Predictor (Li et al., 1999; Romero et al., 1997; 
Romero et al., 2001), and could account for the high number of overlapping peaks 
between 8.0 and 8.5ppm in the 1H dimension. Due to the low concentration of the 
sample, many of these peaks did not have corresponding signals in the triple resonance 
HNCACB or CACBCONH resulting in those peaks were very difficult to reliably assign. The 
HSQC spectrum for the Brk SH3 domain is shown in figure 5.16. 
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Figure 5.16 1H, 15N HSQC of the Brk SH3 domain with peak assignments.  
 
5.9 Titration of the Brk SH3 with the cytoplasmic domain of ADAM15 B 
As with the previous titrations, two samples were made. Sample A contained 0.1 mM 
15N Brk SH3 domain in HEPES buffer. Sample B contained 0.1 mM Brk and 1 mM 
unlabelled ADAM15 B or the unlabelled GB1 tag. These represented the first and final 
points of the titration and intermediate data points were achieved by removal of a small 
volume from sample A and replacing this with an equal volume of sample B, thus 
maintaining the concentration of the 15N Brk SH3 domain and slowly increasing the 
concentration of the unlabelled ligand protein in sample A. Due to time constraints, only 
ADAM15 B was titrated with the Brk SH3 domain as this was representative of all of the 
interactions exhibited with the Src SH3 domain and the Grb2 C-terminal SH3 domain. As 
with the previous titrations, the unlabelled GB1 tag was also titrated with the Brk SH3 
domain in order to confirm that any chemical shift perturbations observed were due to 
the presence of ADAM15 B and not the GB1 tag. 
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Figure 5.17 A) 1H, 15N HSQC spectra for the 15N Brk SH3 domain by itself (navy blue), in the presence of 
0.1 mM GB1 tag (cyan) and in the presence of 1.0 mM GB1 tag (green). Concentration of the Brk SH3 
domain was 0.1 mM in all spectra. B) Chemical shift perturbations caused by the presence of the GB1 tag 
on the spectrum of the Brk SH3 domain at 0.1 mM of each protein. 
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Figure 5.18 A) 1H, 15N HSQC spectra for the 15N Brk SH3 domain by itself (navy blue), in the presence of 
0.1 mM ADAM15 B (cyan) and in the presence of 1.0 mM ADAM15 B (green) and the intermediates in 
intermediate shades as indicated in the key. Concentration of the Brk SH3 domain was 0.1 mM in all 
spectra. B) Chemical shift perturbations caused by the presence of the ADAM15 B on the spectrum of the 
Brk SH3 domain at 0.1 mM of each protein. 
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The chemical shift perturbations were calculated using equation 2 described in section 
5.4. As can be seen in figure 5.17 A, there are some chemical shift perturbations in the 
HSQC of the Brk SH3 domain implying that there is some level of interaction with 
between the GB1 tag and the SH3 domain. This looks to be a significant interaction in 
figure 5.17 A but this is due to the scale of the graph, which is the same as that required 
for the titration with ADAM15 B shown in figure 5.18 B. The CSPs caused by the GB1 tag 
here are similar in magnitude to those observed with the other SH3 domains in this 
thesis. However, a few residues are more heavily affected by the presence of the GB1 
tag that has been previously seen including 16Arg, 17Asp, 18Gln, 21Leu and 65Ala. As 
with the previous titrations, the CSPs caused by the presence of the GB1 tag were 
subtracted from those seen in the titration of the Brk SH3 domain with ADAM15 B, the 
spectra of which can be seen in figure 5.18 A. Figure 5.18 B shows the quantification of 
the CSPs of the Brk SH3 domain caused by the presence of ADAM15 B. There is an 
interaction seen between the Brk SH3 domain and ADAM15 B although the CSPs are not 
large which implies that the interaction is fairly weak. Those residues most affected 
include 34Arg, 56Trp, 74Val, 77Asn and 79Leu. The average CSP was calculated along 
with the standard deviation of the CSPs. The residues which shifted by more than the 
average CSP was mapped in light blue onto the surface model of the Brk SH3 domain, 
with those residues that shifted by more than the sum of the average and the standard 
deviation in middle blue and the residues that shift the most, by more than the sum of 
the average and 2 standard deviation, in dark blue as can be seen in figure 5.19. 
 
Figure 5.19 Chemical shift perturbations caused by the presence of ADAM15 B mapped onto the structure 
of the Brk SH3 domain (2KGT (Ko et al., 2009)) with those residues that shifted by more than the average 
+ 2 standard deviation in dark blue, those that shifted by more than the average + standard deviation in 
middle blue and those that shifted by more than the average in light blue. The centre model is the cartoon 
model of the same. The right model has been rotated through 90° from the orientation of the left model. 
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5.10 Conclusions and Discussion 
In this chapter, the interactions of the SH3 domains of the tyrosine kinases Src and Brk 
have been studied. In the case of the Src SH3 domain, ADAM15 D was shown to not 
interact with the Src SH3 domain at all, likely due to the lack of any polyproline motifs 
within the ICD of ADAM15 D. ADAM15 B, C and E all interact with Src with similar CSP 
intensity and with almost identical interaction interfaces. Several common residues are 
affected by the presence of these ADAM15 ICDs including 17Arg, 21Asp, 40Trp and 
56Ser-58Tyr. ADAM15 A also demonstrated some interaction with the Src SH3 domain, 
involving similar residues as those affected by ADAM15 B, C and E but with significantly 
smaller chemical shift perturbations. 
In order to explain which proline-rich motif from the ADAM15 ICDs is involved in binding 
to the Src SH3 domain, it is necessary to consider the domains common to ADAM15 B, 
C and E along with the proline-rich motifs previously shown to interact with the Src SH3 
domain. Class I poly-proline motifs follow the pattern of + p Ψ P p Ψ P where + stands 
for basic residues and Ψ stands for aliphatic residues and p can be a proline. Class II poly-
proline motifs follow the pattern of Ψ P p Ψ P p +. The SH3 domain of Src has been 
shown to be capable of interacting with SH3-binding proteins containing poly-proline 
motifs of both classes (Teyra et al., 2012). For example, CDC42 will interact with the Src 
SH3 domain through a Class I motif whereas dynamin contains a Class II motif which 
interacts with the Src SH3 domain (Feng et al., 1994). Each ADAM15 ICD contains a 
combination of the 5 potential poly-proline regions, apart from ADAM15 D, as has been 
highlighted in figure 5.20, ADAM15 B contains poly-proline regions 1, 2, 4 and 5, 
ADAM15 C contains all five regions and ADAM15 E contains regions 1, 3, 4 and 5. As 
ADAM15 D is a frame-shift variant, it does not contain any proline-rich regions (Zhong 
et al., 2008).  
When these regions are aligned, it is clear that poly-proline region 2 (P2) and poly-
proline region 3 (P3) have fairly strong sequence homology across the whole region. 
However, the sequences in those two regions, underlined in figure 5.20 B, have strong 
homology with a Class I sequence, RPLPPLP, which has been shown to interact with the 
Src SH3 domain previously through the residues highlighted in green in figure 5.10 
(Sparks et al., 1994). As ADAM15 B, C and E all contain one or both of these poly-proline 
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regions, it is highly likely that it this sequence that is most strongly involved in the 
interaction.  
Figure 5.20 Amino acid alignment of the ADAM15 ICDs. A) Full ICDS with the poly-proline regions 
highlighted. B) The poly-proline regions only aligned in the same colour as in A. 
 
This also goes some way to explain the low level of interaction shown between the Src 
SH3 domain and ADAM15 A. There is no direct interaction between Src and ADAM15 A 
in a biological setting (Zhong et al., 2008) but, in the spectrometer, the presence of 
ADAM15 A does cause some peaks of the Src SH3 domain to shift. Although these are 
larger than for ADAM15 D and several residues cross the average CSP limit and even the 
average plus half the standard deviation limit, it is likely that the shifts observed are due 
to a weak interaction which only occurs due to the high concentration of the proteins in 
the spectrometer compared to endogenous levels. However, the pattern of CSPs agrees 
with that of ADAM15 B, C and E which would not occur if it was a non-specific 
interaction. When the sequence for P4 is compared with that of the RPLPPLP consensus 
sequence, it is apparent that there is a similar motif, KPLPADPQ, present. It is likely that 
this is contributing to the interaction observed here but due to the comparatively small 
interaction seen compared to the other ADAM15 ICDs; however, it is unlikely to have a 
biological function and is only observed here due to the high concentrations involved. 
The low intensity of the CSPs observed supports a lack of biological relevance as this 
implies a weaker binding intensity which would reduce the likelihood of functionality 
within a cell.  
In the case of the interaction observed with the Brk SH3 domain, the residues most 
involved were those of the 34Arg, 56Trp, 74Val, 77Asn and 79Leu. The magnitude of the 
chemical shift perturbations implied a fairly weak interaction. Those residues involved 
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here include several that form the hydrophobic core of the SH3 domain including 56Trp 
which is necessary for required for the auto-inhibition of full length Brk (Ko et al., 2009). 
Of the five most affected residues, three are common to those required for an 
interaction between the SH3 domain and the linker region in full length Brk which forms 
an important part of the auto-inhibition mechanism. Those residues are 34Arg, 56Trp 
and 77Asn which correspond to 22Arg, 44Trp and 65Asn in the full length enzyme. This 
suggests that the interaction between the Brk SH3 domain and ADAM15 B follows a very 
similar pattern to that of the Brk SH3 domain and Brk linker region. The residues from 
the linker region, corresponding to residues 175-179 correspond with a common 
polyproline motif PxPxP, here PEPLP, and it is this region that is required for the auto-
inhibition interaction, particularly the proline residues. Also required for the auto-
inhibition was 182Asp within the linker region (Ko et al., 2009).  
It is still not possible to determine which polyproline region of the ADAM15 ICDs is 
responsible for the interactions with the Brk SH3 domain. The interaction with ADAM15 
B implies a mechanism of interaction similar to that of the interaction between the SH3 
domain and the Brk linker region but sequences that include PxPxP motifs with a satellite 
aspartic acid residue exist in the polyproline regions 2, 3 and 4 of the ADAM15 ICDs. 
Previous pull down assays have indicated that ADAM15 C does not interact with the Brk 
SH3 domain (Zhong et al., 2008). As ADAM15 A and B do, this would imply that 
polyproline region 3 (P3) is not necessary for any potential interaction, as this region is 
not included in either ADAM15 A or B but is present in C, or perhaps even hinders any 
interaction. However, as any potential interaction between ADAM15 E, the only other 
ADAM15 ICD to include P3, and the Brk SH3 domain have yet to be studied,  it is 
impossible to conclude this with any certainty.  
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In summary this chapter has shown that: 
 Purification of the Src SH3 domain was optimised and the Brk SH3 domain 
partially optimised. 
 The [1H-15N]-HSQC of the 15N Src SH3 domain was assigned as with 65% of the 
peaks on the [1H-15N]-HSQC of the 15N Brk SH3 domain. 
 ADAM15 B, C and E cause CSPs in the peaks for 17Arg, 21Asp, 40Trp and 56Ser- 
58Tyr of the 15N Src SH3 domain. 
 ADAM15 D did not interact with the 15N Src SH3 domain. 
 ADAM15 B, C and E likely interact with the 15N Src SH3 domain through a 
RPLPXDPV present in polyproline regions 2 and 3. 
 ADAM15 A interacted with the Src 15N SH3 domain to a lesser extent, likely 
through a similar motif within P4. 
 The 15N Brk SH3 domain interacted with ADAM15 B via residues 34Arg, 56Trp, 
74Val, 77Asn and 79Leu. 
o Similar interaction pattern to inhibitory interaction of Brk linker region 
with Brk SH3 domain when in closed conformation. 
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Chapter 6: General Discussion and Future Work 
 
ADAM15 is a metalloproteinase which is expressed at high levels throughout breast 
cancer progression, particularly in the most aggressive forms (Kuefer et al., 2006). The 
expression of different splice variants, with splicing occurring in the intracellular domain 
as indicated in the schematic in figure 6.1, has been linked to poor prognosis in node-
negative breast cancer in the case of ADAM15 A and B whereas ADAM15 C has been 
correlated with a positive prognosis in node-positive cancer (Zhong et al., 2008). The 
intracellular domain splice variants can interact preferentially with proteins containing 
SH3 domains (Kleino et al., 2009; Zhong et al., 2008) and, as many of these proteins have 
been independently linked to breast cancer, these interactions were investigated here. 
The SH3 domains studied included the C-terminal and N-terminal SH3 domains of Grb2 
and the SH3 domains of the protein tyrosine kinases Src and Brk. Grb2 interacts with all 
the ADAM15 variants other than D, whereas the Src SH3 domain interacts with ADAM15 
B, C and E (Zhong et al., 2008). The Brk SH3 domain will interact with ADAM15 A and B 
but not C or D (Kärkkäinen et al., 2006). ADAM15 E has not been studied with regards to 
potential Brk interactions. Unfortunately, the problematic purifications of the ADAM15 
ICDs meant that potential interactions were only studied from the perspective of the 
SH3 domains but, despite this, it was possible in the case of the C-terminal Grb2 SH3 
domain and the Src SH3 domain to theorise the potential ADAM15 ICD motifs involved 
in the interactions to a greater degree of accuracy.  
Firstly, despite lineage doubts with regards to MDA-MB-435 cells used in previous 
studies (Sellappan et al., 2004), it was confirmed that those interactions observed by 
pull down assay in those studies were consistent in MCF-7 breast cancer cells. Due to 
size restrictions for detection by NMR spectroscopy, the GST fusion tag that was linked 
to the ADAM15 ICDs in the constructs generated by Dr Zaruhi Poghosyan was not 
suitable and the insolubility of the ADAM15 ICDs alone required the substitution of the 
GST tag for a smaller fusion tag which could remain tagged to the ADAM15 ICDs during 
the NMR spectroscopy while maintaining solubility. The immunoglobulin binding 1 
domain from group C and G Streptococcal bacteria (GB1) was chosen (Iwai et al., 2006) 
and the ADAM15 ICD genes were cloned into a vector introducing a His-GB1 tag. This 
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His-tag was used in an attempt to repeat the GST based pull downs from previous studies 
but this was unsuccessful due to non-specific interactions of the SH3 domain containing 
proteins with the Ni ions on the sepharose. Recombinant forms of each of the SH3 
domains in question did pull down the recombinant forms of the ADAM15 ICDs which 
confirmed that in vitro studies such as NMR titrations would be possible.  
Optimisation of the purification of the GB1-tagged ADAM15 ICDs proved to be 
problematic due to the in cell degradation or truncation of the proteins prior to 
purification  but samples were of sufficient quality to use as the unlabelled ligand 
proteins in NMR titrations. The [1H-15N]-HSQC of ADAM15 B was much cleaner than 
expected and opened the opportunities for potential further study. 
The interactions of the C-terminal SH3 domain of Grb2 with the ADAM15 ICDs indicated 
a consistent interaction interface across ADAM15 A, B, C and E with ADAM15 D 
demonstrating no interaction. Residues of Grb2C involved included 22Glu, 44Trp and 
56Phe in all of the interactions and additionally including 13Gln in the interactions with 
ADAM15 A and E and 58Arg in the interactions with ADAM15 B and C. As Grb2C had 
been shown to interact with Gab1 via a non-canonical RxxK motif (McDonald et al., 
2012b), an RGTK motif found in ADAM15 B was altered to AGTA by site-directed 
mutagenesis and the titration with Grb2C was repeated. However this analysis 
confirmed that this alternative motif is not required for interactions with the ADAM15 
ICDs. This supports the conclusion that the interactions observed are due to a more 
typical poly-proline region within the ADAM15 ICD. Those regions common to ADAM15 
A, B, C and E are polyproline regions 1, 4 and 5. As discussed in chapter 4, previous work 
using ADAM15 A demonstrated that the P1 region inhibited interactions between 
ADAM15 A and full length Grb2, whereas P4 was heavily required (Poghosyan, 2001). 
Loss of P5 did reduce the amount of interaction but was not necessary for interaction. 
Therefore it is likely that the interaction between the ADAM15 ICDs and Grb2C is 
mediated mainly by polyproline region 4. The precipitations observed during the 
titrations suggest the formation of aggregates at higher concentrations with other 
polyproline regions potentially involved.  
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Figure 6.1 Schematic of the proline-rich regions of the ADAM15 ICD splice variants with the exons that 
encode for them indicated. Adapted from Zhong et al (2008, (Zhong et al., 2008)). 
 
Issues with the folding of the N-terminal SH3 domain of Grb2 proved very difficult to 
solve and, unfortunately, meant that any titrations of this domain with the ADAM15 
ICDs were unreliable and thus it was not possible to determine which SH3 domain is 
responsible for the interactions between the ADAM15 ICDs and the full length Grb2 
signalling protein. Preliminarily titration studies (data not shown) suggest that Grb2N 
binds to ADAM15 A, B and E and does not bind to ADAM15 C or D. In studies of the Grb2 
SH3 domains interactions with Sos1 (McDonald et al., 2009), Grb2N was capable of 
interacting with all four polyproline motifs in Sos1 but the Grb2C domain bound only to 
the first polyproline region. This region contained a PxΨPxRRR motif. The interaction is 
possible without the terminal two arginine residues but these form additional salt 
bridges between the SH3 domain and the polyproline region and further stabilise the 
interaction. These arginines are not necessary for interactions involving Grb2N 
(McDonald et al., 2009). None of the ADAM15 ICD polyproline regions include a 
PxΨPxRRR motif but the P4 region does include a PPPPRKP motif which is similar to 
other motifs with which Grb2C has been shown to interact, that of PxxxRxxKP. While the 
motif in P4 of the ADAM15 ICD does not fulfil this theoretical motif exactly, it does 
contain the residues required for interaction along with an arginine and lysine with the 
potential to form additional salt bridges to stabilise the interaction.  
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The biological function of the interaction of ADAM15 ICDs with Grb2 remain unclear but 
there are overlaps between their separate functions. For example, Grb2 inhibits FGFR2 
dimers until their exposure to a growth factor such as FGF7 (Lin et al., 2012) and 
ADAM15 B can shed a splice variant of FGFR2, specifically FGFR2iiib in a Src dependent 
manner (Maretzky et al., 2009b). Given their overlapping function and clear roles in 
breast cancer, there is strong indication of a shared biological function. A schematic 
showing the interactions between each ADAM15 ICD observed here is shown in figure 
6.2 along with some of the pathways Grb2 and Src are involved with. 
 
 
Figure 6.2 Schematic of the interactions observed in this thesis between the ADAM15 splice variants and 
the intracellular proteins Grb2 and Src which contain SH3 domains. Signalling pathways in which these 
intracellular proteins have a role in have also been indicated as potential downstream functions of the 
interactions observed. 
 
In the case of the Src interactions with the ADAM15 ICDs, a consistent interface can be 
observed when the Src SH3 domains are exposed to ADAM15 B, C and E including the 
residues 17Arg, 21Asp, 40Trp and 56Ser- 58Tyr. These residues are consistent with 
previous interactions of the Src SH3 domain with small peptides that include a RPLPPLP 
motif (Sparks et al., 1994). Additionally, ADAM15 A, which exhibits no direct interaction 
with Src in a biological setting (Zhong et al., 2008), does interact with the Src SH3 domain 
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in the spectrometer but with much smaller chemical shift perturbations than those 
caused by the other ICDs. These weak perturbations are consistent with a low energy 
interaction that occurs due to the high concentrations of the domains in the 
spectrometer compared to endogenous levels. When this is considered along with the 
lack of interaction of ADAM15 D and that ADAM15 A does not interact directly in a 
biological setting, it is implied that the motif responsible for any interaction with the Src 
SH3 domain is common to ADAM15 B, C and E but exclusive of motifs available in 
ADAM15 A. Polyproline regions 2 and 3 are not common across all three ADAM15 B, C 
and E but there is a common motif across both regions, that of RPLPXDPV. Additionally, 
polyproline region 4 has a KPLPADPQ sequence which is similar enough to potentially be 
accounting for the interaction seen between ADAM15 A and the Src SH3 domain in the 
spectrometer but with no biological relevance.  
The functions of ADAM15 have been linked to Src in more than one case. ADAM15 has 
a role in the regulation of endothelial permeability and neutrophil migration which 
requires the Src/ ERK1/2 signalling and is independent of the catalytic function of 
ADAM15 (Sun et al., 2010). Development of atherosclerotic lesions was increased by 
ADAM15 signalling through Src and Yes leading to the disruption of adherens junction 
integrity and promoting monocyte migration and required a functional cytoplasmic 
domain of ADAM15 (Sun et al., 2012). It is unclear which splice variant of ADAM15 is 
used here but it likely that it was ADAM15 A as this was the first variant of the protein 
discovered and most commonly used in the literature. ADAM15 also contributes to 
apoptosis resistance in rheumatoid arthritis synovial fibroblasts by activating the 
Src/FAK pathway upon exposure to FasL (Bohm et al., 2013). Again, it is likely that this 
study used ADAM15 A. The exclusive use of ADAM15 A in studies which suggest a 
function of the splice variants involving the overlapping roles of ADAM15 A with Src, 
despite a lack of direct interaction between ADAM15 A and Src biologically, means that 
clarity as to the function of the ADAM15 variants is reduced. Additionally, proximity 
ligation assays (personal communication, Dr Christian Roghi) have shown that Src and 
ADAM15 A do localise together. This could be due to the reported ability of FAK to act 
as an intermediate between these proteins (Fried et al., 2012) but this is unclear. It 
would be interesting to repeat these experiments while FAK is knocked down as this 
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would confirm the prediction that FAK is required for functional signalling between 
ADAM15 A and Src. Additionally, expansion of the study into apoptosis resistance in 
rheumatoid arthritis using the other ADAM15 variants has the potential to demonstrate 
whether this effect can be generated by all the variants. If only some of the variants can 
affect apoptosis, their intracellular binding profiles could lead to greater understanding 
as to the function of the different ADAM15 splice variants. However, while increased 
migration and apoptosis resistance are processes common to inflammatory conditions 
and breast cancer progression, there have been no direct links between ADAM15 and 
Src function in cancer discovered.  
Alternatively to roles with complementary functions within the same pathway, it is 
possible that the interactions of the ADAM15 ICDs provide competition for interaction 
with the Src SH3 domain. The Src SH3 domain’s primary functions are to bind to 
substrates and bring them within the vicinity of the kinase domain of Src and as part of 
the inhibitory folding of Src via interactions with the SH2-linker region (Elsberger et al., 
2010).  Given that the downstream functions of Src are similar to several of those 
downstream of ADAM15, such as cell adhesion (Klessner et al., 2009; Serrels et al., 
2009), apoptosis resistance (Bohm et al., 2010; Johnson et al., 2000), angiogenesis 
(Cheranov et al., 2008; Raiter et al., 2010) and FGFR2iib shedding (Maretzky et al., 
2009a), it would seem unlikely that any competition provided by the ADAM15 ICDs 
would be against substrates of the Src protein. However, the SH3 domain of Src is 
required for Csk to phosphorylate Tyr527, which then finds to the SH2 domain of Src, 
forming the inactive, “closed” conformation which is stabilised by interactions between 
the SH3 domain and the linker region (Superti-Furga et al., 1993). If the ADAM15 ICDs 
provided a form of competitive inhibition to Csk’s role in activating Src, the increase in 
activated Src could explain the cross over in downstream functions between ADAM15 
and Src. The variability of interaction potential across the different variants of ADAM15 
with Src could also give some indication as to the functional purpose of the splice 
variants. If confirmed, this would make an interesting therapeutic target, particularly in 
cancer. Reducing Src activity is already a target for several drugs, such as Bosutinib (Puls 
et al., 2011) and Dasatinib (Araujo and Logothetis, 2010). Current trial therapies target 
the kinase domain of Src Family Kinases but, due to strong sequence conservation in this 
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domain, specificity for one member of the family is difficult. If further studies into the 
functional relevance of the interactions between the ADAM15 ICDs and the Src SH3 
domain prove a link between ADAM15 and constitutive activation of Src via competitive 
inhibition of Csk, this could provide a new, more specific, therapeutic target. 
Brk proved difficult to purify in the quantities desired for NMR spectroscopy, and time 
restraints meant that only the interaction with ADAM15 B was studied. Residues 34Arg, 
56Trp, 74Val, 77Asn and 79Leu were all involved in the interaction and these residues 
occupy the hydrophobic pocket of the Brk SH3 domain. Three of these residues, 34Arg, 
56Trp and 77Asn, correspond to those residues within the full length Brk that are 
responsible for the inhibitory interaction between the Brk SH3 domain and Brk linker 
region (Derry et al., 2000). Similar motifs to the Brk linker region exist in polyproline 
regions 2, 3 and 4 of the ADAM15 ICDs so this titration, and the comparison with the Brk 
SH3 domain-linker region interaction, is not currently enough to establish exactly which 
polyproline region from the ADAM15 ICD is responsible for any interaction with the Brk 
SH3 domain. As ADAM15 C does not interact with the Brk SH3 domain. However 
ADAM15 A and B do (Zhong et al., 2008), it is implied that P3 is not required but it is not 
possible to confirm this until studies with ADAM15 E, which also includes P3 are 
conducted. Given that Brk is overexpressed in 86% of invasive ductal breast carcinomas 
(Ostrander et al., 2007) and that high ADAM15 A and B expression have been linked to 
a poorer prognosis in patients with initially non-metastatic breast tumours whereas 
ADAM15 C has no such correlation in the similar patients (Zhong et al., 2008), it could 
be suggested that there is a potential cooperation between Brk and the ADAM15 A and 
B proteins that could be linked to the progression of breast cancer to invasive stages. 
However, without further study, particularly including ADAM15 C and E, this remains a 
hypothesis. 
When the SH3 domains studied here are compared, the low level of sequence identity 
within the SH3 domain family is apparent, as can be seen in figure 6.3. There are only 12 
residues conserved between all three of the domains successfully studied here although 
there are several other residues which are conserved across two of the domains or 
where the sequences include different amino acids of the same type in equivalent 
locations. Highlighted in red in the figure 6.3 are those residues most involved in the 
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interaction of that SH3 domain with ADAM15 B. Only the conserved tryptophan residue 
is consistently involved in all three interactions whereas the interactions with the Brk 
SH3 domain and Src SH3 domain also involve a conserved arginine and a conserved 
asparagine. These residues are all part of the hydrophobic pocket of the SH3 domain 
and suggest a similar interaction mechanism. Indeed, the proposed sequences for the 
motifs involved in these interactions, RPLPXLPV in the case of the Src SH3 domain and 
PEPLP in the case of the Brk SH3 domain, are more similar than that proposed for the 
interaction with Grb2C, that of PXXXRXXKP.  
 
Figure 6.3 Sequence alignment of the SH3 domains of Brk, Grb2C and Src. Highlighted in red are the 
residues most affected by the interaction with ADAM15 B. 
 
Unfortunately, due to the precipitation of the ADAM15 ICDs at concentrations higher 
than 1.5 mM, it was not possible to saturate the interactions studied here, which are 
calculated as a function of the ligand concentration. This means that it was not possible 
to accurately calculate the dissociation constants, Kd, for any of the residues involved in 
the interactions. The error values for the calculated Kds were almost as large as the Kd 
values themselves. However, the Kd value measured at the conserved tryptophan of 
Grb2C and the Brk SH3 domain was in the 10-5 M range and in the 10-6 M range for this 
residue in the Src SH3 domain. The arginine residues involved in the interactions of the 
SH3 domains of Brk and Src both have a dissociation constant in the 10-5 M range. Finally, 
the conserved asparagines involved in the interactions with the Brk and Src SH3 domains 
give dissociation constants in the 10-5 and 10-4 M range respectively.  This is consistent 
with results obtained by of Briony Keir, an undergraduate project student in our 
laboratory, who studied the interaction of 15N ADAM15 B with the unlabelled Src SH3 
domain (Keir and Blumenschein, Unpublished data, 2015).  Although the backbone 
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assignments for the ADAM15 B protein were not obtained, it was possible to distinguish 
which peaks corresponded to the GB1 tag and rule these out from any interaction. When 
the dissociation constants of the residues of ADAM15 B were calculated, although again 
the interaction was not fully saturated, these were in the 10-4 M range. These Kd values 
indicate that the interactions studied here are fairly weak. Other documented SH3 
domain interactions with polyproline regions are in the 10-6 M region (Li et al., 2014; 
Stangler et al., 2007) but these reactions were saturated unlike those here rendering the 
dissociation constants seen in this study are not entirely reliable. As the dissociation 
constant is defined as the ligand concentration at which the protein is half saturated, it 
is not possible to calculate this accurately if the ligand concentration at full saturation is 
unknown. However, it has been shown previously that low energy interactions can still 
be biologically relevant if the local concentration environment within the cell is high 
enough (Mayer, 2001). 
The lack of any interaction of ADAM15 D with any intracellular protein in any published 
literature and this thesis does present an interesting conundrum. As discussed in chapter 
1.3.3, ADAM15 D accounts for 11% of the total ADAM15 expressed across a number of 
healthy tissues, second only to ADAM15 A which accounts for 58.6% of expression 
across those tissues (Kleino et al., 2009). No function has been found for this splice 
variant thus far despite its strong expression. There are no motifs within this intracellular 
domain that correlate with other motifs known to interact with other intracellular 
proteins which leaves little for speculation unless it is to provide a functioning ADAM15 
metalloproteinase which is unaffected by intracellular signalling. Once the primary 
substrate of the ADAM15 metalloproteinase has been identified, it would be fascinating 
to see whether the expression pattern of ADAM15 D correlates with this substrate.  
Other members of the ADAM family have been shown to interact with SH3 domain-
containing proteins including ADAM -7, -10, -12, -19, -22, -29 and -33 (Edwards et al., 
2008). The cytoplasmic domain of ADAM10 is required for correct localisation in 
polarised epithelial cells. This requires the proline-rich regions of the domain which 
implies that this regulation could involve an interaction with an SH3 domain-containing 
protein. If incorrectly localised, ADAM10 is rendered incapable of cleaving E-cadherin 
and thus does not play a role in cell migration (Wild-Bode et al., 2006). An SH3 domain-
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containing protein has been proposed as having a potential role in this. Synapse-
associated protein 97, SAP97, is responsible for the localisation of ADAM10 in synaptic 
membranes and additionally promotes α-secretase activity. The intracellular domain of 
ADAM10 is also involved in the regulation of the constitutive activity of the enzyme, 
although this does not require the polyproline region which interact with SH3 domains 
but an endoplasmic reticulum retention motif (Marcello et al., 2007).  However, the ICD 
does not affect the stimulated activity of ADAM10. Although the pathway of ADAM15 
localisation has yet to be fully elucidated, the SH3 domain-containing proteins 
endophilin 1 and SH3PX1, which both have roles in endocytosis and subcellular 
localisation, only bind to the ICD of the pro-form of ADAM15 (Howard et al., 1999). 
ADAM10 and ADAM15 have both been shown to target E-cadherin for cleavage, 
although the evidence is less clear in the case of ADAM15, and both show some 
interaction preference based upon subcellular localisation. It could be suggested that 
some interactions of the ADAM15 ICDs with SH3 domain-containing proteins have a 
regulatory effect on the ADAM in a similar manner to that of ADAM10.  
The SH3 domain-containing protein PACSIN3 (protein kinase C and casein kinase 
substrate in neurons protein 3) has been shown to interact via its SH3 domain to the 
intracellular domains of ADAMs -9, -10, -12, -15 and -19 and has roles in endocytosis via 
interactions with dynamin and interacts with N-WASP thus conferring a role in 
regulation of the actin cytoskeleton (Mori, 2003). PACSIN3 is functionally important for 
ADAM12 shedding of heparin-binding EGF-like growth factor (HB-EGF) in response to 
PMA or the GPCR agonist angiotensin II. The function of PACSIN3 with regards to the 
acitivity of the other ADAMs that it is capable of interaction with has not been expanded 
upon currently but it has the potential to play a role in ADAM15 activity regulation in a 
similar fashion to its role in the activity of ADAM12. 
The intracellular domain functions of ADAM12, which has 10 potential SH3 domain 
binding motifs (Seals, 2003), have been studied more extensively than that of the 
ADAM15 ICD. Trafficking of ADAM12 to the cell membrane in response to PMA 
stimulation is regulated by its ICD and is also dependent on PKCε (Sundberg et al., 2004). 
Additionally, the ICD of ADAM12 can act as a retention agent, keeping the ADAM12 
protein within the cell and preventing cell surface accumulation via interactions with 
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PI3K and Src, which is activated upon interactions with the ADAM12 ICD (Maretzky et 
al., 2015). The ADAM12 ICD interaction with Src has been confirmed to be via the SH3 
domain of Src and requires the same conserved tryptophan that is required for 
interactions with the ADAM15 ICDs as shown in this thesis. The polyproline region 2 of 
the ADAM12 ICD includes the sequence PSVPARPLPAKP which is not dissimilar to the 
RPLPXDPV sequence seen in the P2 and P3 regions of the ADAM15 ICD (Stautz et al., 
2010). The interaction of Src with ADAM12 is required for the correct subcellular 
localisation of the ADAM, with this interaction promoting cell surface localisation and 
has been shown to enhance Src activity at focal adhesions. ADAM15 B, C and E also 
interact with the Src SH3 domain and has a role in the regulation of cell adhesion, thus 
presenting a potential mechanism by which ADAM15 can influence cell adhesion in a 
similar manner to ADAM12. 
A further link between the ADAM15 ICDs and cell adhesion has been shown through 
studies into the phenotype of MCF-7 cells overexpressing each of the full length 
ADAM15 variants. When ADAM15 E is overexpressed, the amount of the tight junction 
protein, claudin 1, was also highly increased (personal communication, Dr Christian 
Roghi). Tight junctions, also known as occluding junctions, are a method by which cells 
interact with each other and form a virtually impermeable fluid barrier. Claudin 1 also 
has a role in breast cancer and promotes apoptosis in MCF-7 cells (Liu et al., 2012).   
Grb2 also interacts with ADAM12 and is involved in the internalisation of the ADAM via 
the clathrin-dependent pathway (Stautz et al., 2012a). The function of the interaction 
between Grb2 and the ADAM15 ICDs is unknown but a similar pathway to endocytosis 
as followed by ADAM12 is also possible here.   
ADAM12, like ADAM15, has also been shown to the linked to breast cancer progression 
but is not a driver-mutation (Stautz et al., 2012b), that is, it does not cause the 
progression of breast cancer but arises because of the breast cancer. ADAM12 is more 
useful as a marker for breast cancer progression and ADAM15 could fill a similar function 
once ADAM15’s role in breast cancer is elucidated.  
This thesis has shown how the ADAM15 ICDs interact with three different SH3 domains 
from the perspective of the SH3 domain. Further study into the interaction from the 
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perspective of the ADAM15 ICDs would be very useful to extend understanding of these 
interfaces. An extension of this would include studies of the dissociation constants using 
surface plasmon resonance and mutation studies to remove the interactions and 
evaluate the downstream effects of these interaction knock outs in breast cancer cells 
such as MCF-7 and MDA-MB-231 cells. Isothermal calorimetry would be useful in the 
case of the interactions with the Src SH3 domain and Brk SH3 domain as these 
interactions do not cause protein precipitation as the interactions with Grb2C did. 
Further studies of the subcellular localisation of the ADAM15 variants in response to SH3 
domain-containing proteins could expand the potential regulatory role of these 
interactions on ADAM15 function. This study represents a stepping stone into a deeper 
understanding of the role of the ADAM15 ICDs in the progression of breast cancer. 
  
187 
 
Bibliography 
 
2001. Familial breast cancer: collaborative reanalysis of individual data from 52 
epidemiological studies including 58 209 women with breast cancer and 101 986 
women without the disease. The Lancet 358, 1389-1399. 
 
2011a. Breast Cancer. Cancer Research UK, London. 
 
2011b. Breast Cancer Risk Factors. Cancer Research UK, London. 
 
2011c. Skin Cancer - UK mortaility statistics. Cancer Research UK, London. 
 
2011d. TNM Breast Cancer Staging. Cancer Research UK, London. 
 
Acharya, M., Borland, G., Edkins, A.L., Maclellan, L.M., Matheson, J., Ozanne, B.W., 
Cushley, W., 2010. CD23/FcepsilonRII: molecular multi-tasking. Clin Exp Immunol 162, 
12-23. 
 
Ahmed, S., Maratha, A., Butt, A.Q., Shevlin, E., Miggin, S.M., 2013. TRIF-mediated TLR3 
and TLR4 signaling is negatively regulated by ADAM15. Journal of immunology 
(Baltimore, Md. : 1950) 190, 2217-2228. 
 
Al-Fakhri, N., Wilhelm, J., Hahn, M., Heidt, M., Hehrlein, F.W., Endisch, A.M., Hupp, T., 
Cherian, S.M., Bobryshev, Y.V., Lord, R.S., Katz, N., 2003. Increased expression of 
disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of 
integrins alpha5beta1 and alphavbeta3 in atherosclerosis. J Cell Biochem 89, 808-823. 
 
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., 
Hunter, T., Dixon, J., Mustelin, T., 2004. Protein Tyrosine Phosphatases in the Human 
Genome. Cell 117, 699-711. 
 
Araujo, J., Logothetis, C., 2010. Dasatinib: A potent SRC inhibitor in clinical development 
for the treatment of solid tumors. Cancer Treatment Reviews 36, 492-500. 
 
Arribas, J., Esselens, C., 2009. ADAM17 as a therapeutic target in multiple diseases. Curr 
Pharm Des 15, 2319-2335. 
 
Atabey, N., Gao, Y., Yao, Z.J., Breckenridge, D., Soon, L., Soriano, J.V., Burke, T.R., Jr., 
Bottaro, D.P., 2001. Potent blockade of hepatocyte growth factor-stimulated cell 
motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src 
homology 2 domain interactions. J Biol Chem 276, 14308-14314. 
 
Aubele, M., Vidojkovic, S., Braselmann, H., Ritterswurden, D., Auer, G., Atkinson, M.J., 
Tapio, S., Hofler, H., Rauser, S., Bartlett, J.M., 2009. Overexpression of PTK6 (breast 
tumor kinase) protein--a prognostic factor for long-term breast cancer survival--is not 
188 
 
due to gene amplification. Virchows Archiv : an international journal of pathology 455, 
117-123. 
 
Baksi, S., Basu, S., Mukhopadhyay, D., 2014. Mutant huntingtin replaces Gab1 and 
interacts with C-terminal SH3 domain of growth factor receptor binding protein 2 
(Grb2). Neuroscience research 87, 77-83. 
 
Becker, E.D., 1999. High Resolution NMR: Theory and Chemical Applications, 3 ed. 
Academic Press, p. 79. 
 
Belov, A.A., Mohammadi, M., 2012. Grb2, a double-edged sword of receptor tyrosine 
kinase signaling. Science signaling 5, pe49. 
 
Bergers, G., Brekken, R., McMahon, G., Vu, T.H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, 
P., Itohara, S., Werb, Z., Hanahan, D., 2000. Matrix metalloproteinase-9 triggers the 
angiogenic switch during carcinogenesis. Nat Cell Biol 2, 737-744. 
 
Berry, D.M., Nash, P., Liu, S.K., Pawson, T., McGlade, C.J., 2002. A high-affinity Arg-X-X-
Lys SH3 binding motif confers specificity for the interaction between Gads and SLP-76 in 
T cell signaling. Current biology : CB 12, 1336-1341. 
 
Biscardi, J.S., Belsches, A.P., Parsons, S.J., 1998. Characterization of human epidermal 
growth factor receptor and c-Src interactions in human breast tumor cells. Molecular 
carcinogenesis 21, 261-272. 
 
Bode, W., Gomis-Rüth, F.-X., Stöckler, W., 1993. Astacins, serralysins, snake venom and 
matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH 
and Met-turn) and topologies and should be grouped into a common family, the 
‘metzincins’. FEBS Letters 331, 134-140. 
 
Bohm, B., Hess, S., Krause, K., Schirner, A., Ewald, W., Aigner, T., Burkhardt, H., 2010. 
ADAM15 exerts an antiapoptotic effect on osteoarthritic chondrocytes via up-regulation 
of the X-linked inhibitor of apoptosis. Arthritis Rheum 62, 1372-1382. 
 
Bohm, B.B., Aigner, T., Blobel, C.P., Kalden, J.R., Burkhardt, H., 2001. Highly enhanced 
expression of the disintegrin metalloproteinase MDC15 (metargidin) in rheumatoid 
synovial tissue. Arthritis Rheum 44, 2046-2054. 
 
Bohm, B.B., Aigner, T., Roy, B., Brodie, T.A., Blobel, C.P., Burkhardt, H., 2005. 
Homeostatic effects of the metalloproteinase disintegrin ADAM15 in degenerative 
cartilage remodeling. Arthritis & Rheumatism 52, 1100-1109. 
 
Bohm, B.B., Freund, I., Krause, K., Kinne, R.W., Burkhardt, H., 2013. ADAM15 adds to 
apoptosis resistance of synovial fibroblasts by modulating focal adhesion kinase 
signaling. Arthritis Rheum 65, 2826-2834. 
 
189 
 
Bombonati, A., Sgroi, D.C., 2011. The molecular pathology of breast cancer progression. 
The Journal of Pathology 223, 308-318. 
 
Bonnefoy, J.Y., Plater-Zyberk, C., Lecoanet-Henchoz, S., Gauchat, J.F., Aubry, J.P., Graber, 
P., 1996. A new role for CD23 in inflammation. Immunol Today 17, 418-420. 
 
Boyer, B., Bourgeois, Y., Poupon, M.F., 2002. Src kinase contributes to the metastatic 
spread of carcinoma cells. Oncogene 21, 2347-2356. 
 
Brauer, P.M., Tyner, A.L., 2010. Building a better understanding of the intracellular 
tyrosine kinase PTK6 - BRK by BRK. Biochim Biophys Acta 1806, 66-73. 
 
Brenner, B., Gulbins, E., Schlottmann, K., Koppenhoefer, U., Busch, G.L., Walzog, B., 
Steinhausen, M., Coggeshall, K.M., Linderkamp, O., Lang, F., 1996. L-selectin activates 
the Ras pathway via the tyrosine kinase p56lck. Proceedings of the National Academy of 
Sciences of the United States of America 93, 15376-15381. 
 
Brooke, M.A., Nitoiu, D., Kelsell, D.P., 2012. Cell-cell connectivity: desmosomes and 
disease. J Pathol 226, 158-171. 
 
Brown, R.V., Gaerig, V.C., Simmons, T., Brooks, T.A., 2013. Helping Eve overcome ADAM: 
G-quadruplexes in the ADAM-15 promoter as new molecular targets for breast cancer 
therapeutics. Molecules 18, 15019-15034. 
 
Bultmann, A., Li, Z., Wagner, S., Gawaz, M., Ungerer, M., Langer, H., May, A.E., Munch, 
G., 2011. Loss of protease activity of ADAM15 abolishes protective effects on plaque 
progression in atherosclerosis. Int J Cardiol 152, 382-385. 
 
Burstein, H.J., Polyak, K., Wong, J.S., Lester, S.C., Kaelin, C.M., 2004. Ductal carcinoma in 
situ of the breast. The New England journal of medicine 350, 1430-1441. 
 
Cartwright, C.A., Kamps, M.P., Meisler, A.I., Pipas, J.M., Eckhart, W., 1989. pp60c-src 
activation in human colon carcinoma. J Clin Invest 83, 2025-2033. 
 
Castro, N.E., Lange, C.A., 2010. Breast tumor kinase and extracellular signal-regulated 
kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast 
Cancer Res 12, R60. 
 
Chan, K.T., Cortesio, C.L., Huttenlocher, A., 2009. FAK alters invadopodia and focal 
adhesion composition and dynamics to regulate breast cancer invasion. J Cell Biol 185, 
357-370. 
 
Charrier-Hisamuddin, L., Laboisse, C.L., Merlin, D., 2007. ADAM-15: a metalloprotease 
that mediates inflammation. The FASEB Journal 22, 641-653. 
 
190 
 
Chatterjee, V., Beard, R.S., Jr., Reynolds, J.J., Haines, R., Guo, M., Rubin, M., Guido, J., 
Wu, M.H., Yuan, S.Y., 2014. MicroRNA-147b regulates vascular endothelial barrier 
function by targeting ADAM15 expression. PloS one 9, e110286. 
 
Chen, H.Y., Shen, C.H., Tsai, Y.T., Lin, F.C., Huang, Y.P., Chen, R.H., 2004. Brk activates 
rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol 
24, 10558-10572. 
 
Cheranov, S.Y., Karpurapu, M., Wang, D., Zhang, B., Venema, R.C., Rao, G.N., 2008. An 
essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and 
angiogenesis. Blood 111, 5581-5591. 
 
Cortes, J.E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, 
F.E., Apperley, J.F., Khoury, H.J., Talpaz, M., DiPersio, J., DeAngelo, D.J., Abruzzese, E., 
Rea, D., Baccarani, M., Müller, M.C., Gambacorti-Passerini, C., Wong, S., Lustgarten, S., 
Rivera, V.M., Clackson, T., Turner, C.D., Haluska, F.G., Guilhot, F., Deininger, M.W., 
Hochhaus, A., Hughes, T., Goldman, J.M., Shah, N.P., Kantarjian, H., 2013. A Phase 2 Trial 
of Ponatinib in Philadelphia Chromosome–Positive Leukemias. New England Journal of 
Medicine 369, 1783-1796. 
 
D'Aniello, S., Irimia, M., Maeso, I., Pascual-Anaya, J., Jimenez-Delgado, S., Bertrand, S., 
Garcia-Fernandez, J., 2008. Gene expansion and retention leads to a diverse tyrosine 
kinase superfamily in amphioxus. Molecular biology and evolution 25, 1841-1854. 
 
Daugimont, L., Vandermeulen, G., Defresne, F., Bouzin, C., Mir, L.M., Bouquet, C., Feron, 
O., Preat, V., 2011. Antitumoral and antimetastatic effect of antiangiogenic plasmids in 
B16 melanoma: Higher efficiency of the recombinant disintegrin domain of ADAM 15. 
European journal of pharmaceutics and biopharmaceutics : official journal of 
Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 78, 314-319. 
 
Decock, J., Thirkettle, S., Wagstaff, L., Edwards, D.R., 2011. Matrix metalloproteinases: 
protective roles in cancer. J Cell Mol Med 15, 1254-1265. 
 
Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J., Bax, A., 1995. NMRPipe: a 
multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6, 277-
293. 
 
Derry, J.J., Richard, S., Valderrama Carvajal, H., Ye, X., Vasioukhin, V., Cochrane, A.W., 
Chen, T., Tyner, A.L., 2000. Sik (BRK) phosphorylates Sam68 in the nucleus and 
negatively regulates its RNA binding ability. Mol Cell Biol 20, 6114-6126. 
 
Derycke, L.D., Bracke, M.E., 2004. N-cadherin in the spotlight of cell-cell adhesion, 
differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 48, 463-476. 
 
Deuss, M., Reiss, K., Hartmann, D., 2008. Part-time alpha-secretases: the functional 
biology of ADAM 9, 10 and 17. Curr Alzheimer Res 5, 187-201. 
191 
 
Doedens, J.R., Black, R.A., 2000. Stimulation-induced down-regulation of tumor necrosis 
factor-alpha converting enzyme. J Biol Chem 275, 14598-14607. 
 
Druker, B.J., 2002. STI571 (Gleevec) as a paradigm for cancer therapy. Trends in 
molecular medicine 8, S14-18. 
 
Edwards, D., Handsley, M., Pennington, C., 2008. The ADAM metalloproteinases. 
Molecular Aspects of Medicine 29, 258-289. 
 
Elsberger, B., Stewart, B., Tatarov, O., Edwards, J., 2010. Is Src a viable target for treating 
solid tumours? Current cancer drug targets 10, 683-694. 
 
Elsberger, B., Tan, B.A., Mitchell, T.J., Brown, S.B.F., Mallon, E.A., Tovey, S.M., Cooke, 
T.G., Brunton, V.G., Edwards, J., 2009. Is Expression or Activation of Src Kinase 
Associated with Cancer-Specific Survival in ER-, PR- and HER2-Negative Breast Cancer 
Patients? The American Journal of Pathology 175, 1389-1397. 
 
Endsley, M.A., Somasunderam, A.D., Li, G., Oezguen, N., Thiviyanathan, V., Murray, J.L., 
Rubin, D.H., Hodge, T.W., O'Brien, W.A., Lewis, B., Ferguson, M.R., 2014. Nuclear 
trafficking of the HIV-1 pre-integration complex depends on the ADAM10 intracellular 
domain. Virology 454-455, 60-66. 
 
Eto, K., Huet, C., Tarui, T., Kupriyanov, S., Liu, H.Z., Puzon-McLaughlin, W., Zhang, X.P., 
Sheppard, D., Engvall, E., Takada, Y., 2002. Functional classification of ADAMs based on 
a conserved motif for binding to integrin alpha 9beta 1: implications for sperm-egg 
binding and other cell interactions. J Biol Chem 277, 17804-17810. 
 
Feng, S., Chen, J.K., Yu, H., Simon, J.A., Schreiber, S.L., 1994. Two binding orientations 
for peptides to the Src SH3 domain: development of a general model for SH3-ligand 
interactions. Science 266, 1241-1247. 
 
Fincham, V.J., Frame, M.C., 1998. The catalytic activity of Src is dispensable for 
translocation to focal adhesions but controls the turnover of these structures during cell 
motility. Embo j 17, 81-92. 
 
Fourie, A.M., Coles, F., Moreno, V., Karlsson, L., 2003. Catalytic activity of ADAM8, 
ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain 
cleavage of CD23. J Biol Chem 278, 30469-30477. 
 
Fried, D., Böhm, B.B., Krause, K., Burkhardt, H., 2012. ADAM15 Protein Amplifies Focal 
Adhesion Kinase Phosphorylation under Genotoxic Stress Conditions. Journal of 
Biological Chemistry 287, 21214-21223. 
 
Fu, Y., Zagozdzon, R., Avraham, R., Avraham, H.K., 2006. CHK negatively regulates Lyn 
kinase and suppresses pancreatic cancer cell invasion. Int J Oncol 29, 1453-1458. 
192 
 
Galliher-Beckley, A.J., Schiemann, W.P., 2008. Grb2 binding to Tyr284 in TbetaR-II is 
essential for mammary tumor growth and metastasis stimulated by TGF-beta. 
Carcinogenesis 29, 244-251. 
 
Gao, J., Zheng, W., Wang, L., Song, B., 2015. A disintegrin and metallproteinase 15 
knockout decreases migration of fibroblast-like synoviocytes and inflammation in 
rheumatoid arthritis. Molecular medicine reports 11, 4389-4396. 
 
Garner, T.P., Strachan, J., Shedden, E.C., Long, J.E., Cavey, J.R., Shaw, B., Layfield, R., 
Searle, M.S., 2011. Independent interactions of ubiquitin-binding domains in a ubiquitin-
mediated ternary complex. Biochemistry 50, 9076-9087. 
 
Garton, K.J., Gough, P.J., Raines, E.W., 2006. Emerging roles for ectodomain shedding in 
the regulation of inflammatory responses. J Leukoc Biol 79, 1105-1116. 
 
Gasteiger E., H.C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., Bairoch A., 2005. 
Protein Identification and Analysis Tools on the ExPASy Server;, in: Walker, J.M. (Ed.), 
The Proteomics Protocols Handbook. The Humana Press, pp. 571-607. 
 
Giubellino, A., Burke, T.R., Bottaro, D.P., 2008. Grb2 signaling in cell motility and cancer. 
Expert Opinion on Therapeutic Targets 12, 1021-1033. 
 
Giubellino, A., Gao, Y., Lee, S., Lee, M.J., Vasselli, J.R., Medepalli, S., Trepel, J.B., Burke, 
T.R., Jr., Bottaro, D.P., 2007. Inhibition of tumor metastasis by a growth factor receptor 
bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res 67, 6012-6016. 
 
Gomis-Ruth, F.X., 2003. Structural aspects of the metzincin clan of 
metalloendopeptidases. Mol Biotechnol 24, 157-202. 
 
Gonzales, P.E., Solomon, A., Miller, A.B., Leesnitzer, M.A., Sagi, I., Milla, M.E., 2004. 
Inhibition of the tumor necrosis factor-alpha-converting enzyme by its pro domain. J Biol 
Chem 279, 31638-31645. 
 
Gooz, M., 2010. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 45, 
146-169. 
 
Grzesiek, S., Bax, A., 1992a. Correlating backbone amide and side chain resonances in 
larger proteins by multiple relayed triple resonance NMR. Journal of the American 
Chemical Society 114, 6291-6293. 
 
Grzesiek, S., Bax, A., 1992b. An efficient experiment for sequential backbone assignment 
of medium-sized isotopically enriched proteins. Journal of Magnetic Resonance (1969) 
99, 201-207. 
 
Haines, E., Minoo, P., Feng, Z., Resalatpanah, N., Nie, X.M., Campiglio, M., Alvarez, L., 
Cocolakis, E., Ridha, M., Di Fulvio, M., Gomez-Cambronero, J., Lebrun, J.J., Ali, S., 2009. 
Tyrosine Phosphorylation of Grb2: Role in Prolactin/Epidermal Growth Factor Cross Talk 
193 
 
in Mammary Epithelial Cell Growth and Differentiation. Molecular and Cellular Biology 
29, 2505-2520. 
 
Ham, C., 2002. ADAM15 Is an Adherens Junction Molecule Whose Surface Expression 
Can Be Driven by VE-Cadherin. Experimental Cell Research 279, 239-247. 
 
Harvey, A.J., Crompton, M.R., 2003. Use of RNA interference to validate Brk as a novel 
therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. 
Oncogene 22, 5006-5010. 
 
Harvey, A.J., Crompton, M.R., 2004. The Brk protein tyrosine kinase as a therapeutic 
target in cancer: opportunities and challenges. Anti-cancer drugs 15, 107-111. 
 
Hazan, R.B., Qiao, R., Keren, R., Badano, I., Suyama, K., 2004. Cadherin switch in tumor 
progression. Annals of the New York Academy of Sciences 1014, 155-163. 
 
Herynk, M.H., Beyer, A.R., Cui, Y., Weiss, H., Anderson, E., Green, T.P., Fuqua, S.A., 2006. 
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of 
estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 5, 3023-3031. 
 
Highman, V.A., 2012. Protein NMR: A Practical Guide. 
 
Holgate, S.T., 2010. ADAM metallopeptidase domain 33 (ADAM33): identification and 
role in airways disease. Drug News Perspect 23, 381-387. 
 
Hore, P.J., 1995a. Nuclear Magnetic Resonance. Oxford Science Publications, pp. 2-6. 
 
Hore, P.J., 1995b. Nuclear Magnetic Resonance. Oxford Science Publications, pp. 9-10. 
 
Howard, L., Maciewicz, R.A., Blobel, C.P., 2000. Cloning and characterization of ADAM28: 
evidence for autocatalytic pro-domain removal and for cell surface localization of 
mature ADAM28. Biochem J 348 Pt 1, 21-27. 
 
Howard, L., Nelson, K.K., Maciewicz, R.A., Blobel, C.P., 1999. Interaction of the 
metalloprotease disintegrins MDC9 and MDC15 with two SH3 domain-containing 
proteins, endophilin I and SH3PX1. J Biol Chem 274, 31693-31699. 
 
Huebner, K., Kastury, K., Druck, T., Salcini, A.E., Lanfrancone, L., Pelicci, G., Lowenstein, 
E., Li, W., Park, S.H., Cannizzaro, L., et al., 1994. Chromosome locations of genes 
encoding human signal transduction adapter proteins, Nck (NCK), Shc (SHC1), and Grb2 
(GRB2). Genomics 22, 281-287. 
 
Iba, K., Albrechtsen, R., Gilpin, B., Frohlich, C., Loechel, F., Zolkiewska, A., Ishiguro, K., 
Kojima, T., Liu, W., Langford, J.K., Sanderson, R.D., Brakebusch, C., Fassler, R., Wewer, 
U.M., 2000. The cysteine-rich domain of human ADAM 12 supports cell adhesion 
through syndecans and triggers signaling events that lead to beta1 integrin-dependent 
cell spreading. J Cell Biol 149, 1143-1156. 
194 
 
Ikura, M., Kay, L.E., Bax, A., 1990. A novel approach for sequential assignment of 1H, 
13C, and 15N spectra of proteins: heteronuclear triple-resonance three-dimensional 
NMR spectroscopy. Application to calmodulin. Biochemistry 29, 4659-4667. 
 
Iwai, H., Zuger, S., Jin, J., Tam, P.H., 2006. Highly efficient protein trans-splicing by a 
naturally split DnaE intein from Nostoc punctiforme. FEBS Lett 580, 1853-1858. 
 
Izumi, Y., Hirata, M., Hasuwa, H., Iwamoto, R., Umata, T., Miyado, K., Tamai, Y., Kurisaki, 
T., Sehara-Fujisawa, A., Ohno, S., Mekada, E., 1998. A metalloprotease-disintegrin, 
MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain 
shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 17, 
7260-7272. 
 
Janes, P.W., Saha, N., Barton, W.A., Kolev, M.V., Wimmer-Kleikamp, S.H., Nievergall, E., 
Blobel, C.P., Himanen, J.P., Lackmann, M., Nikolov, D.B., 2005. Adam meets Eph: an 
ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in 
trans. Cell 123, 291-304. 
 
Jang, I.K., Zhang, J., Gu, H., 2009. Grb2, a simple adapter with complex roles in 
lymphocyte development, function, and signaling. Immunol Rev 232, 150-159. 
Jiang, C., Wechuck, J.B., Goins, W.F., Krisky, D.M., Wolfe, D., Ataai, M.M., Glorioso, J.C., 
2004. Immobilized Cobalt Affinity Chromatography Provides a Novel, Efficient Method 
for Herpes Simplex Virus Type 1 Gene Vector Purification. Journal of Virology 78, 8994-
9006. 
 
Johnson, D., Agochiya, M., Samejima, K., Earnshaw, W., Frame, M., Wyke, J., 2000. 
Regulation of both apoptosis and cell survival by the v-Src oncoprotein. Cell death and 
differentiation 7, 685-696. 
 
Johnson, D.A., Akamine, P., Radzio-Andzelm, E., Madhusudan, Taylor, S.S., 2001. 
Dynamics of cAMP-Dependent Protein Kinase. Chemical Reviews 101, 2243-2270. 
 
Kairouz, R., Daly, R.J., 2000. Tyrosine kinase signalling in breast cancer: modulation of 
tyrosine kinase signalling in human breast cancer through altered expression of 
signalling intermediates. Breast Cancer Res 2, 197-202. 
 
Kamalati, T., Jolin, H.E., Mitchell, P.J., Barker, K.T., Jackson, L.E., Dean, C.J., Page, M.J., 
Gusterson, B.A., Crompton, M.R., 1996. Brk, a breast tumor-derived non-receptor 
protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. 
J Biol Chem 271, 30956-30963. 
 
Kaneko, T., Li, L., Li, S.S., 2008. The SH3 domain--a family of versatile peptide- and 
protein-recognition module. Front Biosci 13, 4938-4952. 
 
Kang, K.N., Kim, M., Pae, K.M., Lee, S.T., 2002. Characterization of the 5'-flanking region 
of the human PTK6 gene. Biochim Biophys Acta 1574, 365-369. 
195 
 
Kanner, S.B., Reynolds, A.B., Vines, R.R., Parsons, J.T., 1990. Monoclonal antibodies to 
individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine 
kinases. Proceedings of the National Academy of Sciences of the United States of 
America 87, 3328-3332. 
 
Kanomata, N., Kurebayashi, J., Kozuka, Y., Sonoo, H., Moriya, T., 2011. 
Clinicopathological significance of Y416Src and Y527Src expression in breast cancer. 
Journal of Clinical Pathology 64, 578-586. 
 
Kärkkäinen, S., Hiipakka, M., Wang, J.-H., Kleino, I., Vähä-Jaakkola, M., Renkema, G.H., 
Liss, M., Wagner, R., Saksela, K., 2006. Identification of preferred protein interactions by 
phage-display of the human Src homology-3 proteome. EMBO reports 7, 186-191. 
 
Keeler, J., 2006. Understanding NMR Spectroscopy. Wiley. 
Kessels, H.W., Ward, A.C., Schumacher, T.N., 2002. Specificity and affinity motifs for 
Grb2 SH2-ligand interactions. Proceedings of the National Academy of Sciences of the 
United States of America 99, 8524-8529. 
 
Kim, H., Laing, M., Muller, W., 2005a. c-Src-null mice exhibit defects in normal mammary 
gland development and ERalpha signaling. Oncogene 24, 5629-5636. 
 
Kim, H.K., Kong, M.Y., Jeong, M.J., Han, D.C., Choi, J.D., Kim, H.Y., Yoon, K.S., Kim, J.M., 
Son, K.H., Kwon, B.M., 2005b. Investigation of cell cycle arrest effects of actinomycin D 
at G1 phase using proteomic methods in B104-1-1 cells. Int J Biochem Cell Biol 37, 1921-
1929. 
 
Kim, H.K., Nam, J.Y., Han, M.Y., Lee, E.K., Choi, J.D., Bok, S.H., Kwon, B.M., 1999. 
Actinomycin D as a novel SH2 domain ligand inhibits Shc/Grb2 interaction in B104-1-1 
(neu*-transformed NIH3T3) and SAA (hEGFR-overexpressed NIH3T3) cells. FEBS Lett 
453, 174-178. 
 
Kleber, S., Sancho-Martinez, I., Wiestler, B., Beisel, A., Gieffers, C., Hill, O., Thiemann, 
M., Mueller, W., Sykora, J., Kuhn, A., Schreglmann, N., Letellier, E., Zuliani, C., Klussmann, 
S., Teodorczyk, M., Grone, H.J., Ganten, T.M., Sultmann, H., Tuttenberg, J., von Deimling, 
A., Regnier-Vigouroux, A., Herold-Mende, C., Martin-Villalba, A., 2008. Yes and PI3K bind 
CD95 to signal invasion of glioblastoma. Cancer Cell 13, 235-248. 
 
Kleino, I., Ortiz, R.M., Huovila, A.P., 2007. ADAM15 gene structure and differential 
alternative exon use in human tissues. BMC Mol Biol 8, 90. 
 
Kleino, I., Ortiz, R.M., Yritys, M., Huovila, A.-P.J., Saksela, K., 2009. Alternative splicing of 
ADAM15 regulates its interactions with cellular SH3 proteins. Journal of Cellular 
Biochemistry 108, 877-885. 
 
Klessner, J.L., Desai, B.V., Amargo, E.V., Getsios, S., Green, K.J., 2009. EGFR and ADAMs 
cooperate to regulate shedding and endocytic trafficking of the desmosomal cadherin 
desmoglein 2. Mol Biol Cell 20, 328-337. 
196 
 
Ko, S., Ahn, K.E., Lee, Y.M., Ahn, H.C., Lee, W., 2009. Structural basis of the auto-
inhibition mechanism of nonreceptor tyrosine kinase PTK6. Biochem Biophys Res 
Commun 384, 236-242. 
 
Kohda, D., Terasawa, H., Ichikawa, S., Ogura, K., Hatanaka, H., Mandiyan, V., Ullrich, A., 
Schlessinger, J., Inagaki, F., 1994. Solution structure and ligand-binding site of the 
carboxy-terminal SH3 domain of GRB2. Structure (London, England : 1993) 2, 1029-1040. 
 
Kosol, S., Contreras-Martos, S., Cedeño, C., Tompa, P., 2013. Structural Characterization 
of Intrinsically Disordered Proteins by NMR Spectroscopy. Molecules 18, 10802-10828. 
 
Kovrigin, E., 2012. NMR line shapes and multi-state binding equilibria. Journal of 
Biomolecular NMR 53, 257-270. 
 
Kratzschmar, J., Lum, L., Blobel, C.P., 1996. Metargidin, a membrane-anchored 
metalloprotease-disintegrin protein with an RGD integrin binding sequence. J Biol Chem 
271, 4593-4596. 
 
Kuefer, R., Day, K.C., Kleer, C.G., Sabel, M.S., Hofer, M.D., Varambally, S., Zorn, C.S., 
Chinnaiyan, A.M., Rubin, M.A., Day, M.L., 2006. ADAM15 Disintegrin Is Associated with 
Aggressive Prostate and Breast Cancer Disease. Neoplasia 8, 319-329. 
 
Laurie, S.A., Goss, G.D., Shepherd, F.A., Reaume, M.N., Nicholas, G., Philip, L., Wang, L., 
Schwock, J., Hirsh, V., Oza, A., Tsao, M.-S., Wright, J.J., Leighl, N.B., 2014. A Phase II Trial 
of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non–Small-
Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium. Clinical Lung 
Cancer 15, 52-57. 
 
Lee, H., Kim, M., Lee, K.H., Kang, K.N., Lee, S.T., 1998. Exon-intron structure of the human 
PTK6 gene demonstrates that PTK6 constitutes a distinct family of non-receptor tyrosine 
kinase. Molecules and cells 8, 401-407. 
 
Lee, H., Sodek, K.L., Hwang, Q., Brown, T.J., Ringuette, M., Sodek, J., 2007. Phagocytosis 
of collagen by fibroblasts and invasive cancer cells is mediated by MT1-MMP. Biochem 
Soc Trans 35, 704-706. 
 
Lee, H.D., Kim, Y.H., Koo, B.H., Kim, D.S., 2014. Ectodomain of ADAM15 is shed from 
secretory exosomes. BMB reports. 
 
Lee, H.D., Koo, B.H., Kim, Y.H., Jeon, O.H., Kim, D.S., 2012. Exosome release of ADAM15 
and the functional implications of human macrophage-derived ADAM15 exosomes. 
FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 26, 3084-3095. 
 
Levitt, M.H., 2009a. Spin Dynamics: Basics Of Nuclear Magnetic Resonance, 2 ed. Wiley, 
pp. 50-53. 
197 
 
Levitt, M.H., 2009b. Spin Dynamics: Basics Of Nuclear Magnetic Resonance, 2 ed. Wiley, 
p. 39. 
 
Levitt, M.H., 2009c. Spin Dynamics: Basics Of Nuclear Magnetic Resonance, 2 ed. Wiley, 
p. 15. 
 
Levitt, M.H., 2009d. Spin Dynamics: Basics Of Nuclear Magnetic Resonance, 2 ed. Wiley, 
p. 7. 
 
Levitt, M.H., 2009e. Spin Dynamics: Basics Of Nuclear Magnetic Resonance, 2 ed. Wiley, 
pp. 105-113. 
 
Li, X., Romero, P., Rani, M., Dunker, A.K., Obradovic, Z., 1999. Predicting Protein Disorder 
for N-, C-, and Internal Regions. Genome informatics. Workshop on Genome Informatics 
10, 30-40. 
 
Li, Y., Wei, Z., Yan, Y., Wan, Q., Du, Q., Zhang, M., 2014. Structure of Crumbs tail in 
complex with the PALS1 PDZ-SH3-GK tandem reveals a highly specific assembly 
mechanism for the apical Crumbs complex. Proceedings of the National Academy of 
Sciences of the United States of America 111, 17444-17449. 
 
Lin, C.C., Melo, F.A., Ghosh, R., Suen, K.M., Stagg, L.J., Kirkpatrick, J., Arold, S.T., Ahmed, 
Z., Ladbury, J.E., 2012. Inhibition of basal FGF receptor signaling by dimeric Grb2. Cell 
149, 1514-1524. 
 
Liu, D., Ha, C., Zhang, X., Zhang, Z., Liu, P., 2013. Molecular implication of ADAM-15 and 
-17 in intrauterine adhesions. European journal of obstetrics, gynecology, and 
reproductive biology 170, 264-269. 
 
Liu, L., Gao, Y., Qiu, H., Miller, W.T., Poli, V., Reich, N.C., 2006. Identification of STAT3 as 
a specific substrate of breast tumor kinase. Oncogene 25, 4904-4912. 
 
Liu, Y., Wang, L., Lin, X.Y., Wang, J., Yu, J.H., Miao, Y., Wang, E.H., 2012. Anti-apoptotic 
effect of claudin-1 on TNF-alpha-induced apoptosis in human breast cancer MCF-7 cells. 
Tumour biology : the journal of the International Society for Oncodevelopmental Biology 
and Medicine 33, 2307-2315. 
 
Lu, D., Scully, M., Kakkar, V., Lu, X., 2010. ADAM-15 Disintegrin-Like Domain Structure 
and Function. Toxins 2, 2411-2427. 
 
Lucas, N., Day, M.L., 2009. The role of the disintegrin metalloproteinase ADAM15 in 
prostate cancer progression. J Cell Biochem 106, 967-974. 
 
Lucas, N., Najy, A.J., Day, M.L., 2009. The therapeutic potential of ADAM15. Curr Pharm 
Des 15, 2311-2318. 
 
198 
 
Lukong, K.E., Huot, M.E., Richard, S., 2009. BRK phosphorylates PSF promoting its 
cytoplasmic localization and cell cycle arrest. Cellular signalling 21, 1415-1422. 
 
Lukong, K.E., Richard, S., 2008. Breast tumor kinase BRK requires kinesin-2 subunit 
KAP3A in modulation of cell migration. Cellular signalling 20, 432-442. 
 
Lum, L., Reid, M.S., Blobel, C.P., 1998. Intracellular maturation of the mouse 
metalloprotease disintegrin MDC15. J Biol Chem 273, 26236-26247. 
 
Magrane, M., Consortium, U., 2011. UniProt Knowledgebase: a hub of integrated 
protein data. Database : the journal of biological databases and curation 2011, bar009. 
 
Maignan, S., Guilloteau, J.P., Fromage, N., Arnoux, B., Becquart, J., Ducruix, A., 1995. 
Crystal structure of the mammalian Grb2 adaptor. Science 268, 291-293. 
 
Marcello, E., Gardoni, F., Mauceri, D., Romorini, S., Jeromin, A., Epis, R., Borroni, B., 
Cattabeni, F., Sala, C., Padovani, A., Di Luca, M., 2007. Synapse-associated protein-97 
mediates alpha-secretase ADAM10 trafficking and promotes its activity. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 27, 1682-1691. 
 
Maretzky, T., Evers, A., Le Gall, S., Alabi, R.O., Speck, N., Reiss, K., Blobel, C.P., 2015. The 
Cytoplasmic Domain of A Disintegrin and Metalloproteinase 10 (ADAM10) Regulates Its 
Constitutive Activity but Is Dispensable for Stimulated ADAM10-dependent Shedding. J 
Biol Chem 290, 7416-7425. 
 
Maretzky, T., Le Gall, S.M., Worpenberg-Pietruk, S., Eder, J., Overall, C.M., Huang, X.Y., 
Poghosyan, Z., Edwards, D.R., Blobel, C.P., 2009a. Src Stimulates Fibroblast Growth 
Factor Receptor-2 Shedding by an ADAM15 Splice Variant Linked to Breast Cancer. 
Cancer Research 69, 4573-4576. 
 
Maretzky, T., Yang, G., Ouerfelli, O., Overall, C.M., Worpenberg, S., Hassiepen, U., Eder, 
J., Blobel, C.P., 2009b. Characterization of the catalytic activity of the membrane-
anchored metalloproteinase ADAM15 in cell-based assays. Biochem J 420, 105-113. 
 
Martin-Garcia, J.M., Ruiz-Sanz, J., Luque, I., 2012. Interfacial water molecules in SH3 
interactions: a revised paradigm for polyproline recognition. Biochem J 442, 443-451. 
 
Mayer, B.J., 2001. SH3 domains: complexity in moderation. J Cell Sci 114, 1253-1263. 
 
Mazurenko, N.N., Kogan, E.A., Zborovskaya, I.B., Kisseljov, F.L., 1992. Expression of 
pp60c-src in human small cell and non-small cell lung carcinomas. European journal of 
cancer (Oxford, England : 1990) 28, 372-377. 
 
Mazzocca, A., Coppari, R., De Franco, R., Cho, J.Y., Libermann, T.A., Pinzani, M., Toker, 
A., 2005. A secreted form of ADAM9 promotes carcinoma invasion through tumor-
stromal interactions. Cancer Res 65, 4728-4738. 
199 
 
McDonald, C.B., Balke, J.E., Bhat, V., Mikles, D.C., Deegan, B.J., Seldeen, K.L., Farooq, A., 
2012a. Multivalent binding and facilitated diffusion account for the formation of the 
Grb2-Sos1 signaling complex in a cooperative manner. Biochemistry 51, 2122-2135. 
 
McDonald, C.B., Bhat, V., Mikles, D.C., Deegan, B.J., Seldeen, K.L., Farooq, A., 2012b. 
Bivalent binding drives the formation of the Grb2-Gab1 signaling complex in a 
noncooperative manner. The FEBS journal 279, 2156-2173. 
 
McDonald, C.B., Seldeen, K.L., Deegan, B.J., Farooq, A., 2009. SH3 Domains of Grb2 
Adaptor Bind to PXψPXR Motifs Within the Sos1 Nucleotide Exchange Factor in a 
Discriminate Manner. Biochemistry 48, 4074-4085. 
 
Mitchell, P.J., Barker, K.T., Martindale, J.E., Kamalati, T., Lowe, P.N., Page, M.J., 
Gusterson, B.A., Crompton, M.R., 1994. Cloning and characterisation of cDNAs encoding 
a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. 
Oncogene 9, 2383-2390. 
 
Mitchell, P.J., Barker, K.T., Shipley, J., Crompton, M.R., 1997. Characterisation and 
chromosome mapping of the human non receptor tyrosine kinase gene, brk. Oncogene 
15, 1497-1502. 
 
Mori, S., 2003. PACSIN3 Binds ADAM12/Meltrin   and Up-regulates Ectodomain 
Shedding of Heparin-binding Epidermal Growth Factor-like Growth Factor. Journal of 
Biological Chemistry 278, 46029-46034. 
 
Mosnier, J.F., Jarry, A., Bou-Hanna, C., Denis, M.G., Merlin, D., Laboisse, C.L., 2006. 
ADAM15 upregulation and interaction with multiple binding partners in inflammatory 
bowel disease. Lab Invest 86, 1064-1073. 
 
Moss, M.L., Bomar, M., Liu, Q., Sage, H., Dempsey, P., Lenhart, P.M., Gillispie, P.A., 
Stoeck, A., Wildeboer, D., Bartsch, J.W., Palmisano, R., Zhou, P., 2007. The ADAM10 
prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular 
shedding events. J Biol Chem 282, 35712-35721. 
 
Moss, M.L., Stoeck, A., Yan, W., Dempsey, P.J., 2008. ADAM10 as a target for anti-cancer 
therapy. Curr Pharm Biotechnol 9, 2-8. 
 
Muraguchi, T., Takegami, Y., Ohtsuka, T., Kitajima, S., Chandana, E.P., Omura, A., Miki, 
T., Takahashi, R., Matsumoto, N., Ludwig, A., Noda, M., Takahashi, C., 2007. RECK 
modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity. 
Nat Neurosci 10, 838-845. 
 
Murphy, G., 2008. The ADAMs: signalling scissors in the tumour microenvironment. Nat 
Rev Cancer 8, 929-941. 
 
Murphy, G., 2009. Regulation of the proteolytic disintegrin metalloproteinases, the 
'Sheddases'. Semin Cell Dev Biol 20, 138-145. 
200 
 
Murphy, G., Murthy, A., Khokha, R., 2008. Clipping, shedding and RIPping keep immunity 
on cue. Trends Immunol 29, 75-82. 
 
Najy, A.J., Day, K.C., Day, M.L., 2008a. ADAM15 Supports Prostate Cancer Metastasis by 
Modulating Tumor Cell-Endothelial Cell Interaction. Cancer Research 68, 1092-1099. 
 
Najy, A.J., Day, K.C., Day, M.L., 2008b. The Ectodomain Shedding of E-cadherin by 
ADAM15 Supports ErbB Receptor Activation. Journal of Biological Chemistry 283, 18393-
18401. 
 
Nowak, D., Boehrer, S., Hochmuth, S., Trepohl, B., Hofmann, W., Hoelzer, D., Hofmann, 
W.K., Mitrou, P.S., Ruthardt, M., Chow, K.U., 2007. Src kinase inhibitors induce apoptosis 
and mediate cell cycle arrest in lymphoma cells. Anti-cancer drugs 18, 981-995. 
 
Okada, M., Nakagawa, H., 1989. A protein tyrosine kinase involved in regulation of 
pp60c-src function. J Biol Chem 264, 20886-20893. 
 
Ostrander, J.H., Daniel, A.R., Lange, C.A., 2010. Brk/PTK6 signaling in normal and cancer 
cell models. Current opinion in pharmacology 10, 662-669. 
 
Ostrander, J.H., Daniel, A.R., Lofgren, K., Kleer, C.G., Lange, C.A., 2007. Breast tumor 
kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and 
p38 MAP kinases in breast cancer cells. Cancer Res 67, 4199-4209. 
 
Park, S.H., Lee, K.H., Kim, H., Lee, S.T., 1997. Assignment of the human PTK6 gene 
encoding a non-receptor protein tyrosine kinase to 20q13.3 by fluorescence in situ 
hybridization. Cytogenetics and cell genetics 77, 271-272. 
 
Pelisek, J., Pongratz, J., Deutsch, L., Reeps, C., Stadlbauer, T., Eckstein, H.H., 2012. 
Expression and cellular localization of metalloproteases ADAMs in high graded carotid 
artery lesions. Scandinavian journal of clinical and laboratory investigation 72, 648-656. 
 
Petit, V., Boyer, B., Lentz, D., Turner, C.E., Thiery, J.P., Valles, A.M., 2000. 
Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration 
through an association with CRK in NBT-II cells. J Cell Biol 148, 957-970. 
 
Petro, B.J., Tan, R.C., Tyner, A.L., Lingen, M.W., Watanabe, K., 2004. Differential 
expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and 
normal oral epithelium. Oral oncology 40, 1040-1047. 
 
Poghosyan, Z., 2001. Phosphorylation-dependent Interactions between ADAM15 
Cytoplasmic Domain and Src Family Protein-tyrosine Kinases. Journal of Biological 
Chemistry 277, 4999-5007. 
 
Ponnuchamy, B., Khalil, R.A., 2008. Role of ADAMs in endothelial cell permeability: 
cadherin shedding and leukocyte rolling. Circ Res 102, 1139-1142. 
201 
 
Posadas, E.M., Al-Ahmadie, H., Robinson, V.L., Jagadeeswaran, R., Otto, K., Kasza, K.E., 
Tretiakov, M., Siddiqui, J., Pienta, K.J., Stadler, W.M., Rinker-Schaeffer, C., Salgia, R., 
2009. FYN is overexpressed in human prostate cancer. BJU international 103, 171-177. 
 
Prickett, T.D., Agrawal, N.S., Wei, X., Yates, K.E., Lin, J.C., Wunderlich, J.R., Cronin, J.C., 
Cruz, P., Rosenberg, S.A., Samuels, Y., 2009. Analysis of the tyrosine kinome in 
melanoma reveals recurrent mutations in ERBB4. Nature genetics 41, 1127-1132. 
 
Puente, X.S., Sanchez, L.M., Overall, C.M., Lopez-Otin, C., 2003. Human and mouse 
proteases: a comparative genomic approach. Nat Rev Genet 4, 544-558. 
 
Puls, L.N., Eadens, M., Messersmith, W., 2011. Current status of SRC inhibitors in solid 
tumor malignancies. Oncologist 16, 566-578. 
 
Puto, L.A., Pestonjamasp, K., King, C.C., Bokoch, G.M., 2003. p21-activated kinase 1 
(PAK1) interacts with the Grb2 adapter protein to couple to growth factor signaling. J 
Biol Chem 278, 9388-9393. 
 
Qian, F., Hanahan, D., Weissman, I.L., 2001. L-selectin can facilitate metastasis to lymph 
nodes in a transgenic mouse model of carcinogenesis. Proceedings of the National 
Academy of Sciences of the United States of America 98, 3976-3981. 
 
Qiu, H., Miller, W.T., 2002. Regulation of the nonreceptor tyrosine kinase Brk by 
autophosphorylation and by autoinhibition. J Biol Chem 277, 34634-34641. 
 
Rae, J.M., Creighton, C.J., Meck, J.M., Haddad, B.R., Johnson, M.D., 2007. MDA-MB-435 
cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for 
melanoma research. Breast cancer research and treatment 104, 13-19. 
 
Raiter, A., Weiss, C., Bechor, Z., Ben-Dor, I., Battler, A., Kaplan, B., Hardy, B., 2010. 
Activation of GRP78 on endothelial cell membranes by an ADAM15-derived peptide 
induces angiogenesis. J Vasc Res 47, 399-411. 
 
Rawlings, N.D., Morton, F.R., Kok, C.Y., Kong, J., Barrett, A.J., 2008. MEROPS: the 
peptidase database. Nucleic Acids Res 36, D320-325. 
 
Reddy, P., Slack, J.L., Davis, R., Cerretti, D.P., Kozlosky, C.J., Blanton, R.A., Shows, D., 
Peschon, J.J., Black, R.A., 2000. Functional analysis of the domain structure of tumor 
necrosis factor-alpha converting enzyme. J Biol Chem 275, 14608-14614. 
 
Riley, D., Carragher, N.O., Frame, M.C., Wyke, J.A., 2001. The mechanism of cell cycle 
regulation by v-Src. Oncogene 20, 5941-5950. 
 
Roghani, M., Becherer, J.D., Moss, M.L., Atherton, R.E., Erdjument-Bromage, H., Arribas, 
J., Blackburn, R.K., Weskamp, G., Tempst, P., Blobel, C.P., 1999. Metalloprotease-
disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem 274, 3531-
3540. 
202 
 
Romero, Obradovic, Dunker, K., 1997. Sequence Data Analysis for Long Disordered 
Regions Prediction in the Calcineurin Family. Genome informatics. Workshop on 
Genome Informatics 8, 110-124. 
 
Romero, P., Obradovic, Z., Li, X., Garner, E.C., Brown, C.J., Dunker, A.K., 2001. Sequence 
complexity of disordered protein. Proteins 42, 38-48. 
 
Roskoski, R., Jr., 2015. Src protein-tyrosine kinase structure, mechanism, and small 
molecule inhibitors. Pharmacological research : the official journal of the Italian 
Pharmacological Society 94c, 9-25. 
 
Roy, K., Chakrabarti, O., Mukhopadhyay, D., 2014. Interaction of Grb2 SH3 domain with 
UVRAG in an Alzheimer's disease-like scenario. Biochemistry and cell biology = Biochimie 
et biologie cellulaire 92, 219-225. 
 
Ruhe, J.E., Streit, S., Hart, S., Wong, C.H., Specht, K., Knyazev, P., Knyazeva, T., Tay, L.S., 
Loo, H.L., Foo, P., Wong, W., Pok, S., Lim, S.J., Ong, H., Luo, M., Ho, H.K., Peng, K., Lee, 
T.C., Bezler, M., Mann, C., Gaertner, S., Hoefler, H., Iacobelli, S., Peter, S., Tay, A., 
Brenner, S., Venkatesh, B., Ullrich, A., 2007. Genetic alterations in the tyrosine kinase 
transcriptome of human cancer cell lines. Cancer Res 67, 11368-11376. 
 
Saksela, K., Permi, P., 2012. SH3 domain ligand binding: What's the consensus and 
where's the specificity? FEBS Lett 586, 2609-2614. 
 
Scaplehorn, N., Holmstrom, A., Moreau, V., Frischknecht, F., Reckmann, I., Way, M., 
2002. Grb2 and Nck act cooperatively to promote actin-based motility of vaccinia virus. 
Current biology : CB 12, 740-745. 
 
Schlaepfer, D.D., Hanks, S.K., Hunter, T., van der Geer, P., 1994. Integrin-mediated signal 
transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature 
372, 786-791. 
 
Schlaepfer, D.D., Jones, K.C., Hunter, T., 1998. Multiple Grb2-mediated integrin-
stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of 
both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events. Mol Cell 
Biol 18, 2571-2585. 
 
Schlomann, U., Wildeboer, D., Webster, A., Antropova, O., Zeuschner, D., Knight, C.G., 
Docherty, A.J., Lambert, M., Skelton, L., Jockusch, H., Bartsch, J.W., 2002. The 
metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for 
proteolytic activity and cell adhesion. J Biol Chem 277, 48210-48219. 
 
Schmandt, R.E., Bennett, M., Clifford, S., Thornton, A., Jiang, F., Broaddus, R.R., Sun, C.C., 
Lu, K.H., Sood, A.K., Gershenson, D.M., 2006. The BRK tyrosine kinase is expressed in 
high-grade serous carcinoma of the ovary. Cancer biology & therapy 5, 1136-1141. 
 
203 
 
Schonefuss, A., Abety, A.N., Zamek, J., Mauch, C., Zigrino, P., 2012. Role of ADAM-15 in 
wound healing and melanoma development. Exp Dermatol 21, 437-442. 
 
Seals, D.F., 2003. The ADAMs family of metalloproteases: multidomain proteins with 
multiple functions. Genes & Development 17, 7-30. 
 
Seals, D.F., Courtneidge, S.A., 2003. The ADAMs family of metalloproteases: 
multidomain proteins with multiple functions. Genes Dev 17, 7-30. 
 
Sellappan, S., Grijalva, R., Zhou, X., Yang, W., Eli, M.B., Mills, G.B., Yu, D., 2004. Lineage 
infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell 
line. Cancer Res 64, 3479-3485. 
 
Serrels, A., Timpson, P., Canel, M., Schwarz, J.P., Carragher, N.O., Frame, M.C., Brunton, 
V.G., Anderson, K.I., 2009. Real-time study of E-cadherin and membrane dynamics in 
living animals: implications for disease modeling and drug development. Cancer Res 69, 
2714-2719. 
 
She, H.Y., Rockow, S., Tang, J., Nishimura, R., Skolnik, E.Y., Chen, M., Margolis, B., Li, W., 
1997. Wiskott-Aldrich syndrome protein is associated with the adapter protein Grb2 and 
the epidermal growth factor receptor in living cells. Mol Biol Cell 8, 1709-1721. 
 
Shen, C.H., Chen, H.Y., Lin, M.S., Li, F.Y., Chang, C.C., Kuo, M.L., Settleman, J., Chen, R.H., 
2008. Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and 
promote breast carcinoma growth, migration, and invasion. Cancer Res 68, 7779-7787. 
 
Sheppard, D., 2000. In vivo functions of integrins: lessons from null mutations in mice. 
Matrix biology : journal of the International Society for Matrix Biology 19, 203-209. 
 
Shiina, H., Breault, J.E., Basset, W.W., Enokida, H., Urakami, S., Li, L.C., Okino, S.T., 
Deguchi, M., Kaneuchi, M., Terashima, M., Yoneda, T., Shigeno, K., Carroll, P.R., Igawa, 
M., Dahiya, R., 2005. Functional Loss of the gamma-catenin gene through epigenetic and 
genetic pathways in human prostate cancer. Cancer Res 65, 2130-2138. 
 
Simister, P.C., Luccarelli, J., Thompson, S., Appella, D.H., Feller, S.M., Hamilton, A.D., 
2013. Novel inhibitors of a Grb2 SH3C domain interaction identified by a virtual screen. 
Bioorganic & medicinal chemistry 21, 4027-4033. 
 
Simon, J.A., Schreiber, S.L., 1995. Grb2 SH3 binding to peptides from Sos: evaluation of 
a general model for SH3-ligand interactions. Chemistry & Biology 2, 53-60. 
 
Smith, K.M., Gaultier, A., Cousin, H., Alfandari, D., White, J.M., DeSimone, D.W., 2002. 
The cysteine-rich domain regulates ADAM protease function in vivo. J Cell Biol 159, 893-
902. 
 
204 
 
Sommer, L.A., Meier, M.A., Dames, S.A., 2012. A fast and simple method for probing the 
interaction of peptides and proteins with lipids and membrane-mimetics using GB1 
fusion proteins and NMR spectroscopy. Protein Sci 21, 1566-1570. 
 
Soriano, P., Montgomery, C., Geske, R., Bradley, A., 1991. Targeted disruption of the c-
src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693-702. 
 
Sparks, A.B., Quilliam, L.A., Thorn, J.M., Der, C.J., Kay, B.K., 1994. Identification and 
characterization of Src SH3 ligands from phage-displayed random peptide libraries. J Biol 
Chem 269, 23853-23856. 
 
Stangler, T., Tran, T., Hoffmann, S., Schmidt, H., Jonas, E., Willbold, D., 2007. Competitive 
displacement of full-length HIV-1 Nef from the Hck SH3 domain by a high-affinity 
artificial peptide. Biol Chem 388, 611-615. 
 
Stautz, D., Leyme, A., Grandal, M.V., Albrechtsen, R., van Deurs, B., Wewer, U., Kveiborg, 
M., 2012a. Cell-surface metalloprotease ADAM12 is internalized by a clathrin- and Grb2-
dependent mechanism. Traffic (Copenhagen, Denmark) 13, 1532-1546. 
 
Stautz, D., Sanjay, A., Hansen, M.T., Albrechtsen, R., Wewer, U.M., Kveiborg, M., 2010. 
ADAM12 localizes with c-Src to actin-rich structures at the cell periphery and regulates 
Src kinase activity. Exp Cell Res 316, 55-67. 
 
Stautz, D., Wewer, U.M., Kveiborg, M., 2012b. Functional analysis of a breast cancer-
associated mutation in the intracellular domain of the metalloprotease ADAM12. PloS 
one 7, e37628. 
 
Stoeck, A., Keller, S., Riedle, S., Sanderson, M.P., Runz, S., Le Naour, F., Gutwein, P., 
Ludwig, A., Rubinstein, E., Altevogt, P., 2006. A role for exosomes in the constitutive and 
stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J 393, 609-618. 
Stover, D.R., Furet, P., Lydon, N.B., 1996. Modulation of the SH2 binding specificity and 
kinase activity of Src by tyrosine phosphorylation within its SH2 domain. J Biol Chem 271, 
12481-12487. 
 
Sun, C., Beard, R.S., Jr., McLean, D.L., Rigor, R.R., Konia, T., Wu, M.H., Yuan, S.Y., 2013. 
ADAM15 deficiency attenuates pulmonary hyperpermeability and acute lung injury in 
lipopolysaccharide-treated mice. American journal of physiology. Lung cellular and 
molecular physiology 304, L135-142. 
 
Sun, C., Wu, M.H., Guo, M., Day, M.L., Lee, E.S., Yuan, S.Y., 2010. ADAM15 regulates 
endothelial permeability and neutrophil migration via Src/ERK1/2 signalling. Cardiovasc 
Res 87, 348-355. 
 
Sun, C., Wu, M.H., Lee, E.S., Yuan, S.Y., 2012. A disintegrin and metalloproteinase 15 
contributes to atherosclerosis by mediating endothelial barrier dysfunction via Src 
family kinase activity. Arterioscler Thromb Vasc Biol 32, 2444-2451. 
205 
 
Sun, Z.Y., Frueh, D.P., Selenko, P., Hoch, J.C., Wagner, G., 2005. Fast assignment of 15N-
HSQC peaks using high-resolution 3D HNcocaNH experiments with non-uniform 
sampling. J Biomol NMR 33, 43-50. 
 
Sundberg, C., Thodeti, C.K., Kveiborg, M., Larsson, C., Parker, P., Albrechtsen, R., Wewer, 
U.M., 2004. Regulation of ADAM12 cell-surface expression by protein kinase C epsilon. 
J Biol Chem 279, 51601-51611. 
 
Superti-Furga, G., Fumagalli, S., Koegl, M., Courtneidge, S.A., Draetta, G., 1993. Csk 
inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. Embo j 12, 
2625-2634. 
 
Takahashi, H., Nakanishi, T., Kami, K., Arata, Y., Shimada, I., 2000. A novel NMR method 
for determining the interfaces of large protein-protein complexes. Nat Struct Mol Biol 7, 
220-223. 
 
Talamonti, M.S., Roh, M.S., Curley, S.A., Gallick, G.E., 1993. Increase in activity and level 
of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91, 53-60. 
 
Tari, A.M., Lopez-Berestein, G., 2001. GRB2: a pivotal protein in signal transduction. 
Semin Oncol 28, 142-147. 
 
Teyra, J., Sidhu, S.S., Kim, P.M., 2012. Elucidation of the binding preferences of peptide 
recognition modules: SH3 and PDZ domains. FEBS Lett 586, 2631-2637. 
 
Toquet, C., Colson, A., Jarry, A., Bezieau, S., Volteau, C., Boisseau, P., Merlin, D., Laboisse, 
C.L., Mosnier, J.-F., 2012. ADAM15 to α5β1 integrin switch in colon carcinoma cells: A 
late event in cancer progression associated with tumor dedifferentiation and poor 
prognosis. International Journal of Cancer 130, 278-287. 
 
Ungerer, C., Doberstein, K., Bürger, C., Hardt, K., Boehncke, W.-H., Böhm, B., 
Pfeilschifter, J., Dummer, R., Mihic-Probst, D., Gutwein, P., 2010. ADAM15 expression is 
downregulated in melanoma metastasis compared to primary melanoma. Biochemical 
and Biophysical Research Communications 401, 363-369. 
 
Uversky, V.N., 2011. Intrinsically disordered proteins from A to Z. Int J Biochem Cell Biol 
43, 1090-1103. 
 
Vasioukhin, V., Serfas, M.S., Siyanova, E.Y., Polonskaia, M., Costigan, V.J., Liu, B., 
Thomason, A., Tyner, A.L., 1995. A novel intracellular epithelial cell tyrosine kinase is 
expressed in the skin and gastrointestinal tract. Oncogene 10, 349-357. 
 
Vasioukhin, V., Tyner, A.L., 1997. A role for the epithelial-cell-specific tyrosine kinase Sik 
during keratinocyte differentiation. Proceedings of the National Academy of Sciences of 
the United States of America 94, 14477-14482. 
 
206 
 
Verbeek, B.S., Vroom, T.M., Adriaansen-Slot, S.S., Ottenhoff-Kalff, A.E., Geertzema, 
J.G.N., Hennipman, A., Rijksen, G., 1996. c-Src PROTEIN EXPRESSION IS INCREASED IN 
HUMAN BREAST CANCER. AN IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSIS. 
The Journal of Pathology 180, 383-388. 
 
Vidal, M., Gigoux, V., Garbay, C., 2001. SH2 and SH3 domains as targets for anti-
proliferative agents. Critical reviews in oncology/hematology 40, 175-186. 
 
Vidarsson, G., Dekkers, G., Rispens, T., 2014. IgG subclasses and allotypes: from 
structure to effector functions. Frontiers in immunology 5, 520. 
 
Vranken, W.F., Boucher, W., Stevens, T.J., Fogh, R.H., Pajon, A., Llinas, M., Ulrich, E.L., 
Markley, J.L., Ionides, J., Laue, E.D., 2005. The CCPN data model for NMR spectroscopy: 
Development of a software pipeline. Proteins: Structure, Function, and Bioinformatics 
59, 687-696. 
 
Wang, T.C., Jee, S.H., Tsai, T.F., Huang, Y.L., Tsai, W.L., Chen, R.H., 2005. Role of breast 
tumour kinase in the in vitro differentiation of HaCaT cells. The British journal of 
dermatology 153, 282-289. 
 
Weaver, A.M., Karginov, A.V., Kinley, A.W., Weed, S.A., Li, Y., Parsons, J.T., Cooper, J.A., 
2001. Cortactin promotes and stabilizes Arp2/3-induced actin filament network 
formation. Current biology : CB 11, 370-374. 
 
Weaver, A.M., Silva, C.M., 2007. Signal transducer and activator of transcription 5b: a 
new target of breast tumor kinase/protein tyrosine kinase 6. Breast Cancer Res 9, R79. 
Wheeler, D.L., Iida, M., Dunn, E.F., 2009. The Role of Src in Solid Tumors. The Oncologist 
14, 667-678. 
 
Wild-Bode, C., Fellerer, K., Kugler, J., Haass, C., Capell, A., 2006. A basolateral sorting 
signal directs ADAM10 to adherens junctions and is required for its function in cell 
migration. J Biol Chem 281, 23824-23829. 
 
Williamson, M.P., 2013. Using chemical shift perturbation to characterise ligand binding. 
Progress in Nuclear Magnetic Resonance Spectroscopy 73, 1-16. 
 
Wilson, L.K., Luttrell, D.K., Parsons, J.T., Parsons, S.J., 1989. pp60c-src tyrosine kinase, 
myristylation, and modulatory domains are required for enhanced mitogenic 
responsiveness to epidermal growth factor seen in cells overexpressing c-src. Mol Cell 
Biol 9, 1536-1544. 
 
Wittekind, M., Mapelli, C., Lee, V., Goldfarb, V., Friedrichs, M.S., Meyers, C.A., Mueller, 
L., 1997. Solution structure of the Grb2 N-terminal SH3 domain complexed with a ten-
residue peptide derived from SOS: direct refinement against NOEs, J-couplings and 1H 
and 13C chemical shifts. Journal of molecular biology 267, 933-952. 
 
207 
 
Witz, I.P., 2006. The involvement of selectins and their ligands in tumor-progression. 
Immunology letters 104, 89-93. 
 
Xiang, B., Chatti, K., Qiu, H., Lakshmi, B., Krasnitz, A., Hicks, J., Yu, M., Miller, W.T., 
Muthuswamy, S.K., 2008. Brk is coamplified with ErbB2 to promote proliferation in 
breast cancer. Proceedings of the National Academy of Sciences of the United States of 
America 105, 12463-12468. 
 
Xiaohui Duan, X.M.a.W.S., 2013. ADAM15 is involved in MICB shedding and mediates 
the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells. 
Molecular medicine reports 7, 991-997. 
 
Xu, G., Ye, Y., Liu, X., Cao, S., Wu, Q., Cheng, K., Liu, M., Pielak, G.J., Li, C., 2014a. 
Strategies for protein NMR in Escherichia coli. Biochemistry 53, 1971-1981. 
 
Xu, Y., Zhang, H., Lit, L.C., Grothey, A., Athanasiadou, M., Kiritsi, M., Lombardo, Y., 
Frampton, A.E., Green, A.R., Ellis, I.O., Ali, S., Lenz, H.J., Thanou, M., Stebbing, J., Giamas, 
G., 2014b. The kinase LMTK3 promotes invasion in breast cancer through GRB2-
mediated induction of integrin beta(1). Science signaling 7, ra58. 
 
Yasui, A., Matsuura, K., Shimizu, E., Hijiya, N., Higuchi, Y., Yamamoto, S., 2004. 
Expression of splice variants of the human ADAM15 gene and strong interaction 
between the cytoplasmic domain of one variant and Src family proteins Lck and Hck. 
Pathobiology 71, 185-192. 
 
Yin, J., Cai, Z., Zhang, L., Zhang, J., He, X., Du, X., Wang, Q., Lu, J., 2013. A recombined 
fusion protein PTD-Grb2-SH2 inhibits the proliferation of breast cancer cells in vitro. Int 
J Oncol 42, 1061-1069. 
 
Yu, H., Rosen, M.K., Schreiber, S.L., 1993. 1H and 15N assignments and secondary 
structure of the Src SH3 domain. FEBS Lett 324, 87-92. 
 
Zang, X.P., Siwak, D.R., Nguyen, T.X., Tari, A.M., Pento, J.T., 2004. KGF-induced motility 
of breast cancer cells is dependent on Grb2 and Erk1,2. Clin Exp Metastasis 21, 437-443. 
 
Zhang, S., Yu, D., 2012. Targeting Src family kinases in anti-cancer therapies: turning 
promise into triumph. Trends in Pharmacological Sciences 33, 122-128. 
 
Zhang, X.H., Wang, Q., Gerald, W., Hudis, C.A., Norton, L., Smid, M., Foekens, J.A., 
Massague, J., 2009. Latent bone metastasis in breast cancer tied to Src-dependent 
survival signals. Cancer Cell 16, 67-78. 
 
Zhang, X.P., Kamata, T., Yokoyama, K., Puzon-McLaughlin, W., Takada, Y., 1998. Specific 
interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-
15) with integrin alphavbeta3. J Biol Chem 273, 7345-7350. 
208 
 
Zheng, Y., Peng, M., Wang, Z., Asara, J.M., Tyner, A.L., 2010. Protein tyrosine kinase 6 
directly phosphorylates AKT and promotes AKT activation in response to epidermal 
growth factor. Mol Cell Biol 30, 4280-4292. 
 
Zhong, J.L., Poghosyan, Z., Pennington, C.J., Scott, X., Handsley, M.M., Warn, A., 
Gavrilovic, J., Honert, K., Kruger, A., Span, P.N., Sweep, F.C.G.J., Edwards, D.R., 2008. 
Distinct Functions of Natural ADAM-15 Cytoplasmic Domain Variants in Human 
Mammary Carcinoma. Molecular Cancer Research 6, 383-394. 
 
Zhou, P., Wagner, G., 2010. Overcoming the Solubility Limit with Solubility-Enhancement 
Tags: Successful Applications in Biomolecular NMR Studies. Journal of biomolecular 
NMR 46, 23-31. 
 
Zibert, J.R., Wallbrecht, K., Schon, M., Mir, L.M., Jacobsen, G.K., Trochon-Joseph, V., 
Bouquet, C., Villadsen, L.S., Cadossi, R., Skov, L., Schon, M.P., 2011. Halting angiogenesis 
by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin 
lesions. J Clin Invest 121, 410-421. 
 
